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Abstract 
Familial cataract is a heterogeneous disorder, characterised by opacity of the lens 
from an early age, often leading to blindness or severe visual disability. 
Approximately 20% of congenital cataracts are inherited and can occur in isolation or 
as part of over 200 genetic disorders. Many inherited cataracts also have an age of 
onset during childhood and as such are not truly congenital, but have similar 
aetiologies. There have been fourteen genes identified for isolated familial cataract, 
but many of the molecular causes remain unknown. Forty-five pedigrees with various 
forms of familial cataract have been collected from south-eastern Australia. This 
collection includes 40 with autosomal inheritance, four with X-linked inheritance and 
one with Nance-Horan Syndrome (NHS), an X-linked syndrome involving congenital 
cataract, dental abnormalities and mental retardation. 
Linkage studies of the large pedigree with Nance-Horan Syndrome lead to the 
refinement of the critical region for this disorder to 1.3 Mb through informative 
recombination events. Coding regions of all six characterised genes in the region 
were screened for mutations and shown not to be involved. A novel candidate gene 
was identified in the draft human genome sequence using gene prediction programs, 
EST information and comparison with other genomes available in public databases, 
and the genomic structure of the gene was determined experimentally. The gene was 
subsequently found to be expressed in all human tissues examined, including tissues 
affected by NHS such as eye and brain. Additional NHS pedigrees were ascertained 
and mutations of this novel gene were identified by direct sequencing in five of the 
six NHS pedigrees. All mutations caused severe truncation of the predicted protein 
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and were not identified in controls. Hence, this novel gene, although its function 
remains unknown, is believed to be causative for Nance-Horan Syndrome. 
Analysis of known cataract genes and loci by both linkage analysis and mutation 
detection techniques in pedigrees with autosomal dominant congenital cataract 
revealed three mutations in previously known cataract genes. These mutations 
segregate with the cataract phenotype and are thought to be responsible for the 
cataract observed in these pedigrees. In addition, linkage analysis in one large 
pedigree has excluded linkage to most known loci, providing evidence for the 
existence of an additional locus for isolated congenital cataract. 
In summary, the molecular defect was determined in three large pedigrees with 
isolated autosomal dominant congenital cataract, and a novel gene was identified and 
shown to cause Nance-Horan Syndrome. 
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Chapter 1 
Introduction 
1.1 Cataract 
A cataract is defined as any opacity of the lens. The lens is a transparent structure 
within the eye, just behind the iris, which focuses light onto the retina (Figure 1.1). 
The retina then sends the image to the visual cortex for processing within the brain. If 
the lens becomes opaque, vision can become blurred as light is scattered 
inappropriately by the lens. Total opacity of the lens results in blindness as light 
cannot reach the retina. Cataract is the most common cause of blindness worldwide 
(Thylefors et al. 1995). There are both paediatric and adult-onset forms with adult-
onset being the most common. This form is caused by environmental factors 
contributing to oxidative stress (Ottonello et al. 2000) but is also believed to have a 
strong genetic component (Hammond et al. 2000; Hammond et al. 2001; Heiba et al. 
1995). Congenital cataract is a heterogeneous group of disorders involving lens 
opacities, affecting visual function from an early age. The terms congenital and 
infantile are used interchangeably in the clinical setting as the clinical management of 
the disorders is the same (Rahi and Dezateaux 2001), and many cases of familial 
paediatric cataract have similar aetiologies. Throughout this thesis, the term familial 
will be used as a later age of onset is observed in some pedigrees. Reports of the 
incidence of all forms of congenital cataract vary from 1 to 6 per 10,000 live births 
(Francis et al. 2000c; Watts et al. 2000) with a recent study indicating a cumulative 
incidence of around 3.5 per 10,000 live births by age 15 years (Rahi and Dezateaux 
2001). 
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Figure 1.1: The anatomy of the anterior segment of the human eye (adapted 
from the website of the Ophthalmology Department, Hebrew University and Hadassah 
Medical Center; http://www.md.huji.ac.il/depts/ophtha/)  
Familial cataract contributes greatly to blindness in children, costing the community 
both in expensive surgical treatments and long-term support for those remaining 
visually impaired. 
1.2 Lens morphogenesis 
The lens begins to form in utero at around 4 weeks. It is derived from the surface 
ectoderm which thickens to form the lens placode which then invaginates to form the 
lens pit. The lens pit closes over to form the lens vesicle (Figure 1.2). Primary fibre 
cells differentiate from the single layer of epithelial cells on the posterior side of the 
lens vesicle, filling the cavity as they elongate, forming the embryonic nucleus 
(Figure 1.2). Secondary fibres are formed by the division and differentiation of 
epithelial cells on the anterior side, and continue to be laid down throughout 
development and indeed throughout life, forming layers of fibre cells (Larsen 2001). 
The total lens present at birth is known as the nucleus and consists of the embryonic 
and foetal layers. The cells laid down after birth form the cortex (Larsen 2001). The 
points at which secondary fibres meet form Y shaped lines of optical discontinuity 
and are called the Y-sutures. They are present at the anterior and posterior poles of 
the lens (Francis et al. 1999). As fibre cells differentiate all organelles are broken 
down to ensure lens transparency, rendering a cell incapable of protein turnover 
(Francis et al. 2000c; Kannabiran and Balasubramanian 2000). The proteins present 
in primary fibre cells and most secondary fibre cells must remain stable for the life 
span of the person in order to maintain lens transparency. 
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Figure 1.2. Lens Morphogenesis A. and B. Surface ectoderm thickens  to form the lens 
placode. C. Placode invaginates to form the lens pit. D. Lens pit closes over to form the 
lens vesicle. E. Primary fibre cells differentiate from the epithelial cells, filling the cavity 
as they elongate. (From Francis PJ, Berry V, Moore AT, Bhattacharya S. (1999) Lens biology: 
development and human cataractogenesis Trends in Genetics 15(5):191-196.) 
1.3 Molecular mechanisms of the lens 
The majority of soluble lens protein is made up from the crystallin family. These 
proteins are resistant to degradation under physiological conditions. The 1  and y-
crystallins are primarily responsible for the high refractive index of the lens, required 
to focus light onto the retina. Their tertiary structure enable the molecules to associate 
into highly compact oligomers. This reduces the light scattering by internalizing 
hydrophobic residues (Francis et al. 1999). However, over time, they and other trace 
proteins in the lens do become unstable and unfold inappropriately. The a-crystallins 
help overcome this problem by acting as molecular chaperones, binding any 
misfolded protein. They belong to the family of small heat shock proteins which 
perform similar functions in other cells types under stressful conditions (Bova et al. 
2000). a-crystallins are expressed early in fibre cell formation and are thought to be 
involved in the differentiation of the epithelial cell to the fibre cell (Boyle and 
Takemoto, 2000). 
In order to help maintain protein stability an intricate network of cell to cell 
communication is present in the lens. Connexin proteins form hexamers in the cell 
membranes. These heteromeric oligomers are known as connexons. A connexon in 
one cell membrane interacts with that in another to form gap junctions which allow 
the transport of small metabolites directly between cells (Francis et al. 1999). Two 
connexin proteins, CX46 and CX50, are expressed in the lens. Major Intrinsic Protein 
of the lens (MT) forms similar connections between cells to allow the movement of 
water across the membranes (Berry et al. 2000). 
A lens specific cytoskeletal protein, Beaded Filament Structural Protein-2, forms part 
of the intermediate filament in the lens fibre cell cytoskeleton (Jakobs et al. 2000). On 
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electron microscopy, the cytoskeleton takes on a "beaded" appearance. These beads 
are thought to be a-crystallins (Weinreb et al. 2000). While the exact function of the 
beaded filament found only in lens is unknown, the interaction of a-crystallin with the 
filaments may be another mechnism by which a-crystallins protect the cell against 
stresses (Head et al. 2000). 
1.4 Cataract phenotypes 
Cataracts are generally classified according to their appearance and location within 
the lens. 
1.4.1 Nuclear cataract 
Nuclear cataracts are common (Figure 1.3A) and likely to be caused by a gene 
expressed early in development (Francis et al. 2000c). They affect both the 
embryonic and foetal nuclei. The phenotype can vary with some families presenting 
with a dense central opacity surrounded by fine dots, while others have dots 
distributed throughout the nucleus (Ionides et al. 1999). 
1.4.2 Pulverulent cataract 
A variation of the nuclear opacity is the pulverulent cataract (Figure 1.3B). This 
appears as a dust-like opacity with a 'pulverised' appearance. This phenotype varies 
more between family members than a nuclear opacity, and can even vary between 
eyes of the same patient. It is not restricted to the nucleus, although some families do 
present with a clear cortex (Ionides et al. 1999). The Coppock family was originally 
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Figure 1.3. Examples of some cataract phenotypes: A. nuclear cataract; B. pulverulent 
cataract; C. lamellar cataract; D. sutural cataract; E. anterior polar cataract; F. coralliform 
cataract. 
described by Nettleship and Ogilvie (1906) as possessing a central pulverulent 
opacity, confined to the embryonic nucleus. This phenotype is now referred to in the 
literature as a Coppock cataract. The Coppock-like cataract also involves the 
embryonic nucleus. The density of this opacity increases towards the periphery 
(Ionides et al. 1999; Francis et al. 2000c). 
1.4.3 Lamellar cataract 
Another common phenotype is the lamellar cataract (Ionides et al. 1999) (Figure 
1.3C). It is confined to one of the concentric layers of fibre cells and represents a 
disruption for a short period of time during development (Francis et al. 2000c). These 
cataracts are sometimes referred to as zonular. A variation of the lamellar cataract is 
the sutural cataract which occurs around the posterior or anterior Y-sutures where the 
fibre cells join (Figure 1.3D) (Francis etal. 2000c). 
1.4.4 Cortical cataract 
Cortical cataract is rare as an autosomal dominant trait (Ionides et al. 1999). It is 
confined to the lens cortex and does not involve the nucleus. In contrast to lamellar 
cataract, it can affect a sector of the lens, rather than a layer (Ionides et al. 1999). An 
abnormality during the later stages of development is indicated (Francis etal. 2000c). 
1.4.5 Polar cataract 
Cataracts have also been described at both the anterior and posterior poles. Anterior 
polar cataracts have a minimal effect on vision (Figure 1.3E) (Ionides et al. 1999). 
Posterior polar cataracts are relatively common. They can be either stationary at the 
pole, or progress to have cortical extensions or lead to total cataract. This is the end 
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point of progression of many forms of cataract, but can also occur as a distinct 
phenotype (Ionides et al. 1999; Francis et al. 2000c). 
1.4.6 Cerulean cataract 
The Cerulean or "blue dot" cataract develops during early childhood and is not truly 
congenital. It consists of discrete opacities throughout the lens with a characteristic 
blue-white colour. Opacities are more numerous in the cortex, where they may form 
wedge-like shapes (Francis et al. 2000c). 
1.4.7 Aculeiform cataract 
A rare form of congenital cataract is the coralliform or aculeiform phenotype which 
consists of projections from the nucleus resembling coral (Figure 1.3F). This type 
originates from the foetal nucleus as well as post-natal regions, indicating a 
congenital opacity with progression (fleon et al. 1998; Francis et al. 2000c). 
1.5 Treatments 
1.5.1 Surgery 
The only treatment for cataract is surgery to remove the opacification, followed by 
visual correction with an implanted lens contact lenses and/or glasses. There are 
several types of surgery for removing an °pacification. A lensectomy involves 
removing the lens, anterior capsule, cortex, nucleus and posterior capsule as well as 
the anterior vitreous (Figure 1.1). This technique ensures that the posterior capsule 
will not opacify following surgery (Eckstein et al. 1999). The alternative to this 
highly specialized surgery is a lens aspiration, which removes the anterior capsule, 
cortex and nucleus, leaving the posterior capsule in place. Lens aspiration often 
requires a secondary procedure to remove the posterior capsule, if it has opacified 
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following surgery. The capsule is sometimes punctured during the initial surgery to 
prevent this post-operative complication. 
1.5.2 Complications of surgery 
Other post-operative complications of surgery include retinal detachment and 
glaucoma. Retinal detachment is not a common complication. Eckstein etal. (1999), 
report only two detached retinas, both following lensectomy surgery in a study 
involving 65 children. However, the follow up period in this study was only 3 years. 
The estimated mean interval from surgery to retinal detachment is 22 years, 
(determined from a retrospective study of 341 congenital cataract patients who had 
undergone cataract surgery) making most studies of insufficient length to gain 
accurate figures (Francis et al. 2001). Eckstein et al. (1999) also reported that only 
two eyes developed secondary glaucoma (in different patients than the retinal 
detachments). Other reports indicate the incidence of secondary glaucoma following 
cataract surgery are much higher. Ariturk etal. (1998) report an incidence of 28.7% 
after a mean follow up of 4.5 years following surgery and 60% after 5-10 years. It 
appears the likelihood of observing secondary glaucoma is dependent on several 
factors including the surgical technique, age of the patient at the time of diagnosis and 
at surgery and length of the follow up period (Ariturk et al. 1998). 
1.5.3 Outcomes 
Visual outcomes for children following cataract surgery vary. Up to one third of 
congenital cataract patients will remain legally blind, with only 30%-50% of patients 
achieving a visual acuity of 20/40 or better (Francis et al. 2001). The main cause of 
poor visual acuity is deprivational amblyopia, particularly when the opacity is very 
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dense at birth. This condition occurs when one eye fails to be stimulated during visual 
development and becomes 'lazy'. It is thought that early intervention of these dense 
opacities will prevent amblyopia, while some milder cataracts may benefit from later 
intervention enabling primary intraocular lens placement (Francis et al. 2001). 
Insights into the development of the lens have been gained from studying the genetics 
of familial cataract. As the understanding of the molecular mechanisms increase, 
treatments can be better developed and tailored for individual needs. 
1.6 Familial forms 
For the 50% of cases of congenital cataract where a cause can be determined, the 
most common is a genetic abnormality (Francis et al. 2001). Non-genetic causes 
include intrauterine insults such as rubella and cytomegalovirus infection (Francis et 
al. 2001). There are approximately 200 genetic disorders that involve congenital 
cataract, including Down Syndrome (OMIM# 190685) and metabolic disorders such 
as galactosaemia (omrm# 230400) and hyperferritinaemia cataract syndrome 
(OMIM# 600886), but the most common form is non-syndromic isolated cataract 
inherited in an autosomal dominant fashion (Francis et al. 1999). Autosomal 
recessive forms have been described, although mainly in consanguineous populations 
(Pras etal. 2000; Heon etal. 2001; Pras etal. 2001; Pras etal. 2002), and X-linked 
forms are also reported (Fraccaro et al. 1967; Francis et al. 2002). 
To date, fourteen known genes have been described for autosomal dominant 
congenital (or familial) cataract (ADCC) (Glaser etal. 1994; Litt et al. 1997; 
Kannabiran et al. 1998; Litt et al. 1998; Semina et al. 1998; Shiels et al. 1998; Heon 
etal. 1999; Mackay et al. 1999; Stephan etal. 1999; Berry etal. 2000; Conley et al. 
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2000; Jakobs etal. 2000; Berry etal. 2001; Bu etal. 2002; Mackay etal. 2002). Each 
family studied so far has a mutation in only one of these genes. So although ADCC is 
genetically heterogeneous it is a monogenic Mendelian disorder. In addition to the 
known genes at least five other loci have been implicated (Eiberg et al. 1988; 
Armitage etal. 1995; Eiberg etal. 1995; Berry et al. 1996; Ionides et al. 1997; 
Ionides et al. 1998; Yamada et al. 2000; Vanita et al. 2001b). To date, two genes 
(Pras etal. 2000; Pras etal. 2002) and two loci (Fleon etal. 2001; Pras etal. 2001) 
have been identified in autosomal recessive congenital cataract (ARCC). X-linked 
congenital cataract has been mapped to Xp22.3 in some families (Francis et al. 2002). 
The identified genes and loci detected in the absence of other syndromic features are 
listed in Table 1.1. 
1.7 Cataract genes 
1.7.1 Syndromic cataract genes, including Nance-Horan Syndrome 
Congenital cataract is a feature of numerous developmental syndromes, including 
Lowe Oculocerebralrenal Syndrome (0M11\4# 309000), Walker-Warburg Syndrome 
(OMIM# 236670), Stickler Syndrome (OMIM# 108300) and Cataract-Microcornea 
Syndrome (OMIM# 116150). One gene identified for a cataract syndrome is the 
transcription factor musculoaponuerotic fibrosarcoma oncogene (MAF) (Jamieson et 
al. 2002). The promoters of lens specific proteins carry binding sites for this factor 
which is involved in the regulation of their transcription. In one pedigree congenital 
cataract segregates at a translocation breakpoint within a genomic control region of 
this gene. Individuals with an unbalanced translocation also have Peter's anomaly 
(OMIM#603807) which includes corneal opacities and iris adhesions. In a second 
pedigree a point mutation (R288P) of the gene was found to segregate with congenital 
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cataract, microcornea and iris coloboma. This mutation is in the DNA binding domain 
of the protein (Jamieson et al. 2002). 
A well documented phenotype is the Cataract-Dental Syndrome (OMIM# 302350) 
otherwise known as Nance-Horan Syndrome (NHS). This was first described 
independently in 1974 by Nance et al. (Nance et al. 1974) and Horan and Billson 
(Horan and Billson 1974) and consists of bilateral congenital cataract and 
characteristic dental anomalies in affected males (Walpole et al. 1990). The disorder 
is X-linked, with carrier females presenting with milder sutural cataracts with or 
without dental anomalies. The phenotype of the cataract in females is comparable to 
that seen in isolated X-linked congenital cataract (X-linked CCT) which has been 
reported as a separate disorder. Both NHS and X-linked CCT have been mapped to 
Xp22.3 (Francis et al. 2002; Toutain et al. 2002) and it has been suggested that they 
may in fact be allelic. Only three large families have been described for X-linked 
CCT. The diagnosis in smaller pedigrees is reliant on the phenotype and apparent 
transmission pattern, rather than confirmation by linkage studies. Therefore some 
small families identified with X-linked CCT may in fact have an autosomal dominant 
form. Investigation of NHS and identification of the causative gene are described in 
Chapters 3 and 4. 
1.7.2 Autosomal dominant and recessive congenital cataract genes 
Any protein that is expressed in the lens is a candidate gene for congenital cataract. 
Many of these have already been shown to be involved in the disorder. The most 
highly expressed genes in the lens are the crystallins. These proteins are present in the 
lens in high concentrations, creating a suitable refractive index to allow the focussing 
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Table 1.1: Genes, mutations and mapped loci associated with congenital cataract 
phenotypes 
Locus Gene Mutation Phenotype No. of 
families 
Reference 
lpter- 
p36.1 
Progressive, central and 
zonular 
1 (Eiberg eta!. 1995) 
Posterior polar 1 (Ionides etal. 1997) 
1q21.1 CX50 E48K Zonular pulverulent 1 (Berry etal. 1999) 
P88S Zonular pulverulent I (Shiels etal. 1998) 
I247M Zonular pulverulent 1 (Polyakov etal. 2001) 
2q33.3 CRYGC T5P Coppock-like 1 (Eldon etal. 1999) 
235insGCGGC Zonular pulveru lent 1 (Ren et al. 2000) 
R168W Lamellar 1 (Santhiya etal. 2002) 
CRYGD R14C Punctate progressive 1 (Stephan etal. 1999) 
P24T Lamellar 1 (Santhiya et al. 2002) 
R37S Crystalline 1 (Kmoch etal. 2000) 
R58H Aculeiform 1 (Eldon etal. 1999) 
R156X Central nuclear 1 (Santhiya et al. 2002) 
3p22.2- 
p21.3 
Recessive 3 (Pras etal. 2001) 
3q22.1 BFSP2 AE233 Cortical 1 (Jakobs et al. 2000) 
R287W Progressive 1 (Conley et al. 2000) 
9q13-q22 Recessive, progressive 
pulverulent 
1 (Heon etal. 2001) 
10q24.32 PITX3 S13N Congenital cataract 1 (Semina etal. 1998) 
550deIG Congenital cataract 1 (Yang et al. 2002) 
655insl7pb ASMD and cataract 1 (Semina etal. 1998) 
655insl7pb Posterior Polar 1 (Finzi etal. 2002) 
11.13 PAX6 018W Con. enital cataract 1 (Wolf et al. 1998) 
11q23.1 CRYAB RI 20G Desmin related 
myopathy and cataract 
1 (Vicart etal. 1998) 
450delA Posterior polar 1 (Berry etal. 2001) 
12q13.3 MIP E134G Lamellar, foetal nucleus 1 (Berry et al. 2000) 
T138R Progressive 
polymorphic 
1 (Berry et a/. 2000) 
13q12.11 CX46 N63S Zonular pulverulent 1 (Mackay et al. 1999) 
1137insC Pulverulent 1 (Mackay etal. 1999) 
P1 87L Pulverulent 1 (Rees et al. 2000) 
15q21-q22 
. 
Central pouchlike, 
sutural 
I (Vanita etal. 2001b) 
16q22.1 HSF4 A2OD Lamellar 1 (Bu et al. 2002) 
I87V Lamellar 1 (Bu et al. 2002) 
L1 15P Lamellar 1 (Bu etal. 2002) 
R120C Marner's cataract 1 (Bu etal. 2002) 
17p13 Anterior polar 1 (Berry etal. 1996) 
17q11.2 CRYBA I Splice site Zonular sutural 2 (Kannabiran etal. 1998; 
Bateman etal. 2000) 
17q24 Cerulean 1 (Armitage etal. 1995) 
19q13.33 LIM2 F105V Recessive, pulverulent 
cortical 
1 (Pras etal. 2002) 
20p1 2-q 12 Posterior polar 1 (Yamada etal. 2000) 
21q22.3 CRYAA W9Stop Recessive 1 (Pras et al. 2000) 
RI 16C Zonular, central nuclear 1 (Litt etal. 1998) 
22q11.23 CRYBB2 Q155X Cerulean 1 (Litt etal. 1997) 
Q155X Coppock-like 1 (Gill etal. 2000) 
Q155X Sutural, punctate 1 (Vanita etal. 2001a) 
22q12.1 CRYBB1 G220X Pulverulent 1 (Mackay et al. 2002) 
Xp22.3 Total in males, Sutural 
in females 
2 (Fraccaro et al. 1967; 
Francis et al. 2002) 
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of light onto the retina (Kannabiran and Balasubramanian 2000). This family of 
proteins has three subtypes, known as a, 13 and y. They are expressed in a sequential 
pattern during development, with the a-crystallins expressed early, followed by the 13- 
and y-crystallins as the fibre cell matures (Boyle and Takemoto 2000). Mutations of 
the a-crystallins have been identified in a nuclear cataract (Litt et al. 1998), a 
posterior polar phenotype (Berry et al. 2001), and also a recessive form (Pras et al. 
2000). Mutations of both 13-  and y-crystallins have been shown to cause a range of 
congenital cataract phenotypes (Litt etal. 1997; Kannabiran etal. 1998; Ikon et al. 
1999; Stephan et al. 1999; Gill etal. 2000; Ren et al. 2000; Mackay et al. 2002). 
Investigations of crystallin genes are described in Chapter 5. 
Other proteins are also integral in maintaining lens transparency. Connexins are 
involved in cell homeostasis by the transport of small molecules between cells 
(Francis etal. 1999; Kannabiran and Balasubramanian 2000). Connexin 46 (CX46) 
and Connexin 50 (CX50) are expressed in human lens fibre cells and mutations in 
both have been linked to zonular pulverulent congenital cataract (Shiels etal. 1998; 
Berry et al. 1999; Mackay et al. 1999; Rees et al. 2000). Connexin gene 
investigations are presented in Chapter 6. 
Major Intrinsic Protein of the lens (MIP) a member of the aquaporin family (AQO) of 
transmembrane water channels, is responsible for the transport of water between fibre 
cells (Berry et al. 2000). Two mutations have been identified in this gene, one in a 
pedigree with polymorphic progressive cataract and the other with stable lamellar 
cataract (Berry et al. 2000). 
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The Beaded Filament Structural Protein-2 (BFSP2) is a cytoskeletal protein (Conley 
et al. 2000; Jakobs et al. 2000). Mutations of this gene have been associated with 
nuclear and sutural cataracts. BFSP2 plays an important structural role during early 
development and later growth of the lens. This is indicated by the differing 
phenotypes associated with two mutations of this gene. 
The Mauler cataract consists of zonular stellate and anterior polar opacities (Marner 
1949). This phenotype was mapped to 16q22.1 (Eiberg etal. 1988; Marner etal. 
1989). Linkage to this region was also demonstrated in a Chinese pedigree with 
lamellar cataract (Bu et al. 2002). The candidate gene Heat Shock Factor 4 (HSF4) 
was investigated in the Chinese pedigree and a causative mutation identified. 
Missense mutations were also detected in two other Chinese pedigrees with lamellar 
cataract (Bu et al. 2002). Following this discovery, the HSF4 gene was investigated in 
a Danish kindred with Mamer cataract and the causative mutation was identified (Bu 
et al. 2002). 
PAX6 and PITX3 and are also transcription factors and are involved in eye 
development. Mutations in both have been associated with syndromic forms of 
cataract such a aniridia (Wolf et al. 1998) and anterior segment dysgenesis (Semina et 
al. 1998), although congenital cataract has been found to occur in isolation as well. 
1.8 Summary 
Congenital and familial cataract are a very heterogeneous group of disorders. A total 
of 14 genes have been identified and five loci described for isolated autosomal 
dominant congenital/familial cataract. Autosomal recessive cataract has been linked 
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to four separate loci, for which two of these genes have been described, and X-linked 
cataract has been mapped to Xp22.3. As the sequencing of the human genome is 
completed, the gene identification process is becoming more rapid. The identification 
of genes involved in disease has contributed to our understanding of lens biology and 
development through the detailed functional investigations of cataract-causing 
mutations such as those in cc-crystallins that affect the chaperone function (Kumar et 
al. 1999; Shroff et al. 2000) and in MIP that affect protein trafficking (Francis et al. 
2000b). This knowledge will continue to increase as novel mutations and genes are 
identified. The collection of large multigenerational pedigrees is crucial to the process 
of gene identification and therefore biological understanding of lens development and 
disease processes. 
1.9 Aims 
While many genes for congenital cataract are well described, there remain many loci 
for which the gene is unknown and also families in which none of these genes or loci 
explain the molecular causes of their disease. The heterogeneity of the disorder has 
slowed progress in the understanding of congenital cataract as studies have been 
limited to linkage-based analyses of single large pedigrees. It is still unknown how 
many loci are involved in inherited paediatric cataract, and to what extent the loci 
contribute to later-onset cataract. Our clinical collaborators have identified and 
collected samples from 45 congenital or familial cataract pedigrees from south-
eastern Australia. The primary objective of this study was identification of causative 
mutations for the cataract phenotype in these families. The family collection included 
the pedigree which provided the original Nance-Horan Syndrome description and 
several other X-linked pedigrees which have facilitated the identification and 
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characterisation of the gene responsible for NHS. Using linkage analyses and 
mutation screening approaches we investigated the known genes and loci in the 
pedigrees with autosomal or unknown inheritance. 
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Chapter 2 
Materials and Methods 
2.1 Patient ascertainment 
2.1.1 Ethics approval 
Ethics approval for this study was obtained from the Human Research Ethics 
Committees of the Royal Children's Hospital, Melbourne, the Royal Victorian Eye 
and Ear Hospital, Melbourne, and the University of Tasmania, Hobart, and adhered to 
the tenets of the Declaration of Helsinki. 
2.1.2 Familial cases 
The Royal Children's Hospital and the Royal Victorian Eye and Ear Hospital, 
Melbourne, Australia, have undertaken to ascertain and recruit as many pedigrees as 
possible with congenital or familial cataract from south-eastern Australia. These 
facilities have a referral base for almost all paediatric cataracts in the Australian states 
of Victoria and Tasmania (Wirth et al. 2002). The records of all paediatric cataract 
patients over the 25 years prior to 2000 were reviewed. The incidence of paediatric 
cataract was determined to be 2.2 per 10,000 live births in this population. The study 
involved the review of 421 cases belonging to 391 families. 342 children had no 
known family history of congenital cataract while 79 children from 54 families had a 
family history. These 54 families were contacted to take part in a study into the 
genetic causes of congenital cataract. Genealogical research revealed that ten of these 
families were related and formed four larger pedigrees. Three others either could not 
be contacted or declined to participate. Buccal swabs were therefore collected from a 
total of 45 families for DNA extraction. The families are caucasian from European 
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(primarily British) descent. The breakdown of inheritance patterns included 34 
families with autosomal dominant inheritance, two with autosomal recessive, five 
were considered to be X-linked (including one with NHS) and four were of uncertain 
inheritance. These 45 pedigrees (shown in full in Appendix 1) form the basis of this 
study which aimed to identify the genes responsible for the cataract phenotype in 
these families. 
2.1.3 Control individuals 
Unaffected controls for allele frequency estimation and mutation screening were 
ascertained from nursing homes in Launceston, Tasmania. All individuals were 
ophthalmically examined and found to be free of ophthalmic disorders, including any 
form of cataract. Although the controls are residents of south-eastern Australia and 
are caucasian from European descent, they were recruited from a more restricted 
sampling and are elderly and disease-free, so they are not representative of the 
population at large. However, they are ideal for investigating whether the mutations 
identified are also found in cataract-free individuals, and therefore likely to be 
common polymorphisms without causative effects. 
Allele frequencies were also obtained from the database maintained by the Centre 
d'Etude Polymorphisme Humain (CEPH) (http://www.cephb.fr/) . These frequencies 
were obtained from a collection of Caucasian pedigrees from Utah, U.S.A. and 
France. 
2.2 Genetic material 
Buccal mucosa swabs were the most common sample type collected. DNA was 
extracted from the swabs using the PureGene DNA isolation kit (Gentra Systems). 
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All reagents were supplied in the kit unless otherwise indicated. The buccal mucosa 
of participants was scraped with a cytology brush which was then immersed in 300 IA 
of cell lysis solution in a screw-cap tube. Brushes were transported in this state, then 
stored at 4°C until extraction. Samples were incubated overnight at 55°C with 1.5 Ill 
of 20 mg/ml Proteinase K (Sigma-Aldrich). After cooling to room temperature, 1.5 
of 5 mg/ml RNaseA was added, the tube inverted several times to mix, and the 
sample incubated at 37°C for 15 minutes. The sample was again allowed to cool to 
room temperature before the addition of 1001A1 of Protein Precipitation Solution, 
mixing by inversion and incubation on ice for 5 minutes. The sample was centrifuged 
at 13,000 rpm for 3 minutes and the supernatant added to a clean tube containing 
200111 of isopropanol (Sigma-Aldrich) and 0.5 p.1 of 20 mg/ml glycogen (Sigma-
Aldrich). The tube was again mixed by inversion and incubated at room temperature 
for 5 minutes before centrifuging at 13,000 rpm for 5 minutes. The supernatant layer 
was then discarded and 300 [1,1 of 70% molecular grade ethanol (Sigma-Aldrich) 
added to the pellet. The sample was again centrifuged at 13,000 rpm for 1 minute, the 
supernatant discarded and the pellet allowed to air dry. Once completely dry, the 
pellets were resuspended in 20 IA of DNA Hydration Solution with heating to 65°C 
for 1 hour. All DNA samples were stored at 4°C. 
Whole blood was collected in 10 mL EDTA tubes from consenting individuals in 
pedigrees ctas16 (III:5, 1118, III:9, TV:3, IV:5, IV:6, IV:7, V:4, V:5, V:7 and VI:1), 
ctas17 (IV:7, V:3, V:8, VI:1), ctas35 (I:1), ceeh42 (TII:2, IV:1) and crch2551 (IV:2, 
V:3, V:4, V:5, V:7). DNA was extracted by technician Michele Brown using the 
Nucleon BACC3 kit (Amersham Pharmacia Biotech). Four times the volume of the 
sample of Reagent A was added and mixed for 4 minutes at room temperature. The 
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samples were centrifuged at 1300g for 5 minutes and the supernatant discarded. The 
pellet was resuspended in 2 mL of Reagent B and transferred to a clean tube before 
adding 15 !al of 50 [tg/m1RNase and incubating at 37°C for 30 minutes. Protein was 
precipitated by the addition of 500 ill of sodium perchlorate solution and the samples 
mixed by inversion. Two ml of chloroform was added and mixed by inversion before 
the addition of 300 p,1 of Nucleon resin without remixing the phases. The samples 
were centrifuged at 1300g for 3 minutes. The upper phase was transferred to a clean 
tube and 2 volumes of cold absolute ethanol added. The sample was mixed by 
inversion until the precipitate appeared, followed by centrifuging at 4000g for 5 
minutes. The supernatant was discarded. The pellet was washed with cold 70% 
ethanol and centrifuged again at 4000g for 5 minutes. The pellets were air dried and 
resuspended in 100 i.t1 of TE buffer. 
2.3 General PCR conditions 
All PCR reactions were conducted using Corbett Research 960C cooled thermal 
cyclers, unless otherwise noted. 10x PCR buffer was prepared, containing 100 mM 
Tris HC1, 500 mM KC1, and variable concentrations of MgC1 2 , ranging from 10- 
35 mM. PCR reactions were carried out in a total volume of either 10 or 301.11 and 
contained between 1.0 and 3.5 rnM final Mg2+ concentration, 0.2 mM dNTP 
(Promega), 0.811M of each primer and 0.005 U/1.1.1 Taq DNA Polymerase (Qiagen). 
Reactions underwent 30 cycles of 94°C for 30 seconds, primer pair specific annealing 
temperature for 30 seconds and 72°C for 30 seconds followed by 72°C for 10 
minutes. Annealing temperatures and optimal Mg 2+ concentrations, listed in 
Appendix 3, were determined empirically for each primer pair by cycling of a range 
of temperatures and Mg2+ concentrations in a PC-690G gradient thermal cycler 
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(Corbett Research) and assessment of the optimal conditions by visualisation on 
agarose gel containing 0.3 ng/ml ethidium bromide. 
2.4 Primer Extension Preamplification (PEP) 
This PCR-based technique was used as a method of whole genome amplification to 
provide sufficient DNA for multiple PCR-based analyses from buccal mucosa swabs. 
Each reaction contained 50 ng genomic DNA, 2.0 mM Mg 2+, 0.2 mM dNTP 
(Promega), 20 pmol/[tlpolyN 15mer primer (Operon technologies) and 5U Taq DNA 
polymerase (Qiagen). Reactions underwent 50 cycles of 94°C for 1 minute, 37°C for 
2 minutes and 55°C for 4 minutes followed by a final extension of 72°C for 10 
minutes. Products were electrophoresed on 1% agarose gel containing 0.3 ng/ml 
ethidium bromide to confirm the presence of high molecular weight product. Samples 
were diluted 1:8 with distilled water for use in PCR. 
2.5 Fluorescent genotyping 
The forward PCR primer for each marker was labelled at the 5' end with either 6- 
FAM, TET, HEX or NED (Sigma-Aldrich). PCR reactions were carried out in 10 Ill 
reaction volumes. Fragments labelled with 6-FAM or TET underwent 25 
amplification cycles, while those with HEX or NED underwent 35 cycles. One IA of 
each PCR reaction was pooled into an 8 vtl final volume, with between 3 and 7 
markers per pool, such that markers that had a similar expected size in the same pool 
were labelled with different colours. Pools were electrophoresed using an ABI 
PRISM 310 Genetic Analyzer (Applied Biosystems) with POP4 polymer (Applied 
Biosystems). Data were collected automatically and analysed with the Genescan® and 
Genotyper® software (Applied Biosystems). 
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2.6 Single-Stranded Conformational Polymorphism Analysis (SSCP) 
PCR used for SSCP analysis of the crystallin genes in Chapter 5 primers are listed in 
Appendix 2. Both forward and reverse primers were end-labeled with y 32P-ATP in 
reactions containing 0.2 U/p1 T4 polynucleotide kinase (New England Biolabs), 3 p.M 
of primer, 1X PNK Buffer (New England Biolabs) and 1.6 pCi/p1 of 1 32P-ATP 
(Geneworks). Reactions were incubated at 37°C for 30 minutes and terminated at 
70°C for 10 minutes. Each exon was amplified by PCR in 10 p.1 reaction volumes as 
described above, except that each reaction contained 0.7 pM of each unlabeled primer 
and 0.11 pM of each labeled primer. 
Five pl of the PCR products were added to 35 pl of SSCP Stop Solution (95% 
deionised formamide, 10 mM NaOH, 0.25% Bromophenol blue, 0.25% Xylene 
Cyanol, all reagents from Sigma-Aldrich), denatured at 95°C for 2 minutes and snap 
cooled on ice. 4 IA was loaded onto a 0.4mm, 0.5X Mutation Detection Enhancement 
(MDE) Gel (Edwards Instrument Co.) and electrophoresed in 0.6X TBE buffer at 8W 
for 16 hours at room temperature. lx TBE buffer contained 0.1 M Trizma base, 0.1 
M Boric acid and 2 mM EDTA (all from Sigma-Aldrich). The gel was transferred to 
3MM paper (Whatman) and exposed to Kodak Biomax MR film (Amersham 
Pharmacia Biotech) in the presence of Cronex Lightning Plus intensifying screens 
(Dupont) at -80° C for 24 hours, before being developed by hand with D-19 developer 
(Kodak) and fixed with Hypam Rapid Paper and Film Fixer (Ilford). Films were 
visually examined for mobility shifts. 
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2.7 DNA Sequencing 
2.7.1 Protocol for Beckman CEQ2000 
The sequencing of candidate genes for NHS described in Chapter 3 was carried out 
using a CEQ2000 automated DNA sequencer (Beckman Coulter). PCR products were 
sequenced with forward and reverse primers used to generate the PCR product 
(Appendix 2). Fragments were PCR amplified in 30 III volumes, purified with Ultra 
Clean PCR clean up kit spin columns (MoBio) and cycle sequenced with QuickStart 
Ready Reaction Mix (Beckman Coulter) in 10 Ill reactions consisting of 4 pi Ready 
Reaction Mix, 3.2 pmol of primer and 30-90 ng of PCR product. Samples underwent 
30 cycles of 95°C for 10 seconds, 50°C for 5 seconds and 60°C for 4 minutes. 
Precipitation was carried out with 1W of 20 mg/ml glycogen, 2 41 of 100 mM EDTA, 
2 pi of 3M sodium acetate (pH 5.2) and 50 p,1 of 100% molecular grade ethanol (all 
from Sigma-Aldrich). Samples were immediately centrifuged at 13,000 rpm for 20 
minutes and the supernatant discarded. The pellet was washed with 200 IA of 70% 
ethanol and then centrifuged at 13,000 rpm for 5 minutes. The supernatant was again 
discarded and the wash step repeated. The pellets were vacuum dried and 
resuspended in Sample Loading Solution (Beckman Coulter) before electrophoresis 
on the CEQ2000. 
2.7.2 Protocol for ABI PRISM 310 Genetic Analyzer 
The sequencing of the NHS gene and crystallin and connexin genes in Chapters 4, 5 
and 6 was carried out on an ABI PRISM 310 Genetic Analyzer (Applied Biosystems). 
Fragments were prepared as above but cycled with Big Dye Terminator Ready 
Reaction Mix (Applied Biosystems) over 25 cycles. Products were precipitated with 
2 p.1 of 3M sodium acetate (pH 4.2) and 50 III of 100% molecular grade ethanol 
(Sigma-Aldrich). Following a 15 minute incubation at room temperature, samples 
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were centrifuged at 13,000 rpm for 20 minutes. The supernatant was discarded and 
the pellet washed with 200 p.1 of 70% molecular grade ethanol. Samples were then 
centrifuged at 13,000 rpm for 5 minutes and the supernatant discarded. The pellet was 
dried by a 1 minute incubation at 95°C with the lid open and was resuspended in 15 
ill of Template Suppression Reagent (Applied Biosystems). Samples were 
electrophoresed on an ABI PRISM 310 Genetic Analyzer (Applied Biosystems) with 
POP6 polymer (Applied Biosystems). Data were collected automatically and analysed 
using Sequence Analysis@ (Applied Biosystems) and Sequencher@ (GeneCodes) 
software. 
2.8 Denaturing High Performance Liquid Chromatography (dHPLC) 
Each fragment to be analysed by dHPLC was amplified in a 30111 PCR reaction with 
the primers listed in Appendix 2. When searching for recessive mutations, known 
wild type DNA must be added to the sample to allow the formation of heteroduplexes 
between mutant and wild type strands. As the mutation causing this dominant disease 
should be heterozygous in affected individuals, no additional wild type DNA was 
added to reactions as heteroduplexes will form naturally. The melt temperature of the 
fragment was calculated at the Stanford dHPLC Melt Program Website 
(http://insertion.stanford.edu/melt.html) . The best temperature for visualisation of the 
mutation was found experimentally using positive controls identified by sequencing, 
starting with the calculated temperature and moving up and down in 1°C increments 
until the clearest difference between wild type and mutant samples was seen. 
Samples were injected onto a Helix dHPLC column packed with 1000 alkylated 
silica (Varian). The column had an internal diameter of 3.0 mm and was 75 mm long. 
The acetonitrile concentration was increased from 45% to 68% by increasing the flow 
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rate of Buffer B (Varian) while decreasing the flow rate of Buffer A (Varian). Data 
were collected automatically and analysed using the Star Reviewer software (Varian). 
2.9 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
RNA from the cortex and cerebellum of an adult human male obtained post-mortem 
was reverse transcribed in 10 il reactions containing 1X first strand buffer 
(Invitrogen), 10 mM dithiothreitol (Invitrogen), 0.5 inM dNTP (Promega), 1 liM gene 
specific reverse primer and Superscriptffl RNase If Reverse Transcriptase 
(Invitrogen). Reactions were incubated at 37°C for 1 hour. The resulting cDNA was 
then diluted by V2 for use in 30 [11PCR reactions as described in section 2.4 except 35 
cycles with an annealing temperature of 58°C were used. Where non-specific 
products or smears were obtained, the reactions were repeated with higher annealing 
temperatures. Products were purified with Ultra Clean PCR clean up kit spin columns 
(MoBio) or excised from the gel and extracted with a Qiaquick Gel Extraction Kit 
(Qiagen) before sequencing as described in Chapter 2.7.2. 
2.10 5' Random Amplification of cDNA Ends (5'RACE) 
This technique was carried out using the GeneRacer Ready cDNA kit (Invitrogen). 
The RNA used for the RT-PCR experiments was known to be degraded and was 
thought unlikely to contain full-length transcripts which are necessary for 5'RACE. 
Pre-prepared cDNA from adult human brain was supplied. Prior to purchase the RNA 
had been treated to ligate an oligo of known sequence (5'- 
CGACUGGAGCACGAGGACACUGACAUGGACUGAAGGAGUAGAAA-3') to 
the 5' end of all full length mRNA, then reverse transcribed to produce cDNA. This 
cDNA was used as the template in PCR reactions using the supplied primer (5'- 
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GCACGAGGACACUGACAUGGACUGA-3') targeted to the ligated oligo and 
gene-specific primers targeted to predicted exons 3, 4, 5, and 6 of the novel gene 
(Appendix 2). Nested reactions were also carried out using the nested primer supplied 
(5'-GGACACTGACATGGACTGAAGGAGTA-3'). The supplied protocol was 
followed for PCR. Platinum HiFi Taq Polymerase (Invitrogen) was used, as advised. 
The product obtained was cleaned with Ultra Clean PCR clean up kit spin columns 
(MoBio) and sequenced directly as described above for other PCR products. 
2.11 Computer based methods 
2.11.1 Linkage simiulations and analysis 
Linkage simulations were carried out by SLINK (Ott 1989; Weeks et al. 1990) and 
are described in sections 3.3.2 and 5.2.2. Two-point linkage analysis was carried out 
with the FASTLINK package (Lathrop et al. 1984, with modification by Cottingham 
et al. 1993) and is described in detail in sections 3.3.3 and 5.2.4. Multipoint linkage 
analysis and haplotype estimation were carried out with X-linked Genehunter Plus 
(Kong and Cox 1997) and is described in section 3.3.3. 
2.11.2 Database mining 
Microsatellites for linkage analysis were obtained from the Genome Database 
(http://www.gdb.org). Map locations were determined from the location database 
(http://cedar.genetics.soton.ac.uk/public_html/ldb.html)  and the physical locations 
from UCSC genome browser (http://genome.ucsc.edu). 
Database tools used for the identification of the novel NHS gene are indicated in 
Chapter 4. 
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Chapter 3 
Refinement of the Critical Region for Nance-Horan 
Syndrome 
3.1 Background 
3.1.1 Nance-Horan Syndrome 
Nance-Horan Syndrome (NHS [OMIM #302350]) was first described in 1974 as an 
X-linked syndrome involving congenital cataract and dental anomalies (Horan and 
Billson 1974; Nance etal. 1974). Ophthalmological findings in affected males 
include bilateral severe congenital cataract involving the foetal nucleus and posterior 
Y-suture with variable zonular extensions into the posterior cortex and requiring 
surgery. Microcornea, nystagmus and microphthalmia have also been reported in 
some pedigrees (Lewis et al. 1990; Stambolian et al. 1990; Walpole et al. 1990). 
Dental abnormalities include screwdriver blade-shaped incisors, supernumerary 
maxillary incisors (meisiodens) and diastema (Walpole et al. 1990). Several families 
were reported to have lateral brachymetacarpalia (Lewis et al. 1990) and some 
affected males display mental retardation (Toutain et al. 1997a). Characteristic 
dysmorphic facial features, which may be subtle, include large anteverted pinnae, 
long narrow face and prominent nose and nasal bridge (Lewis et al. 1990; Walpole et 
al. 1990). The disorder appears to be inherited in a codominant fashion, with 
heterozygous females often expressing some level of phenotype but rarely as severely 
as males. Features in females include posterior Y-sutural cataracts with little or no 
loss of vision, and characteristic dental abnormalities (Walpole et al. 1990; Zhu et al. 
1990). Typical characteristics are depicted in Figure 3.1. 
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A 
B 
Figure 3.1. Clinical features of Nance-Horan Syndrome A. Examples of sutural cataract 
observed in females. B. Characteristic dental anomalies including screwdriver blade 
shaped notched incisors and diastema. (B. reproduced with permission of the publisher from 
Horan MB, Billson FA (1974) X-linked cataract and hutchinsonian teeth Aust Paediat J 10:98-102) 
Initially, NHS was mapped to a region of approximately 25cM on Xp21.1-p22.3 
(Lewis et al. 1990; Zhu et al. 1990) which was substantially refined to 16cM between 
DXS237 and DXS451 (Stambolian et al. 1990). Progress on the genetics of NHS then 
slowed with only three more studies published between 1990 and 2000 (Bergen et al. 
1994; Toutain et al. 1997b; Zhu et al. 1998), when our study commenced. These 
studies ultimately reduced the critical region to 3.5cM of the genetic map, or 5.8Mb 
of the physical map, between STR markers DXS1053 and DXS443. 
3.1.2 X-linked cataract 
X-linked total congenital cataract (X-linked CCT [OMIIVI#302200]) without dental 
anomalies has also been reported, although its existence as an entity separate from 
NHS has been debated. Several families with varying phenotypes have been reported. 
Fraccaro et al. (1967) described a pedigree with cataract that appeared to be X-linked. 
Males presented with bilateral nuclear cataract while females had posterior sutural 
cataract with little effect on vision. This family demonstrated possible linkage to the 
Xg blood group on the X chromosome (Fraccaro et al. 1967). 
In 1969 Krill et al. reported a family with an apparently X-linked progressive 
cataract. Males presented initially with sutural opacities and punctate opacities of the 
nucleus and cortex that progressed to almost total cataract in older men. The females 
had a non-progressive sutural cataract. Intrafamilial variation between females was 
described and postulated to be caused by random X inactivation. Only one affected 
male had offspring and his one son was said to be unaffected although he was not 
examined by the authors. Because of the rarity of affected males with offspring in the 
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described pedigrees, it is difficult to definitively classify these pedigrees as X-linked 
in the absence of linkage studies. 
Recently, a pedigree was reported in which the males presented with severe cataract 
that required removal in the first few months of life. Some affected males also 
displayed cardiac abnormalities. Affected females had a milder central nuclear 
opacity not requiring treatment until the sixth decade (Francis et al. 2002). Again, 
none of the affected males had offspring, but linkage to the X chromosome was 
suspected based on the differences in phenotype between males and females, which 
are not reported in families with ADCC. Detailed linkage studies revealed significant 
linkage to the X chromosome, with the critical region being defined as less than 
2.5cM between markers DX59902 and DXS999 (Francis et al. 2002). This is within 
the 3.5cM NHS region between DXS1053 and DX5443 reported by Zhu et al. (Zhu et 
al. 1998). As these two disorders are now known to map to the same region, it is not 
certain whether isolated X-linked cataract is a separate disorder or allelic with NHS 
(Francis et al. 2002). Both disorders appear to be phenotypically variable between 
families and may in fact represent a spectrum with the same underlying molecular 
cause. 
3.2 Aims 
We aimed to identify the gene for NHS and assess its role in isolated X-linked 
cataract. We first used a linkage approach to confirm the linkage to Xp22.13 and 
investigated recombination events to refine the region. We then screened all 
characterised genes in the critical region for mutations in NHS patients. 
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3.3 Methods 
3.3.1 Pedigrees 
Cataract pedigree ascertainment and recruitment is described in Chapter 2.1.2. 
3.3.2 Simulations 
Simulations using the SLINK program (Ott 1989; Weeks et al. 1990) using a single 
marker with four equally frequent alleles over 200 replicates were carried out on all 
five pedigrees believed to be X-linked to determine the power of the study for linkage 
analysis. 
3.3.3 Linkage analysis 
Seven STR markers across 12cM of the X chromosome, encompassing the region 
previously shown to be linked to NHS, were typed in these five pedigrees. The map 
order was tel-DXS1224-2.8cM-DXS1053-2.3cM-DXS1195-0.1cM-DXS418-0.2cM-
DXS999-2.8cM-DXS365-3.2cM-DXS989-cen. Primer sequences for the PCR 
amplification of all markers are available from the Genome Database 
(http://www.gdb.org). Allele frequencies were estimated from 22 unrelated 
unaffected individuals from south-eastern Australia (frequencies are shown in 
Appendix 3). The disease gene frequency was set to 0.0001. A codominant model 
was used with penetrance set at 1.0 in hemizygous males and homozygous females 
and 0.5 in heterozygous females, to indicate incomplete penetrance as the exact level 
of penetrance is unknown. No other linkage studies for Nance-Horan Syndrome 
specify the model used. A report by Francis et al (2002) investigating isolated X-
linked cataract used both a recessive model and a dominant model. The exact 
penetrance in females is unknown in the case of NHS, but a recessive model seems 
unlikely given the numbers of females with a detectable phenotype. A conservative 
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value of 0.5 for heterozygous females was chosen. Two-point LOD scores were 
generated for each marker in MUNK (Lathrop et al. 1984, with modification by 
Cottingham et al. 1993) using crch2551 alone as well as all the families combined. 
Multipoint parametric LOD scores and haplotypes were generated with X-linked 
GeneHunter Plus (Kong and Cox 1997) using the same model as for two-point 
analysis. Map distances were obtained from the Genetic Location Database (GLD, 
http://cedar.genetics.soton.ac.uldpublic_html/ldb.html). When genetic distances are 
small they may be inaccurate due to low numbers of observed recombinations but the 
GLD maps integrate both physical and genetic information (Collins et al. 1996a; 
Collins et al. 1996b) and hence should be quite accurate. 
3.3.4 Identification of novel STR markers 
The sequences of clones making up contig NT_011586 were downloaded from 
Genbank (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Nucleotide)  and were 
searched for dinucleotide repeats of all combinations of greater than 15 repetitive 
units. The distance from published markers was determined in physical distance from 
the genomic sequence. Over such small distances, the genetic distances become 
innacurate and physical mapping is stronger. The sequence surrounding each 
dinucleotide repeat was then masked using Repeat Masker 
(http://ftp.genome.washington.edu/cgi-bin/RepeatMasker; A.F.A. Smit and P. Green, 
unpublished) to ensure it was not part of a larger complex repeat that would interfere 
with PCR amplification. Markers were named for the repetitive element followed by 
the clone name. Primers were designed for all remaining markers and sequences are 
given in Appendix 2. Allele frequencies for informative markers were estimated from 
22 unrelated unaffected individuals and are shown in Appendix 3. 
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3.3.5 Sequencing of candidate genes 
Coding exons from all genes in the critical region were directly sequenced in two 
affected females (V:3 and V:9), one affected male (V:5) and one unaffected female 
(III:6) from pedigree crch2551. Primer sequences used for the amplification of each 
exon are given in Appendix 2 and methods are given in Chapter 2.4 and 2.7.1. 
3.4 Results and Discussion 
3.4.1 Pedigrees 
Investigation of the pedigrees with congenital cataract collected in south-eastern 
Australia revealed two families with NHS (crch25 and crch51). Crch51 was the 
pedigree originally described by Horan and Billson (1974). Genealogical research 
revealed that the two families were related and the combined pedigree was named 
crch2551. A total of six generations, with DNA available from 11 affected individuals 
and 9 unaffected individuals across four generations, were identified (Figure 3.2). 
In addition to this family, four pedigrees (crch02, crch05, crch20 and crch24) 
appeared to have isolated X-linked cataract on the basis of the phenotype and a 
segregation pattern consistent with an X-linked trait (Figure 3.3). Carrier females 
presented with variable mild sutural cataract while the affected males had dense 
bilateral nuclear cataracts. The possibility of NHS was raised in pedigree crch02 but 
the dental phenotype was not typical and no mental retardation was noted (J.E. Craig, 
pers. comm.). 
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3.4.2 Simulations 
Simulations using SLINK in these five pedigrees indicated a maximum LOD score of 
4.68 using a single marker with four equally frequent alleles over 200 replicates. The 
average LOD score simulated in this group of pedigrees was 2.3 over 200 replicates 
for the study. For the X chromosome a LOD score of 2.0 is considered significant 
evidence for linkage. Whereas a LOD score of 3.0 is required for genome-wide 
significance, an X-linked disorder is already known to map to the X chromosome, so 
the threshold can be reduced to the same level as required for the confirmation of 
linkage to a single autosome (Lander and Kruglyak 1995). The analysis of crch2551 
alone revealed a simulated maximum LOD score of 2.1 with an average of 1.1, 
indicating that this pedigree theoretically may have sufficient power to demonstrate 
linkage in its own right (Table 3.1). 
Table 3.1: Simulated maximum and average LOD scores in X-linked pedigrees 
at 0=0.01. 
Pedigree 
Maximum 
LOD 
Average 
LOD 
CRCH2551 2.1 1.1 
CRCH02 0.8 0.4 
CRCH05 0.4 0.2 
CRCH20 0.3 0.2 
CRCH24 1.1 0.6 
All Pedigrees 4.6 2.3 
3.4.3 Linkage analysis 
3.4.3.1 Pedigree crch2551  
Two-point LOD scores were generated at a range of recombination fractions for all 
seven published markers by MLINK ( Lathrop et al. 1984, with modification by 
Cottingham et al. 1993) for pedigree crch2551 (Table 3.2). The maximum LOD score 
obtained was 2.39, indicating significant linkage at this marker. This score is larger 
than the maximum simulated score, most likely due to the unlikely situation of four 
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equally frequent alleles employed in the simulations. Crch2551 displays negative 
LOD scores for DXS1053, DXS1195, DXS365 and DXS989, indicating no evidence 
of linkage to these markers (at 0=0). 
Inspection of the haplotypes showed that all affected individuals share alleles at 
DXS418 and DXS999, the two markers that gave the highest two-point LOD scores 
(Figure 3.2). This suggested a common haplotype in this small region. Additional 
markers were required to confirm the haplotype and better define the recombinations 
observed in individuals VI:6 and V:2. No additional STR markers were available 
from the current databases, so novel dinucleotide repeats were identified from the 
draft human genome sequence (Appendix 2). Four of the eight typed markers were 
informative in pedigree c. rch2551. The LOD scores are presented in Table 3.2 and the 
haplotypes in Figure 3.2. 
Table 3.2: Two-point LOD scores for pedigree crch2551. 
Theta 0.00 0.001 0.01 0.02 0.03 0.04 0.05 0.10 0.20 0.30 0.40 
DXS1224 -03 -0.26 0.71 0.97 1.10 1.19 1.24 1.32 1.18 0.86 0.46 
DXS1053 -.0 -1.33 -0.36 -0.08 0.07 0.17 0.24 0.42 0.45 0.34 0.18 
DXS1195 -00 -2.60 -0.66 -0.10 0.20 0.41 0.55 0.92 1.01 0.81 0.46 
TG Z93022 1.19 1.18 1.16 1.14 1.11 1.09 1.07 0.95 0.72 0.50 0.27 
DXS418 2.39 2.38 2.34 2.30 2.25 2.20 2.16 1.91 1.42 0.91 0.41 
CA Z93929 1.49 1.48 1.45 1.42 1.38 1.34 1.31 1.13 0.76 0.40 0.12 
CA2 Z92542 1.73 1.72 1.69 1.66 1.62 1.59 1.55 1.37 0.98 0.61 0.27 
TG/AG Z92542 -.0 -1.91 -0.93 -0.66 -0.50 -0.40 -0.33 -0.13 0.00 0.02 0.02 
DXS999 -.3 0.06 1.02 1.27 1.40 1.48 1.52 1.57 1.32 0.92 0.47 
DXS365 -03 -5.57 -3.12 -2.40 -1.94 -1.61 -1.36 -0.64 -0.10 0.05 0.05 
DXS989 -.0 -3.62 -1.66 -1.09 -0.78 -0.56 -0.40 0.01 0.20 0.14 0.03 
*novel markers are named for the repetitive element followed by the clone name in 
which it was identified 
A shared haplotype was detected in the region of interest extending from TG Z93022 
to DXS999 (Figure 3.2). A recombination was observed inindividual VI:6 between 
CA2 Z32542 and DXS999, defining the proximal marker as DXS999. The distal 
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marker was also confirmed by a recombination in unaffected individual V:2 between 
DXS1195 and DXS418. The additional novel markers TG/AG Z92542 and TG 
Z93022 were not able to refine these recominations further as they were 
uninformative in the recombinant indivudual's mothers. A third recombination was 
observed between DXS999 and DXS365 in individual IV:6. This was not further 
investigated as it does not reduce the critical region for the NHS gene any more than 
the recombinations in individuals V:2 and VI:6. 
A multipoint analysis using X-linked GeneHunter Plus in crch2551 with all 11 
informative markers gave a maximum LOD score of 3.01 at CA2 Z92542, providing 
further significant evidence for linkage to this region (Figure 3.4A,B). Linkage is 
excluded by the large negative LOD scores distal to DXS1195 and proximal to 
DXS999, in agreement with the two-point LOD scores and observed recombinant 
events. TG/AG Z92542 gives negative LOD scores in both two-point and multipoint 
analyses, indicating no linkage to this marker even though it is within the region 
defined by the recombinants. The marker is homozygous in all affected individuals 
except V:3 and her daughters VI:3 and VI:4 so all linkage information comes from 
these individuals. Individual VI:4 has not been examined and therefore is coded as 
'unknown phenotype' in the anaysis. If she is coded as 'affected' the LOD scores are 
less negative. This marker is generally uninformative leading to small negative LOD 
scores, although the scores do become positive at larger values of theta, consitent 
with the positive scores at marker DXS999. Additionally, the maker is homozygous 
in the mother or recombinant individual VI:6, making it impossible to determine if 
the recombination event is distal or proximal to TG/AG Z92542 in the multipoint 
analysis. 
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in A. C. Information content of the markers used across the whole region. 
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GeneHunter Plus is restricted in the size of the pedigrees it can analyse. When the 
pedigree exceeds the maximum size, the program excludes individuals from the 
analysis, beginning with the least informative. For example individual V:2 was 
excluded, as he was unaffected and had no affected offspring. However, haplotype 
analysis revealed that individual V:2 was a recombinant and informative. Alternative 
individuals were therefore manually removed from the analysis to force the inclusion 
of this individual. The maximum LOD score obtained without individual V:2 was 2.9 
while a score of 3.0 was obtained with the inclusion of V:2. Both LOD scores provide 
significant evidence for linkage on the X chromosome, suggesting that in a fully 
penetrant single gene disorder where sufficient power is present, the overall 
significance of the results is unlikely to be greatly affected even when individuals 
who provide useful information are removed by the program. LLNKMAP from the 
LINKAGE package (Lathrop et al. 1984) was also used to confirm these multipoint 
results with a subset of markers from the study and consistent results were obtained. 
LlNKMAP can analyse pedigrees of arbitrary size, but is limited by the number of 
markers it can compute at one time. 
The recombinations observed in this pedigree, along with the significant two-point 
and multipoint LOD scores, indicate that the critical region for the NHS gene is 
defined distally by DXS1195 and proximally by DXS999. Additional recombinations 
observed in this pedigree and crch24 do not add further information. Following this 
discovery refinement of the NHS locus to the same region was reported by Toutain et 
al. in a study of 11 pedigrees with NHS. 
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3.4.3.2 Isolated X-linked cataract pedigrees  
Two point LOD scores were generated for each marker by MUNK. The values are 
presented in Table 3.3 for all 5 families combined and excluding crch2551. Although 
crch2551 provides most of the evidence for linkage, the smaller families are 
contributing positively to the signal (Table 3.3B). The negative LOD scores observed 
at most markers in Table 3.3A are considerably influenced by Crch2551, in which 
linkage is excluded to most markers by recombinant individuals. 
Table 3.3: Two-point LOD scores at a range of recombination fractions. A. All 
pedigrees, B. Excluding crch2551 
A. 
Locus 0.00 0.001 0.01 0.02 0.03 0.04 0.05 0.10 0.20 0.30 0.40 
DXS1224 - ,o -1.42 0.48 1.02 1.30 1.50 1.60 1.85 1.70 1.24 0.65 
DXS1053 ...3 -2.41 -0.46 0.09 0.38 0.57 0.71 1.01 1.00 0.73 0.37 
DXS1195 --. -2.30 -0.37 0.18 0.48 0.67 0.81 1.13 1.15 0.88 0.48 
DXS418 4.29 4.28 4.20 4.11 4.02 3.94 3.85 3.39 2.47 1.53 0.67 
DXS999 -.° -0.56 0.43 0.71 0.86 0.96 1.02 1.16 1.05 0.76 0.40 
DXS365 *3 -6.43 -3.10 -2.40 -1.44 -1.02 -0.72 0.10 0.54 0.48 0.25 
DXS989 ".3 -2.00 -0.06 0.47 0.75 0.93 1.05 1.29 1.13 0.71 0.27 
B. 
Locus 0.00 0.001 0.01 0.02 0.03 0.04 0.05 0.10 0.20 0.30 0.40 
DXS1224 -2.20 -1.16 -0.22 0.05 0.20 0.29 0.36 0.52 0.52 0.38 0.19 
DXS1053 --. -0.70 -0.10 0.17 0.31 0.40 0.46 0.60 0.55 0.38 0.19 
DXS1195 0.30 0.30 0.29 0.28 0.27 0.27 0.26 0.21 0.13 0.06 0.02 
DXS418 1.90 1.89 1.86 1.81 1.78 1.73 1.69 1.48 1.05 0.63 0.25 
DXS999 -0.62 -0.61 -0.59 -0.56 -0.54 -0.51 -0.49 -0.40 -0.26 -0.16 -0.07 
DXS365 -0.87 0.10 0.36 0.50 0.58 0.64 0.74 0.63 0.42 0.20 
DXS989 1.62 1.62 1.59 1.56 1.53 1.49 1.46 1.29 0.93 0.57 0.24 
Haplotypes were generated for each pedigree and are shown in Figure 3.3. Analysis 
of crch05 indicates that this pedigree does not demonstrate linkage to this region of 
the X chromosome because the discordant siblings in the third generation have the 
same haplotype passed down from their maternal grandmother. The phenotype of 
male individual III:3 was determined on clinical examination to be unaffected. This 
diagnosis can be accurately made in males as they appear to show complete 
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penetrance of the disease due to hemizygosity of the X chromosome. The genotyping 
was repeated and the same result was obtained, suggesting a different etiology for the 
cataracts in this pedigree. It is possible that there is a second X chromosome locus for 
isolated X-linked cataract, but it is also possible that this small family has an 
autosomal dominant form. Although the phenotype is much more severe in the one 
male present than in his female relatives who had mild sutural lens opacities, it is 
difficult to draw conclusions about sex-specific severity of the phenotype in this 
family. The other three small pedigrees (crch02, crch20 and crch24) have segregating 
haplotypes across the NHS region, consistent with linkage, but the pedigrees do not 
have sufficient power to give significant LOD scores individually. The phenotype in 
individual crch24 IV:2 is unkown as she was not examined by an ophthalmologist, 
although she appears to carry the risk haplotype. A recombination between DXS1224 
and DXS1053 in individual 	of crch24 indicates exclusion of the disease gene 
from the region distal to DXS1224 and is consistent with the findings in crch2551. 
While these smaller pedigrees appear consistent with linkage to this region of 
Xp22.13, supporting the hypothesis that NHS and X-linked cataract are allelic, they 
do not refine the critical region further as there are no recombinations within the 
region defined by pedigree crch2551. 
3.4.4 Candidate genes 
The critical region for NHS as defined by DXS1195 and DXS999 is 1.3Mb in length. 
There are 6 characterised genes in the region, all of which are candidates for NHS: 
SCML1, SCML2, RAI2, STK9, RS1 and PPEF1. 
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The Sex-comb on midleg-like 1 and 2 (SCML1 and SCML2) genes are transcription 
factors involved in the regulation of HOX genes. They have homology to the Sex-
comb on midleg (Scm) gene in Drosophila, which is involved in the regulation of 
transcription of homeotic genes, the Drosophila equivalent to the human HOX genes. 
Scm is a member of the Polycomb (PcG) group of genes, which are transcriptional 
repressors. These genes (along with the trithorax group that act as activators) ensure 
the correct spatial expression of the homeotic genes that drive normal segmental 
development in Drosophila (van de Vosse et al. 1998; Montini et al. 1999). Mice 
with mutations in the murine equivalent of the PcG genes display axial skeletal 
malformations and other abnormalities. Both SCMLI and SCML2 are involved in 
development, are expressed in a range of both adult and foetal tissues and are located 
within the critical region for NHS on Xp22.13. As such they were considered to be 
candidate genes for this disorder. 
RAI2 is the human homologue of the murine retinoic-acid induced gene. It was 
excluded as the causative gene for NHS by the direct sequencing of nine unrelated 
NHS patients (Walpole et al. 1999), however, we felt it important to confirm this 
finding in our pedigree. 
STK9 is a serine-threonine kinase with homology to cell cycle proteins (Montini et al. 
1998). This 20 exon gene is also expressed in a range of adult human and mouse 
tissues, including brain. Although its exact role has not yet been elucidated, it was 
considered to be a candidate for NHS. 
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Mutations of the RS1 gene have been shown to cause X-linked retinoschisis 
(XLRS1), which involves degeneration of the retina (Huopaniemi et al. 1999). This 
small 6 exon gene is almost exclusively expressed in the retina (Huopaniemi et al. 
2000). Given the syndromic features of NHS, this gene was not a promising candidate 
but was included in the study for completeness and because it causes an ocular 
phenotype. 
PPEF1 encodes a novel serine-threonine protein phosphatase with EF hand motif. 
The function of this protein has not been fully elucidated, but it is expressed almost 
exclusively in brain, particularly in sensory neurons derived from the neural crest 
(Montini et al. 1997). This gene was considered as a candidate because of its location 
within the critical region and undetermined target protein. 
All coding regions of these genes were sequenced in 65 amplimers (Chapter 2.7.1) 
with the primers listed in Appendix 2 in two affected females (V:9, V:3), one affected 
male (V:5) and one unaffected female (111:5) of pedigree 2551. The sequence 
obtained was compared to that in the Genbank. No segregating mutations were 
identified in the coding regions of these six genes, suggesting that they are not 
responsible for the phenotype in this family. Three non-segregating polymoprhisms 
were indentified and presented in Table 3.4. An A to G substitiution at nucleotide 796 
was detected in the RA11 gene, coding for K226R variant. An E42K variant was 
detected in the SCML1 gene an S7T in the PPEF1 gene. The variants did not 
segregate with disease in the four individuals sequenced and were not further 
investigated. The presence of cryptic splice sites or promoter mutations was not ruled 
out. Based on the nature of the disease (ie pleiotropic, developmental and severe), it 
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was thought that a coding mutation was more likely to account-for the disease rather 
than regulatory mutations. Also, although the genomic structure of the genes was 
known, their functions and regulation were not well defined, making it difficult to 
assess the key promoter regions. This approach did run the risk of missing a causative 
mutation. Investigation of predicted novel genes in the region was undertaken and is 
presented in Chapter 4. 
Table 3.4: Polymorphisms identified in candidate genes 
Gene l Nucleotide* Exon Variant Individual
RAI1 
Amino Acid Change 
796 Exon 1 A>G 1(226R V:3, V:9 
SCML1 123 Exon 4 G>A E42K V:9 
PPEF1 18 Exon 4 T>A S7T 111:5 
*Nucleotides counted from start of translation 
tOnly individuals V:3, V:5, V:9 and lII:5 were investigated 
No variants were confirmed in RS 1, SCML2 or STK9 in these 4 individuals 
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Chapter 4 
The Identification of the Nance-Horan Syndrome Gene 
4.1 Background 
The refinement of the Nance-Horan Syndrome (NHS) critical region and exclusion of 
the six candidate genes by direct sequencing in the large Australian pedigree 
described in Chapter 3 represents a significant advance in the knowledge of the 
genetics of NHS. However, the causative gene remained to be identified. We next 
undertook an investigation of predicted genes in the draft human sequence, both "in 
silico" and in vitro. 
4.2 Methods 
4.2.1 Prediction of novel genes 
There are numerous predicted genes and EST clusters in the region. We began the 
search for novel candidate genes for NHS by comparing computer predicted genes 
with mRNA and EST information mapping between DXS1195 and DXS999 on the X 
chromosome. GeneScan (Burge and Karlin 1997) predicts 22 genes in the region. 
This is the largest number of genes predicted by any of the programs represented at 
the University of California at Santa Cruz (UCSC) genome browser 
(http://genome.ucsc.edu), which at the time of analysis included Acembly 
(http://www.acedb.org/Cornell/acembly/),  Twinscan (Korf et al. 2001), Fgenesh++ 
(Salamov and Solovyev 2000), Geneid (Parra et al. 2000) and Genescan (Burge and 
Karlin 1997). These predictions were used as the basis for initial comparisons, and 
evidence such as ESTs from other species was compared to these. Expression profiles 
for predicted genes were investigated by the examination of the tissues from which 
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supporting ESTs were obtained. A candidate (similar to L0C90334) was chosen on 
the basis of its expression profile and conservation in the mouse and cow and the 
predicted structure is depicted in Figure 4.1A and B. 
4.2.2 RT-PCR for the identification of transcripts 
Primers were designed to capture the predicted exons of the chosen candidate by RT-
PCR. These are presented in Appendix 2, with the strategy depicted in Figure 4.1C. 
The reverse primers in predicted exons 4, 5, 6 and 8 were used in separate reactions to 
reverse transcribe total RNA from normal adult human brain (described in Chapter 
2.9) as the RNA used was known to have undergone some degradation (by 
visualisation on 1% agarose stained with ethidium bromide, Figure 4.1C). Therefore 
the predicted full-length transcript targeted by an oligo-dT primer would be relatively 
long and likely to be degraded. The four templates were then used in PCR reactions 
with appropriate combinations of primers targeted to the predicted exons. All RT-
PCR products were sequenced using the method described in Chapter 2.7.2. 
4.2.3 Mutation screening 
All detected regions of the novel gene (later determined to be causative for NHS) 
were sequenced in affected individuals from all X-linked pedigrees using intronic 
primers given in Appendix 2. Remaining family members were then screened for the 
identified mutations. Greater than 200 control chromosomes from unaffected, 
unrelated individuals collected from nursing homes in Launceston, Tasmania were 
screened for the identified mutations. 
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Figure 4.1. A. Predicted gene structure. B. key ESTs involved in the prediction. 
C. RT-PCR strategy for detection of transcripts and degraded human brain RNA 
leading to reverse transcription with gene specific reverse primers. D. RT-PCR 
products amplified with annealing temperature of 60°C on 1.5% agarose gel 
stained with ethidium bromide with expected and observed product sizes. PCR 
with primers 5F and 6R was further optimised to obtain a single band. 5'RACE 
product was amplified from a nested reaction with primer 5R and nested primer 
supplied with kit (see section 2.10) 
4.2.4 In Silico investigations 
Nucleotide and protein database searches were carried out through the website of the 
National Centre for Biotechnology Information (NCBI) by BLAST algorithms 
(Altschul et al. 1997) blastn, blastx and tblastx against the non-redundant (nr) 
databases, EST database (dbEST), high-throughput genomic sequences (htgs) 
database and species-specific databases. The putative promoter was identified using 
the Neural Network Promoter Prediction tool (Reese 2001) and subcellular 
localisation of the putative NHS protein has been predicted using PSORTIII 
(http://psort.nibb.ac.j p/form2.html). 
4.3 Results 
4.3.1 In silico identification of a novel candidate gene 
The expression profiles of predicted genes were investigated by examining the tissues 
from which ESTs supporting the prediction were obtained. Expression in eye was 
considered to be of importance, given the characteristic ocular features of NHS. 
One gene predicted by GeneScan matched ESTs extracted from human foetal eye and 
human brain, two tissues that are affected in NHS. This prediction was similar to 
L0C90334 in Genbank. Microsatellite marker DXS418, which gave the peak linkage 
signal, was located within a predicted intron. Further investigation of this predicted 
gene revealed identity to several spliced ESTs, from human, mouse and cow, 
providing evidence that the predicted exons are transcribed together and conserved 
amongst species. A reading frame was identified through all 8 predicted exons and 
the same gene was found to be predicted in the mouse genome in the syntenic region 
of chromosome X. There were many other predicted genes in the region, however, the 
lack of evidence for expression in eye and the lower level of conservation in mouse 
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led to them being given a lower priority. A BLAST search of the predicted protein 
against proteins in the databases did not reveal any significant homologies, indicating 
that this gene may encode a protein of novel class. The predicted gene structure and 
key ESTs are presented in Figure 4.1 along with the strategy for identifying 
transcripts. 
4.3.2 RT-PCR and sequence confirmation offragments 
Single PCR products were obtained with the primers designed to amplify predicted 
exons 3-4, 3-5, 5-6, and 6-8. No products were obtained by PCR with primers 
designed to capture exons 1 and 2. These two predicted exons are not predicted in the 
mouse sequence, although two alternative exons are postulated. The results of 
sequencing of RT-PCR products are presented in Figure 4.1D and 4.2A. The 
fragment amplified with primer 3F and 4R was of the predicted length (262 bp) and 
showed sequence identity with predicted exons 3 and 4. The 3' splice site of exon 3 
was found to be identical to the EST BF776631, which covers predicted exons 3, 4 
and 5 (Figure 4.1B), rather than the splice site predicted by GeneScan 60 bp further 
downstream. The fragment amplified with primers 3F and 5R was also of the 
predicted size (344 bp) and showed sequence identity with predicted exons 3, 4 and 5 
as expected. The 3' splice site of exon 3 was confirmed. The fragment amplified with 
primers 5F and 6R was 326 bp long. This was larger than the predicted size of 194 
bp. Sequencing of this product revealed sequence identity with predicted exons 5 and 
6, and also with a 132bp region in the predicted intron separating these exons. A 
novel exon, 5a, was identified from these results as indicated in Figure 4.2A. The 
sequencing of the PCR products obtained using primers 6F and 8R showed sequence 
identity with exons 6, 7 and 8 as predicted. These results indicate that the predicted 
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Figure 4.2. A. RT-PCR results; predicted exons plus exon 5a detected. No evidence 
for exons 1 and 2. B. 5'RACE results; exon 4a detected. No evidence  for exon 4 
splicing directly to exon 4a. Evidence for two isoforms. C. Final structure determined; 
exon 1 identified by RT-PCR, two isoforms and two open reading frames. Location of 
ESTs, Unigene clusters and human contigs indicated. 
gene is transcribed in normal adult human brain, although its structure is not exactly 
as predicted. 
4.3.3 Further investigations of genomic structure 
4.3.3.1 5'RACE  
In an attempt to identify the 5' region more accurately, 5' random amplification of 
cDNA ends (5'RACE) was used (Chapter 2.10). A smear containing products of 
varying molecular weight was obtained using primer 6R (Appendix 2) and the 
5'RACE primer provided in the kit (Invitrogen). This product was then used as a 
template for nested PCR using the 5'nested primer provided and primer 5R. A small 
specific product was obtained and was sequenced which revealed identity to a region 
in the predicted intron between exons 4 and 5. This novel exon is labelled 4a in 
Figure 4.2B. Forward and reverse primers specific to this exon were designed 
(Appendix 2) and RT-PCR carried out on the original brain cDNA used for the 
previous RT-PCR experiments. A band of the predicted size (137 bp) was detected 
using primers 4aF and 5R and was shown by sequencing to have the same sequence 
as the fragment detected by 5'RACE. No fragments could be amplified using 3F and 
4aR, suggesting that this novel exon does not splice to predicted exons 3 and 4 and 
raising the possibility of two isoforms. This is supported by the presence of only the 
one product amplified by primers 3F and 5R. 
4.3.3.2 RT-PCR to investigate the 5' end 
The work of Dr James McKay in this laboratory revealed that zebrafish (Danio rerio) 
EST AL926872 shows sequence similarity to predicted exon 3 at its 3' end and 
indicated the presence of additional sequence in the longer isoform. The 5' end of the 
EST was found to be homologous to human clone AL84533 that was unlocalised at 
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the time of the investigation. It has now been mapped distal to the identified gene in 
contig NT_038053. A forward primer was designed to capture this predicted 5' exon 
in conjunction with a reverse primer in predicted exon 3 (Appendix 2). A product of 
the predicted size was obtained and subsequent sequencing revealed the expected 
product. The acceptor splice site of exon 3 as predicted was confirmed, as was the 
donor splice site of the new exon, indicated as exon 1 in Figure 4.2C. There is an in 
frame methionine 565 nucleotides from the 3' splice site (Figure 4.2C). There are in 
frame stop codons upstream of this translation start site, indicating that there is no 
more coding sequence 5' to this ATG and this exon represents the first translated 
exon. Notably, the microsatallite marker defining the proximal end of the critical 
region, DXS1195, is within the large first intron of this gene (Figure 4.2C). 
Investigations are continuing into the structure and splicing alternatives of the 5' end 
of this gene. 
4.3.3.3 Identification of the promoter 
Work done by our collaborator Dr Jozef Gecz at the Women's and Children's 
Hospital, Adelaide, Australia, identified a NotI site indicating a CpG island upstream 
of exon 1. Analysis of the nearby sequence using Neural Network Promoter 
Prediction tool identified a transcription start site (score 1.0) at position -338 with 
respect to the putative ATG translation start site. This would make exon 1 903 bp in 
length. The sequence surrounding the transcription start site is: 
GCCCATTTATATAGGCGGCGGCGACGGCAGTGGCCGGgGTGGCGACG, 
with the first transcribed base (g) of the mRNA in lower case. This promoter has not 
been further investigated. 
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4.3.3.4 Identification of the 3'UTR 
Work also carried out by the group of Dr Gecz aligns Unigene EST clusters 
Hs.77385, Hs.282164 and Hs.21470 to form the 3'UTR of this gene as part of exon 8 
(Figure 4.2C). There is an in frame stop codon in exon 8, indicating the end of the 
coding region. A polyadenylation signal was identified in Hs.21470 3,538 bp past the 
stop codon, indicating the end of the transcript. Primers used for these RT-PCR 
experiments are given in Appendix 2. 
4.3.3.5 Genomic structure 
Overall, this novel gene, designated here as NHS was found to consist of 9 exons, 
which are possibly transcribed as two major isoforms A (8.7 kb), and B (7.7 kb). The 
longer isoform A consists of all exons except lb and contains an open reading frame 
encoding a putative 1630 amino acid protein with translation start methionine in exon 
1 (Figure 4.2C). The shorter isoform B consists of exons lb through 8 and encodes a 
putative 1335 amino-acid protein with translation beginning in exon 4 (Figure 4.2C). 
Intron/exon boundaries are given in Table 4.1. 
Table 4.1: Intron/Exon boundaries of the NHS gene. 
Exon 3'acceptor splice site 5' donor splice site Exon size 
(bp) 
Intron size 
(bp) 
1 GAGGCAGTGCgtgagtaccc 903 —350000 
2 tgtcttgcagCCGTCTCCAA CTGCGCAGAGgtgacagatc 153 4440 
3 tccttctcagAACACCGGAG CITITTAACGgtaagtttgg 134 27626 
lb CICTGACAAGgtaagtaaat 138 1217 
4 ttgtttgcagTCCCATCCCC AATGTTACTGgtatcgttct 193 2665 
5 tgggttgcagGAGTTGGCTT CAAGAAATAGgtgtgatatc 132 916 
6 tgtgccctagATTCTGATGA TCATTGAAAGgtcagtcact 2982 320 
7 ttattttaagAATCATCACC TCATTCACAGgtgaggcaac 127 3082 
8 tttctcaaagATCCAAGAGG GCAAATAAACGTGACTGCA 4134 
* Exons are indicated in capital letters, and introns in lower case. The consensus 
splice sites are indicated in bold. 
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4.3.4 Mutation screening 
4.3.4.1 Crch2551  
Individuals V:9, V:3, V:5, III:5 of pedigree crch2551 (Figure 4.3A) were directly 
sequenced at all coding fragments using primers in Appendix 2. One sequence variant 
was detected in exon 6 fragment D and consisted of a single C nucelotide insertion at 
position 2387, with nucleotide 1 being the first base of codon 1 in exon 1 (Figure 
4.3B, Figure 4.5). The insertion was identified in all affected individuals and no 
unaffected individuals. VI:4 is a female carrier of the mutation, but has not been 
examined clinically for NHS. The mutation was not detected in 202 control 
chromosomes from residents of nursing homes in Launceston, Tasmania, Australia 
who had been examined for eye disease. The insertion disrupts the predicted reading 
frame, resulting in a premature translation stop site, severely truncating the protein. 
4.3.4.2 Screening of X-linked pedigrees 
The other X-linked pedigrees in this collection were screened for mutations in this 
gene, including the entire 3'UTR. No mutations were identified in pedigrees crch02, 
crch20 or crch24. 
4.3.4.3 Ascertainment and screening of additional NHS pedigrees  
Additional NHS patients (and where possible their family members) were ascertained 
from Australia and the U.K. (Figure 4.4). Pedigree cwa70 is from Western Australia 
and was originally described in 1990 as having NHS (Walpole et al. 1990). Pedigrees 
UK1, UK4, UK5 and UK6 were diagnosed with NHS. Pedigrees UK2 and UK3 were 
believed to have isolated X-linked cataract (J.E. Craig and I.M. Russell-Eggitt, pers. 
comm.). Genotyping of the microsatellite markers previously used to detect linkage 
with this region revealed that pedigree UK2 contained no segregating haplotype and 
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Figure 4.3. A. Pedigree crch2551. Shaded symbols indicate presence of 
ophthalmologist-confirmed Nance-Horan Syndrome. Individual VI:4 has not 
been examined. B. Sequence variant 2387insC detected in pedigree crch2551 in 
exon 6 of the novel gene. 
the data were iriconsistent with linkage to this region. Pedigree UK2 was not 
investigated further. The data from all other pedigrees studied were consistent with 
linkage, as all affected individuals within each pedigree displayed a common 
haplotype, but were not significant evidence for linkage due to the small size of the 
pedigrees. 
Truncation mutations were detected in four of the five NHS families (Figures 4.4 and 
4.5). 3459deIC (Ala1153fs) was found in cwa70, 1117C>T (Arg378X) arising de 
novo was detected in a male infant from pedigree UK4, and pedigree UK1 revealed a 
400deIC (Arg134fs) mutation. Two sequence variants were identified in a female 
index case of UK5. This patient displays a C to G substitution in the 3' acceptor 
splice site of exon 3, as well as 718insG (G1u240fs) at the first base of the exon. The 
proband's mother displays the same genotype, indicating that the 2 mutations are in 
cis. All identified mutations resulted in a truncated form of the predicted protein and 
were absent in 200 control chromosomes. No coding mutations in this gene were 
detected in pedigree UK6 or the isolated X-linked cataract pedigree UK3. 
4.3.5 Expression analyses 
In addition to the RT-PCR carried out in human adult brain, work carried out in the 
laboratories of Dr Gecz and Dr Jamie Craig (Department of Ophthalmology, Flinders 
University, Adelaide, South Australia) have indicated that the NHS gene is expressed 
in all tissues tested. RT-PCR using the primers designed to amplify exons 6-8 was 
carried out in human adult and foetal brain, lens, retina, retinal pigment epithelium, 
lymphocytes, and fibroblasts. PCR amplimers were obtained from all tissues, 
although the levels in lymphocytes and fibroblasts were very low data not shown). 
Human Fetal Multiple Tissue Northern Blot 11 (cat# 7756-1, Clontech) was 
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Figure 4.4. Additional NHS pedigrees and identified mutations. Pedigrees without identified mutations can be found in 
Appendix 1. 
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Figure 4.5: Transcription map of critical region and genomic structure of the NHS gene with location of identified mutations. 
Intragenic microsatellite markers DXS1195 and DXS418 are indicated. NLS = putative Nuclear Localisation Signal. 
hybridised with 3 independent probes generated from exon 6, exons 6-8 and the 
3'UTR of the novel gene. Transcripts of approximately 8.5 and 7.5 kb were detected 
in all tissues analysed, which included brain, heart, skeletal muscle, colon, thymus, 
spleen, kidney, liver, small intestine, placenta, lung and peripheral blood leukocyte, 
all at low levels (not shown). A mouse aging blot, (cat# MBAB 1009-1 and product# 
1009-1-D103 Seegene) containing RNA from mouse brain tissues at different 
developmental stages indicated broad temporal expression in foetal and adult brain 
(Figure 4.6B). 
4.3.6 Computational analyses 
Work conducted by Dr McKay and Dr Gecz revealed orthologs in mouse, rat, 
chicken, cow, zebrafish and pufferfish with ESTs identified in all species. The 
genomic structure of the gene was shown to be conserved in mouse, rat and pufferfish 
through homology searches of genomic sequence and the GeneScan gene prediction 
program. The NHS protein shows no significant homology on BLAST search to any 
known protein or class of proteins and hence represents a novel class. Similarity 
between the NHS homologs is relatively high, with the human NHS protein 76%, 
76% and 42% identical to the mouse, rat and pufferfish NHS proteins, respectively. 
Four putative monopartite nuclear localisation signals were detected at amino acid 
positions 371-379: RRRKLRRRIC; 438-444: PSRRRIR; 822-825: RICPK; and 1026- 
1034: PGGSKRKPK. These are indicated on Figure 4.5. An NHS paralog (NHP) was 
identified on human chromosome 6. This predicted gene (similar to K1AA1357) has 
24% identity at the amino acid level by BLAST. EST information suggests that NHP 
is expressed in a range of tissues including foetal eye, is likely to have two isoforms 
and homologs exist in other species. 
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Figure 4.6. A. RT-PCR from human adult brain, fetal brain, retina and lens tissues. 
RNA was reverse transcribed and amplified using primers from exon 6 and 8. RT-minus 
controls were negative for each tissue. Expression was also documented from retinal 
pigment epithelium, placenta, lymphocytes, and fibroblasts. B. Mouse northern blot 
(Seegene, Korea) containing 20 mg of total RNA per lane from mouse brain at various 
developmental stages. The probe was generated from the 3' end of the mouse nhs gene. 
Hybridisation was carried out in ExpressHyb solution (Clontech) at 68°C as per 
manufacturer's instructions. (Experiments performed by Shiwani Sharma and Marie 
Shaw, Department of Ophthalmology, Flinders University, Adelaide, South Australia 
and Marie Shaw, Women's and Children's Hospital, Adelaide, South Australia) 
4.4 Discussion 
4.4.1 Evidence for the NHS gene 
Mutations resulting in the truncation and likely loss of function of the predicted 
protein have been identified in a novel gene segregating with NHS in 5 pedigrees. We 
have directly documented NHS gene expression in normal human lens and brain and 
in most other human tissues (some at very low level). Mouse expression data indicate 
expression in brain over multiple developmental stages. Therefore, this gene has an 
expression profile consistent with the spectrum of clinical features of cataract, dental 
abnormalities and mental retardation seen in NHS. 
4.4.2 The critical region 
Marker DXS1195 was defined as the distal marker of the NHS critical region 
(Chapter 3). However, this marker is in the first intron of the NHS gene. Therefore 
individual V:2 of crch2551 with the recombination proximal to this marker received 
exon 1 from his mother's (IV:2) affected chromosome and the rest of the gene from 
the non-disease chromosome. While there was no variation detected in exon 1 that 
would allow for direct confirmation of this, the three distal microsatellites (DXS1195, 
DXS1053 and DXS1224), clearly indicate that a recombination has occurred. The 
mutation in pedigree crch2551 is in exon 6 (Figure 4.5). Individual V:2 does not carry 
the mutation, as determined by direct sequencing, consistent with his unaffected 
status. The mutation is within the critical region identified by this individual (also 
defined by Toutain et al. (2002)). However, the mutation in pedigree UK1 is distal to 
this critical region (Figure 4.5). Therefore, the critical region identified by any given 
pedigree does not limit the entire gene to that region. A second pedigree (eg UK1 if it 
was large enough for linkage analysis) may define a different region, based on the 
location of the pedigree specific mutation. In the case of a gene spread over such a 
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large distance as NHS (approximately 400 kb), these regions may not necessarily 
overlap. What was actually identified in this study was a critical region for the 
causative mutation in pedigree crch2551. 
4.4.3 Analysis of the amino acid sequence 
The NHS gene is conserved, with uncharacterised orthologs in pufferfish, zebrafish, 
mouse, rat and cow. Based on EST information and draft assemblies where available, 
all species appear to have both isoforms. There is no significant homology to any 
characterised protein and therefore the function of the NHS gene and its product is 
unknown. A BLAST search of the protein sequence reveals limited homology to 
dentin sialoprotein. This is a serine-rich structural protein found in dentin, the layer of 
tooth below the outer enamel. The homology is due to the high serine content rather 
than actual significant sequence alignment. 
No known protein domains were detected by the blastp algorithm at the NCBI blastp 
program website. Four monopartite nuclear localisation signals (NLS) were detected 
(Figure 4.5). These consensus amino acid sequences target proteins to the nucleus. 
Whether or not these sequences are functional in this protein is under investigation in 
collaborating laboratories. The targeting of this protein to the nucleus would support a 
developmental role for the protein, consistent with the pleiotropic nature of NHS. The 
disorder is congenital, with multiple tissues affected from an early age. However 
diagnosis may be delayed as features are often difficult to recognise in early infancy 
because the teeth are not erupted. 
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4.4.4 The effect of the mutations 
All mutations identified are predicted to result in truncation of the protein, removing 
the putative NLS regions. There does not appear to be any genotype-phenotype 
correlations with regard to the removal of these putative nuclear localisation 
sequences. The phenotype is equally severe in individuals whose mutations remove 
all four signals (eg. UK1) as in individuals for whom the mutation does not affect 
these sequences (Cwa70) (Figure 4.5). Therefore, it is likely that the phenotype is 
caused at least in part by a loss of function, rather than simply a loss of subcellular 
localisation. Alternatively, truncation mutations can result in nonsense-mediated 
m1ZNA degradation, resulting in insufficient protein levels and haploinsufficiency 
rather than disrupted function. 
The mutations in pedigrees UK1 and UK5 in exons 1 and 3 respectively (Figure 4.5), 
indicate that loss of the long isoform is sufficient to cause disease. Additionally, in 
families bearing a mutation affecting only the longer isoform, there is no correlation 
between this and severity of disease. Therefore a disruption to the ratio of the two 
isoforms may play a role in etiology of the disease in these pedigrees. 
The short arm of the X chromosome contains many genes that escape X inactivation, 
including genes on Xp22 (Carrel et al. 1999). This would explain the apparent 
intermediate phenotype in females giving the appearance of co-dominant inheritance. 
Also, the ratio of isoforms may be further disrupted in females with a mutation 
affecting only the longer isoform. 
The significance of the two variants identified in UK5 is unknown. The G insertion 
results in a predicted truncated form of the protein, with the loss of the C-terminal end 
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of the protein. Alternatively, it is possible that the C/G substitution causes an 
alteration in the splicing of the NHS gene. Either mechanism is predicted to cause the 
loss of function of the NHS protein. 
4.4.5 Genetic heterogeneity or unidentified mutations? 
A mutation was not identified in NHS pedigree UK6. Although demonstrating typical 
NHS features, this pedigree is too small to demonstrate linkage to the NHS region. 
The NHS phenotype is quite variable, with features overlapping with other 
syndromes. Thus the absence of mutations in the pedigree UK6 index case could 
represent genetic heterogeneity. The phenotype may be caused by non-coding 
mutations undetected by the current study affecting splicing efficiency and/or relative 
amounts of the two isoforms, or there may remain additional exons to be identified, 
particularly at the 5'end. It is also plausible that mutations located some distance from 
the gene may produce expression of this phenotype. Such effects have recently been 
reported for another developmentally regulated gene, PAX6. Deletions approximately 
20 kb 3' to the polyadenylation signal were shown to prevent transcription of the 
allele, presumably by interfering with a locus control region (Lauderdale et al. 2000). 
4.4.6 Xcat mouse model 
The Xcat mouse phenotype has been proposed as an animal model of NHS, based on 
the phenotype of X-linked cataract and the localisation of the Xcat mutation to the 
syntenic region of the mouse chromosome X (Favor and Pretsch 1990). This 
phenotype should be examined in relation to the murine homologue of NHS. The 
mutation was originally created by radiation of DBA/2 male mice and the phenotype 
identified in an F 1 female (Favor and Pretsch 1990). The phenotype consists of a 
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bilateral total opacity of the lens in hemizygous males, with varying severity of 
nuclear and cortical opacity in heterozygous females. The mice do not display the 
dental features characteristic of NHS in humans and may be better described as an 
animal model of isolated X-linked cataract rather than NHS. 
4.4.7 X-linked cataract 
Recently, Francis et al. (2002) described a large pedigree with isolated X-linked 
cataract consisting of severe congenital cataract requiring extraction in males and a 
milder progressive phenotype in females. This phenotype was shown to link to a 
region overlapping with, but larger than the critical region for NHS, suggesting the 
disorders may be allelic. We identified 4 small pedigrees (crch02, crch20, crcii24 and 
UK3) with a phenotype and inheritance pattern suggesting X-linked inheritance. 
Haplotypes across Xp22 were consistent with linkage to this region, although there 
was insufficient power to generate a significant LOD score. No mutations were 
identified in the NHS gene in these pedigrees. It is possible that these pedigrees are 
not truly X-linked. This cannot be definitively confirmed with pedigrees of this size. 
Further characterisation of the promoter and distal regulatory elements of the NHS 
gene and investigation in larger X-linked pedigrees identified in other studies such as 
that of Francis et al. (2002) is required before it can be definitively excluded as the 
cause of isolated X-linked cataract. This phenotype may be caused by mutations in 
uncharacterised regions of the gene. Alternatively, a second gene in the region may 
be the cause of isolated cataract. There are many other predicted genes within the 
region localised by Francis et al. (2002). 
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One Australian pedigree and one UK pedigree were shown not to link to Xp22 by 
investigation of the haplotypes. However, the phenotype and inheritance pattern 
indicate X-linked inheritance. This suggests that there may be a second locus for X-
linked cataract on the X chromosome. 
4.4.8 Summary 
Our findings provide evidence that mutations in this novel gene, NHS, are causative 
of Nance-Horan Syndrome. This discovery will enable prenatal diagnosis in families 
known to have blindness and mental disability due to NHS, and facilitate early 
diagnosis in sporadic cases, followed by appropriate treatment. Further studies are 
required to establish the function of the NHS gene product, thereby identifing a novel 
molecular pathway for cataract development. In addition, delineation of NHS gene 
function will increase understanding of odontogenesis, craniofacial and neural 
development. 
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Chapter 5 
The Investigation of Crystallin Genes in Autosomal 
Dominant Paediatric Cataract Pedigrees 
5.1 Background 
The refractive index of the lens is the key to its ability to focus light onto the retina. 
There is a gradient of refractive index from the centre to the periphery created by a 
gradient of protein concentration (Kannabiran and Balasubramanian 2000). Lens fibre 
cells have around double the protein content of other cell types to maintain the 
refractive index (Francis et al. 1999). The a-, 13- and y-crystallins make up 80-90% of 
the soluble protein in the lens fibre cell (Hejtmancik 1998). They are crucial in 
maintaining the transparency and refractive index of the lens to allow the focussing of 
images onto the retina. 
The a-crystallins are members of the small heat shock family of proteins. They are 
expressed at high levels in the lens and act both as a structural component and as 
molecular chaperones, helping to maintain the stability of lens proteins and 
transparency of the lens throughout life (Horwitz et al. 1999). While aA-crystallin 
(CRYAA) is predominantly expressed in the lens, it can be found in trace quantities 
in other tissues such as brain, liver, spleen, retina and thymus (Vicart et al. 1998). 
aB-crystallin (CRYAB) is also abundantly expressed in lens, but in contrast to 
CRYAA is also expressed at relatively high levels in cardiac and skeletal muscle, 
brain, retina and lung (Vicart et al. 1998). Lens transparency is maintained by high 
levels of soluble protein remaining correctly folded and aggregated in solution. 
However, because proteins in the lens can be as old as the organism itself, a 
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mechanism is required to maintain their structural integrity and solubility. a-
crystallins are believed to play this role. Subunits of both CRYAA and CRYAB 
aggregate into variable heterogeneous multimeric protein structures with a molecular 
weight of 300,000 to 1 million Daltons. Each molecule can contain between 15 and 
50 subunits. This variability in quaternary structure has impeded attempts to elucidate 
the structure using common techniques (Horwitz et al. 1999). These large proteins are 
capable of binding irreversibly to unfolded or denatured protein, preventing 
inappropriate light scattering aggregation of all lens proteins. Whilst crystallins make 
up the majority of soluble lens fibre cell protein, the trace proteins such as 
glyceraldehyde-3-phosphate dehydrogenase, enolase, leucine aminopeptidase and 
aldehyde dehydrogenase are thought to be more susceptible to denaturation (Velasco 
etal. 1997). 
Several mutations in the CRYAA (Litt et al. 1998) and CRYAB (Berry et al. 2001) 
genes act in a dominant fashion to cause congenital cataract. The mutations cause a 
decrease in chaperone activity, and affect the quaternary aggregation of the protein 
leading to progressive opacification (Kumar et al. 1999; Shroff et al. 2000). The 
R116C mutation of CRYAA has been associated with a congenital zonular central 
nuclear opacity in a large family. The opacity in this family is progressive, with the 
development of cortical and posterior subcapsular cataract during the 4' decade (Litt 
et al. 1998). Functional studies of this mutation have indicated that the addition of 
cysteine at this position reduces the chaperone activity of CRYAA. The mutation 
affected the quaternary structure, with the mutant protein forming an aggregate of 
twice the size of wildtype protein at physiological temperatures (Shroff et al. 2000). 
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The equivalent residue of cryaB is Arginine-120. The R120G mutation of CRYAB 
was found in a family with both desmin related myopathy (a condition with weakened 
cardiac and skeletal muscle) and cataract segregating together (Vicart et al. 1998). 
CRYAB has been shown to interact with cytoskeletal components and may be 
involved in the remodelling of the cytoskeleton that occurs during development, and 
also following stresses (Bova et al. 1999). The R120G mutation of CRYAB appears 
to affect is ability to interact with other proteins, in particular the desmin intermediate 
filaments, causing inappropriate aggregation of this protein (Bova et al. 1999). In 
addition to this, the 450delA mutation of CRYAB has been associated with isolated 
posterior polar cataract. Unlike the opacity caused by the mutation to CRYAA, this 
opacity was not progressive (Berry et al. 2001). It is hypothesised that this mutation, 
which results in a shortened protein with 35 novel amino acids at the C terminus may 
affect both the post-translational modification of the protein, and its chaperone 
function. 
A mutation in CRYAA has also been reported to cause autosomal recessive congenital 
cataract. The W9STOP mutation was identified in the homozygous state in affected 
members of an inbred Persian family (Pras et al. 2000). This stop mutation would 
result in no expression of CRYAA protein in the cell. Heterozygosity was insufficient 
to cause disease, suggesting that the short abberant protein is unable to aggregate or 
precipitate to cause cataract in the way that dominant mutations do. It was shown that 
a targeted disruption of the cryaa gene in mouse caused cataracts with inclusion 
bodies consisting of CRYAB, suggesting that a mixture of CRYAA and CRYAB is, 
necessary to maintain the soluble quaternary structure. This was supported by in vitro 
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experiments indicating the ratio 3:1 CRYAA to CRYAB gave the highest chaperone 
activity (Horwitz etal. 1999). 
The p- and y-crystallins do not share structural similarities with the a-crystallins, but 
are expressed at very high levels in the lens fibre cells. They share both tertiary and 
secondary structure, consisting of two globular domains, each of which contains two 
Greek-key motifs, named for their similarity to a common element in Greek pottery 
(Hejtmancik 1998; Slingsby and Clout 1999) (Figure 5.1). Each Greek key motif 
consists of four anti-parallel 13-strands. The two Greek key motifs form a wedge 
shaped 13-sheet sandwich, containing hydrophobic side chains known as the py 
domain fold (Slingsby and Clout 1999). This burying of the hydrophobic side chains 
contributes significantly to the solubility of these proteins and hence the transparency 
of the lens (Francis et al. 1999). 
Figure 5.1.13y domain fold (from Slingsby C, Clout N. J. (1999) Structure of the crystallins, Eye 
13(3b): 395-402). 
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p-crystallins have N and C terminal extensions that allow the formation of oligomers 
not seen in y-crystallins which remain as compact monomers (Slingsby and Clout 
1999). The peptide sequence of the linker region between the two globular domains 
varies significantly between p and y crystallins and is also thought to be important in 
the dimer formation of the p-crystallins (Kannabiran and Balasubramanian, 2000). 
The p-crystallins are divided into acidic (BA1, BA2, BA3 and BA4) and basic (BB1, 
BB2 and BB3) groups, based on their charge. The basic proteins have both N and C 
terminal extensions, whereas the acidic proteins only have an N terminal extension 
(Slingsby and Clout, 1999). A second copy of CRYBB2 is present in the human 
genome but is thought to be a pseudogene on the basis of sequence changes at the 
splice sites compared with functional CRYBB2 (Brakenhoff et al, 1992). Each 
protein is encoded by a separate gene except for BA1 and BA3 which are encoded by 
the same gene using alternative translation initiation codons. The BA3 polypeptide 
has an extra 17 residues on the amino terminus (Werten et al, 1996). The P-
crystallins form homodimers as well as heterodimers of both basic and acidic forms. 
The largest oligomers are probably octamers (Kannabiran and Balasubramanian, 
2000). 
Truncation mutations have been reported in three P-crystallin genes. The shortened 
polypeptides lack the crucial fourth Greek-key motif necessary for correct folding, 
exposing hydrophobic residues (Slingsby and Clout 1999). The phenotypes associated 
with P-crystallin gene mutations include the Cerulean and Coppock-like cataract. 
Both are caused by the same truncating mutation, Q155X, of CRYBB2, which may 
result in the protein being unable to aggregate into higher order structures (Litt et al. 
1997; Gill et al. 2000). A pulverulent phenotype is also associated with a truncation 
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mutation, G220X, of CRYBB1 which results in insoluble protein and is probably due 
to the disruption of the fourth Greek-key motif. This may also be the mechanism 
involved in the truncation mutation of CRYBB2 (Mackay et al. 2002). A splice site 
mutation of CRYBA11A3 is associated with a zonular sutural cataract (Kannabiran et 
al. 1998). This mutation is predicted to either cause the formation of unstable mRNA 
or truncate the protein inappropriately. 
The lack of terminal extensions and the different linker region in y-crystallins allow 
the two domains to interact with each other, rather than with another molecule as the 
P-crystallins do. This gives the y-crystallins a very compact structure as monomers 
(Kannabiran and Balasubramanian, 2000). Seven of the y-crystallin genes are 
clustered on chromosome 2q33-q35, and the yS gene is located on chromosome 3 
(Santhiya et al. 2002). Within the chromosome 2 cluster, CRYGA and CRYGB are 
expressed early, and only at low levels. CRYGC and CRYGD are the most abundant y-
crystallins in the mature lens. CRYGE, CRYGF and CRYGG are pseudogenes in 
humans and are not expressed (Francis et al. 2000b). Pulverulent phenotypes are 
associated with two reported mutations of CRYGC, T5P and 235insGCGGC, both of 
which are likely to affect the folding of the protein (Heon et al. 1999; Ren et al. 
2000). The R168W mutation is associated with a lamellar cataract (Santhiya et al. 
2002). Mutations of CRYGD are associated with an aculeiform cataract (R58H) 
(Heon etal. 1999) and a progressive opacity of the embryonic nucleus (R14C) 
(Stephan et al. 1999). The R58H mutation probably introduces hydrogen bonds that 
affect protein folding (Heon etal. 1999), whereas the R14C mutation increases the 
surface hydrophobicity of the protein and is predicted to allow the formation of 
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intermolecular disulfide bonds. The mechanism of opacification may be similar to 
that in age-related cataract (Stephan et al. 1999). 
The phenotypes resulting from mutations of the crystallin genes indicate their 
importance in normal vision. Disruption to their structures results in lens opacities 
leading to severe visual impairment. This is the largest group of proteins shown to 
cause congenital cataract. At the outset of this study, mutations had only been 
described in five of these genes: CRYAA (Litt etal. 1998), CRYBA1/A3 (Kannabiran 
et al. 1998), CRYBB2 (Litt et al. 1997), CRYGC (Heon et al. 1999) and CRYGD 
(Heon et al. 1999), and were subsequently detected in CRYAB (Berry et al. 2001) and 
CRYBB1 (Mackay et al. 2002). Mutations in each of these identified cataract genes 
have so far been described in only a few pedigrees each and only 16 pedigrees have 
been identified with crystallin gene mutations. This is indicative of the heterogeneity 
of the disorder. In order to detect causative mutations in our south-eastern Australian 
familial paediatric cataract population, large families were assessed by linkage 
analysis, while the genes known to cause cataract at the beginning of this study were 
screened in smaller families by SSCP. We investigated crystallin genes known to be 
associated with non-syndromic congenital or paediatric cataract in 40 pedigrees with 
autosomal dominant or recessive inheritance. 
5.2 Methods 
5.2.1 Primer Extension Preamplification 
Genomic DNA from all individuals was amplified using the Primer Extension 
Preamplification method described in Chapter 2.4. 
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5.2.2 Linkage analysis simulations 
Simulations were carried out using the SUNK program (Ott 1989; Weeks et al. 
1990). A single marker with four equally frequent alleles was simulated with 200 
replicates at a recombination fraction of 0.05 for all extended pedigrees to determine 
those that were suitable for linkage analysis. 
5.2.3 Genotyping 
Microsatellite markers representing the seven crystallin genes were chosen on the 
basis of their proximity to the gene and their reported heterozygosities. The closest 
marker with a heterozygosity >0.7 was chosen (Table 5.1). CRYAB was not reported 
Table 5.1: Location of markers for linkage analysis of crystallin genes 
Gene Marker Chromosome 
Genetic Position 
of Marker (cM) 1 
Distance from 
Gene (Mb)2 
Distance from 
Gene (cM) 3 
CRYGD D2S2358 2 203.4 1.6 1.12 
CRYGC D2S2358 2 203.4 1.6 1.12 
CRYAB D11S1347 11 105.74 0.4 0.56 
CRYBA1 D17S841 17 50.74 0.04 0.04 
CRYAA D21S1890 21 52.5 0.2 0.34 
CRYBB2 D22S926 22 21.47 0.2 0.28 
CRYBB1 D22S926 22 21.47 1.2 1.67 
Genetic position obtained from the Marshfield map 
2  Physical distances obtained from the UCSC Human Genome Browser 
3 	- Distance from gene in cM calculated from region specific recombination rates 
(Payseur and Nachman 2000) 
in the literature as a cause of cataract until after the completion of the screening phase 
of the study (Berry et al. 2001), however a marker from chromosome 11 was included 
to represent this locus. Mutations of the CRYBB1 gene (Mackay et al. 2002) were also 
only reported recently however this locus is represented by the same marker as 
CRYBB2 as these genes map to the same region. Primer sequences were obtained 
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from the Genome Database (http://www.gdb.org). The four pedigrees were 
genotyped at all markers as described in Chapter 2.5. Allele frequencies were 
estimated from all founders in the pedigrees and are given in Appendix 3. 
5.2.4 Linkage analysis 
Two-point linkage analysis was carried out in MUNK, part of the FASTLINK 
package (Lathrop et al. 1984, with modification by Cottingham et al. 1993). Disease 
gene frequency was set to 0.0001. Penetrance was set at 0.0 in wild type 
homozygotes and 0.95 in heterozygotes and mutant homozygotes, indicating highly 
penetrant dominant inheritance, reflecting the pattern of segregation observed in the 
pedigrees. LOD scores were calculated at a range of recombination fractions between 
0 and 0.5 for each marker. Affected individuals of linked pedigrees were then 
sequenced at the appropriate candidate genes as described in Chapter 2.7.2. 
5.2.5 Single Stranded Conformational Polymorphism Analysis 
The proband from each pedigree was screened by SSCP analysis, as described in 
Chapter 2.6, at coding exons of CRYAA, CRYBAl/A3, CRYBB2, CRYGC and 
CRYGD. CRYAB and CRYBB1 had not been linked to congenital cataract at the 
beginning of this study and were therefore not included. Primer sequences for PCR 
amplification of all exons are given in Appendix 2. Samples showing altered 
mobility, together with other family members, were further investigated by direct 
sequence analysis of genomic DNA using methods described in Chapter 2.7.2. As 
congenital cataract is a heterogeneous disorder and it was expected that each pedigree 
would be likely to have a different mutation, unaffected controls were not included. 
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5.2.6 Restriction digest 
Exon 3 of CRYBA1/A3 was amplified by PCR, as described in Chapter 2.3, from all 
individuals of pedigree crch08. Ten ill of PCR product were digested with 1U of 
NlaIII (New England Biolabs) at 37°C for 1 hour. Products were electrophoresed on 
2% agarose gel and stained with ethidium bromide. 
5.2.7 Denaturing High Performance Liquid Chromatography (dHPLC) 
Family members of pedigree ctas17 and 50 unaffected unrelated residents of 
Tasmanian nursing homes were screened for CRYGD mutations using dHPLC as 
described in Chapter 2.8. Individuals from pedigree ctas17 (IV:3. N:7, V:15 and 
VI:8) who had been sequenced were used as positive controls. The fragment was 
injected onto a Varian Helix dHPLC column at 64°C. 
5.3 Results 
5.3.1 Linkage analysis simulations 
Results of the simulations are given in Table 5.2. A recombination fraction of 0.05 
was chosen as the markers to be used in the analysis would not be within the 
candidate gene. Four pedigrees were determined as suitable for linkage analysis; 
crch13, crch30, crch32 and ctas17 (Figure 5.2). Pedigree crch08 would also have 
provided sufficient power, however a causative mutation was identified in this 
pedigree by SSCP prior to this pedigree being typed at the described microsatellite 
markers. Pedigree ctas16 appears to be quite large (Appendix 1) but only ten samples 
were available thereby reducing the power to detect linkage. 
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Figure 5.2. Pedigrees used in linkage analysis: A. Crch13, B. Crch30, C. Crch32, D. Ctas17. 
Table 5.2: Simulated maximum and average LOD scores in pedigrees with 
autosomal inheritance. 
Pedigree 
Maximum 
LCD 
Average 
LCD 
CEEH42 0.74 0.26 
CRCH08 7.80 4.30 
CRCH10 0.65 0.32 
CRCH13* 5.07 2.11 
CRCH19 1.27 0.42 
CRCH23 1.39 0.53 
CRCH27 0.95 0.36 
CRC H28 0.89 0.33 
CRCH30* 2.54 0.91 
CRCH32* 9.32 5.89 
CTAS16 1.02 0.22 
CTAS17* 6.33 3.55 
* Pedigrees selected for linkage analysis. 
5.3.2 Linkage analysis 
Table 5.3 shows the results of the linkage analyses: LOD scores at a range of 
recombination fractions and the maximum LOD scores. A significant result was 
obtained for pedigree crch13 at a marker representing the Connexin 46 (CX46) gene 
and is discussed in Chapter 6. This pedigree was not typed at the remaining loci. 
Pedigree crch30 did not provide any evidence for linkage at the y-crystallin locus 
(CRYGC and CRYGD), CRYAA nor CRYBB2. Results at the two remaining loci were 
equivocal. This pedigree is relatively small and of borderline power for detecting 
linkage as indicated by the SLINK simulations (Figure 5.2, Table 5.1). To obtain a 
significant result at the remaining loci would require typing additional markers that 
may be more informative in this particular pedigree. Additionally, multipoint analysis 
and inspection of the haplotypes could provide more information. Due to time 
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constraints and the identification of other significant results to investigate, this has not 
been done at this time. 
Linkage to the five crystallin loci could be excluded for pedigree crch32. Marker 
Dl 1S1347 is only excluded to a recombination fraction of 0.002, however, since the 
CRYAB gene is only about 250 kb from this marker (Nov. 2002 assembly), linkage to 
the gene of interest can be excluded. 
A significant result of 3.72 at 0=0.06 from D2S2358 (representing the y-crystallin 
locus) was obtained for pedigree ctas17. Following this result, this pedigree was not 
typed at the remaining loci. 
Table 5.3: Two-point LOD scores calculated with founder frequencies. 
Pedigree Gene Marker 0.0 , 0.1 0.2 0.3 0.4 max LOD theta 
crch13 CRYGC/GD D2S2358 -11.53 -2.64 -1.15 -0.44 -0.10 0.00 0.50 
CRYBA1 D17S841 -8.32 -2.89 -1.43 -0.64 -2.0 0.00 0.50 
crch30 CRYGC/GD D2S2358 -8.62 -3.39 -1.78 -0.89 -0.33 0.00 0.50 
CRYAB D11S1347 -5.25 -1.48 -0.84 -0.46 -0.19 0.00 0.50 
CRYBA1 D17S841 0.10 0.08 0.07 0.05 0.02 0.10 0.00 
CRYAA D21S1890 -0.69 0.30 0.29 0.18 0.06 0.32 0.14 
CRYBB2 D22S926 -4.10 -1.23 -0.64 -0.35 -0.15 0.00 0.50 
crch32 CRYGC/GD D2S2358 -20.87 -3.39 -1.64 -0.50 -0.02 0.04 0.45 
CRYAB D11S1347 -5.21 0.53 0.65 0.52 0.29 0.66 0.18 
CRYBA1 D17S841 -7.33 -2.00 -0.72 -0.14 0.06 0.07 0.42 
CRYAA D21S1890 -6.62 -1.38 -0.22 0.16 0.17 0.20 0.37 
CRYBB2 D22S926 -16.44 -7.70 -1.11 -2.05 -0.78 0.00 0.50 
ctas17 CRYGC/GD D2S2358 2.94 3.61 2.89 1.88 0.80 3.72 0.06 
CRYBA1 D17S841 -11.27 -4.06 -2.10 -1.03 -0.39 0.00 0.50 
5.3.3 Mutation identification in pedigree etas] 7 
The two crystallin genes previously shown to segregate with congenital cataract at 
this locus, CRYGC and CRYGD, were sequenced in three affected and one unaffected 
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individual in pedigree ctas17. Two sequence variants in CRYGD were identified. The 
first was a synonymous C—>T substitution at nucleotide 51, the third base of codon 17 
encoding tyrosine (Figure 5.3A). This polymorphism does not affect the protein and 
was previously described by Heon et al. (1999). The second was a non-synonymous 
C—>A transversion at the first base of codon 24 (nucleotide 70), resulting in an amino 
acid substitution from proline to threonine (Figure 5.3B). Both these mutations were 
then screened in the entire pedigree and 100 normal chromosomes by dHPLC. Four 
profiles were observed, corresponding to wild type at both loci, heterozygous at base 
51, heterozygous at base 70, or heterozygous at both, as determined by sequencing a 
subset of individuals (Figure 5.4A). The 51C—>T polymorphism did not segregate 
with disease in the pedigree and was found at a prevalence of 25% in controls (Figure 
5.4B). The P24T mutation segregated with disease (Figure 5.3C) and was not 
detected in controls or any other pedigree in the collection (Figure 5.4B). 
The phenotype in pedigree ctas17 is quite severe. All affected individuals had surgery 
prior to age 3 years, with the exception of two patients who had surgery at 
approximately 7 years of age. Thus the cataract phenotype was only well documented 
for a few patients. It was described as possessing a flaky nuclear cataract, which 
looked like silica and was associated with a poor red reflex. Aphakic acuities varied 
from 6/6 to no perception of light. Thirteen of the 20 patients with documented 
acuities had at least 6/15 vision in one eye. Nystagmus was rare and only two family 
members were legally blind (<6/60) (D.A. Mackey, pers. comm.). 
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5.3.4 Single-Stranded Conformational Polymorphism Analysis 
Since many of the pedigrees are too small to detect linkage, SSCP was used to screen 
them for mutations in the five crystallin genes previously found to cause non-
syndromic inherited cataract. Probands from the large pedigrees studied by linkage 
analysis were also included, in case mutations could be detected by this methodology 
where linkage results were inconclusive. SSCP screening revealed one causative 
mutation and four polymorphisms (Table 5.4, Figure 5.5). All mutations identified in 
PEP DNA through SSCP were subsequently confirmed by direct sequencing of 
genomic DNA, indicating that the use of PEP DNA did not introduce spurious SSCP-
positive PCR artifacts. Interestingly, the CRYGD P24T mutation detected in pedigree 
ctas17 following linkage analysis was not detected in the proband by SSCP. 
Table 5.4: Variants of crystallin genes detected by SSCP in familial cataract 
families. 
Gene Exon/ 
Intron 
Pedigree Position Base 
Change 
Predicted Effect on 
Protein 
Crystallin 
BA1/A3 
Exon 3 Crch08 +1 G—A Donor Splice Site 
Crystallin 
BA1/A3 
Exon 5 Multiple Codon 
148 
C—>T None (Gly) 
Crystallin 
BA1/A3 
lntron 
2 
Crch10 +73 T—>G None 
Crystallin 
BA1/A3 
Intron 
3 
36, 39, 41, 
45 
+16 C—>T None 
Crystallin 
BB2** 
Intron 
3 
Crch40 +1 G—>A Donor Splice Site 
* Intron position numbers refer to the number of nucleotides past the 3' end of the 
exon. 
**The variant observed in CRYBB2 is most likely in the pseudogene CRYBB2-2. 
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Figure 5.5. SSCP shifts observed (marked with an arrow) and sequencing of appropriate individuals. A. CRYBAl/A3, 
exon 3 shift 1. B. CRYBAI/A3 exon 5. C. CRYBA1/A3 exon 2. D. CRYBAl/A3 exon 3 shift 2. E. CRYBB2 exon 3. 
A gel shift was observed by SSCP in the CRYBAl/A3 gene in the large pedigree 
crch08 prior to linkage analysis being carried out. The clinical features of the phakic 
patients in this Australian family of European origin showed a consistent spectrum of: 
1) Y-sutural opacities, 2) mild opacification throughout the region of the foetal 
nucleus, and 3) peripheral cortical dot opacities, all with variable severity. Some 
patients were operated on in childhood, whilst some older mildly affected individuals 
with good acuity were unaware of the diagnosis prior to our study (D.A. Mackey, 
pers. comm.). The phenotype is depicted in Figure 5.6A. 
The CRYBA1/A3 gene was sequenced from genomic DNA and a G-->A transversion 
was detected at the intron 3 5' donor splice site (Figure 5.5A). This mutation 
cosegregates in pedigree crch08 with autosomal dominant congenital cataract (Figure 
5.6B) as demonstrated by RFLP analysis. The mutation introduces a restriction site 
for N1a111, resulting in three fragments in affected heterozygotes although the smallest 
band was not clear on the gel. Individual 11E3 of pedigree crch08 does not have 
clinically relevant cataract. He was initially diagnosed as unaffected but was 
reassessed once his status as carrier of the mutation was identified. Mild opacities 
consistent with his age were noted, but it is not conclusive whether he has the same 
phenotype as the remainder of the pedigree. This may represent reduced penetrance 
of the mutation, or a broader spectrum of the clinical features than originally thought. 
A silent polymorphism in the third base of codon 148 (C-->T) was detected in exon 5 
of the CRYBA1/A3 gene in 5 pedigrees (Table 5.4, Figure 5.5B). Polymorphisms were 
also detected in introns 2 and 3 of this gene in 1 pedigree each. None segregated with 
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Figure 5.6. A. Photograph of the lens of individual IV:6 of pedigree crch08 showing the opacities of the nucleus and cortex. 
B. Restriction Fragment Length Polymorphism analysis of the mutation detected at the donor splice site of exon 3 of the 
CRYBAI/A3 gene in pedigree crch08. Shaded symbols indicate presence of ophthalmologist-confirmed cataract. The proband is 
indicated with an arrow. Wild type individuals display only the 263bp band, representing the undigested product. Individuals 
heterozygous for the mutation display the indigested 263bp band and the 172bp representing the digestion product. The 
remaining 91bp band is not clear on the gel. 
disease (Table 5.4, Figure 5.5C & D) as determined by direct sequencing of 
additional family members. 
A 	transversion was identified at the 5' donor splice site of intron 3 of the 
CRYBB2 gene (Figure 5.5E) in a small nuclear pedigree (crch40) with a posterior 
subcapsular autosomal dominant congenital cataract. However this mutation did not 
segregate with disease as it was present in the unaffected father and only one of his 
two affected offspring. The affected mother was wildtype at this nucleotide position 
(Figure 5.7). This mutation may in fact be in the CRYBB2 pseudogene fragment 
CRYBB2-2. 
5.4 Discussion 
5.4.1 Patient ascertainment 
The pedigrees studied represent a comprehensive collection of almost all inherited 
cataract in south-eastern Australia. All patients with cataract requiring surgery in the 
Australian states of Victoria, Tasmania and southern New South Wales are referred to 
the Royal Children's Hospital and the Royal Victorian Eye and Ear Hospital, 
Melbourne, Australia. Only those cases of inherited cataract where none of the family 
members required specialist medical care would have been overlooked (Wirth et al. 
2002) although the study did not include sporadic cases that may later be shown to be 
familial (eg. de novo mutations or recessive inheritance). Participation rates were 
high, and consequently the pedigrees are likely to be representative of familial 
cataract in south-eastern Australia. This collection is valuable for the determination of 
the relative contribution of each congenital cataract gene to the overall causes of 
congenital cataract as well as for the identification of cataract genes. 
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Figure 5.7. Crch40 with genotypes observed at the exon 3 donor splice site of 
CRYBB2, thought to reflect genotypes of putative pseudogene CRYBB2-2. 
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Figure 5.8. PSIPRED predictions of the structure of human CRYGD protein A. Wild 
type B. P24T mutation. Yellow arrows represent n-sheet. Green cylinders represent a-
helix. The confidence in the prediction is indicated by the height of the blue bars at 
each amino acid on a scale of 1-10. 
5.4.2 Crystallin gene mutations 
Mutations in seven crystallin genes (Litt et al. 1997; Kannabiran et al. 1998; Litt et 
al. 1998; Eldon etal. 1999; Ren et al. 2000; Berry et al. 2001; Mackay etal. 2002) 
have been shown to cause monogenic paediatric cataract, although only five (CRYAA, 
CRYBA1/A3, CRYBB2, CRYGC, CRYGD) had been reported at the commencement of 
this study. Mutations in crystallin genes represent 45% of the reported paediatric 
cataract mutations to date. We screened all genes by linkage and the five latter genes 
by SSCP in a familial cataract population from south-eastern Australia, and detected 
two causative mutations: CRYGD P24T and a CRYBA1/A3 splice site mutation, as 
well as five non-disease causing polymorphisms. 
5.4.3 Mutations of CRYGD 
Several other mutations of CRYGD have been reported. An R58H mutation has been 
associated with aculeiform cataract (Heon et al. 1999), an R14C mutation with a 
juvenile onset punctate progressive form (Stephan etal. 1999), an R156X mutation 
with a central nuclear phenotype (Santhiya et al. 2002) and R375 was reported as a de 
novo mutation in a boy with a crystalline cataract (Kmoch et al. 1999). The P24T 
mutation identified in ctas17 is associated with a nuclear phenotype and was 
previously shown to cause lamellar cataract in an Indian pedigree (Santhiya et al. 
2002). Although CRYGD is expressed throughout the lens from the early stages of 
lens fibre cell differentiation, different mutations of this gene can have remarkably 
different effects on lens phenotype, and the one mutation (P24T) can cause different 
phenotypes. Such phenotypic heterogeneity has been reported for the Q155X 
mutation of CRYBB2 which has been detected in three pedigrees with different 
phenotypes. The first family had Cerulean cataract (Litt et al. 1997), the second 
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possessed a Coppock-like phenotype (Gill et al. 2000) and the third had sutural 
cataract with punctate and Cerulean opacities (Vanita et al. 2001a). 
The Indian study of Santhiya et al. (2002) investigated seven small pedigrees with 
varying types of autosomal dominant congenital cataract and found mutations in the 
CRYGD gene in two of them. In contrast, our study involves 34 autosomal dominant 
congenital cataract pedigrees, with only one CRYGD gene mutation identified. This 
difference in the prevalence of y-crystallin mutations may reflect ethnic differences 
between the south-eastern Australian population, which is predominantly of European 
descent, and the Indian population, or may have occurred by chance considering the 
relatively small number of families studied. 
5.4.4 Predicted effects of P24T mutation on CRYGD structure and function 
P24 is in the third 13-sheet of the first Greek-key motif. The structure of the 7- 
crystallins has been solved by X-ray diffraction, but structural prediction programs 
such as PSI-PRED (http://bioinfics.ucl.ac.uk/psipred)  do not predict a 13-sheet at this 
location. PSI-PRED predicts codon 24 to be in a linking region between the second 13- 
sheet and a short a-helix. The substitution of the proline at this location for the 
mutant threonine removes the prediction of the helix (Figure 5.8). X-ray diffraction of 
bovine CRYGD has indicated that this region is in fact a short 13-sheet (Chirgadze et 
al. 1991). However, most species, including the cow, have a serine at residue 24 of 
CRYGD whereas all human y-crystallins have a proline that is the site of the mutation 
in this pedigree. 
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Like human CRYGD, bovine yB-crystallin has a proline at this position and X-ray 
diffraction of this protein shows n-sheet in this location indicating that a wild type 
proline is compatible with the Greek-key motif formation (Wistow etal. 1983). The 
substitution identified in ctas17 replaces this proline with threonine, a polar amino 
acid. The wildtype serine in bovine and murine CRYGD forms a hydrogen bond with 
Asn50, whereas the proline in humans does not. It is possible that the introduction of 
the polar amino acid in the human CRYGD forms a similar hydrogen bond, which 
may affect the structure and stability of the protein in the human lens. Similarly the 
R58H mutation of CRYGD, reported in a pedigree with aculeiform cataract, is 
predicted to introduce a hydrogen bond that could affect the three-dimensional 
structure of the protein (Heon etal. 1999). 
5.4.5 Possible effect of P24T on splicing efficiency 
Splicing of exons is a process that is not well understood. It is widely accepted that 
there are well conserved consensus sequences that indicate exons to the splicing 
machinery, such as the 5' and 3' splice sites and the intronic branch site. However, 
while these signals are necessary for correct splicing, they are not sufficient. Recently 
a group of proteins responsible for the enhancement of exonic splicing have been 
reported (Cartegni et al. 2002). These proteins are rich in serine and arginine and 
hence are called SR proteins. They bind to consensus sequences within exons known 
as exonic splicing enhancers (ESEs). Additionally, there are similar proteins that 
exert a silencing effect although these are even less well characterized (Cartegni et al. 
2002). The CRYGD exon 2 sequence was searched for these ESEs around the position 
of the mutation identified in ctas17 using the ESE finder (http://exon.cshl.edu/ESE/) . 
Scores above a threshold indicate the presence of a putative ESE. Recognition sites 
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with scores above the threshold values were identified for proteins SF2/ASF, SC35 
and SRp40 in this region of exon 2 of CRYGD (Table 5.5). When the P24T mutation 
was introduced, the two overlapping binding sites for SC35 were lost. 
Table 5.5: Scores obtained for SR protein binding sites around the P24T 
mutation of CRYGD. 
Protein 
Threshold score* 
SF2/ASF 
1.956 
SC35 
2.383 
Srp40 
2.670 
Wildtype 
Mutant 
3.018 
4.011 
2.714, 2.589** 3.082 
4.819 
* The threshold score is the score required before a site is deemed to be a putative 
ESE (Cartegni et al. 2002). 
** Two overlapping sites were detected for SC35. 
The presence of a score above the threshold indicating a consensus binding site does 
not necessarily indicate an active ESE and the highest score is not necessarily the best 
ESE (http://exon.cshl.edu/ESE/) . The mechanisms of ESE action have not yet been 
fully elucidated and certain combinations of sites in a particular location may be 
required. There could also be a silencer that negates the effect of the ESE. 
Nevertheless, it is possible that the P24T mutation has its effect on the phenotype not 
by destabilising the protein, but by affecting splicing of the pre-mRNA, resulting in 
unstable messenger or aberrant protein. Interestingly, the mouse CRYGD sequence 
displays similar consensus sites to the human gene in this area, despite having a 
serine at codon 24 where humans have a proline. The SRp40 site is in exactly the 
same position, although the SC35 site is shifted 3bp upstream and the SF2/ASF site is 
shifted 5bp upstream. Again, it is difficult to determine which of these, if any, are 
actually having an effect without further studies. 
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5.4.6 Predicted effects of CRYBA1 /A3 splice site mutation 
The splice site mutation in intron 3 of the CRYBA1/A3 gene described here segregates 
with disease and is likely to be causative. A mutation identical to that found in the 
present study was previously reported by Kannabiran et al. (1998) in a three-
generation Indian family with posterior and anterior sutural cataract and not found in 
a control population of 140 chromosomes. The phenotype in pedigree crch08 appears 
to match the description of the phenotype in the Indian family. The mutation would 
affect both the CRYBA1 and CRYBA3 proteins as both are translated from the same 
mRNA (Werten et al. 1996). The same base was reported as substituted for a C in 
another pedigree with a similar phenotype (Bateman et al. 2000). 
Mutations of this base are predicted to disrupt the splicing of the mRNA of this gene. 
There are several possible outcomes. It could cause skipping of exon 3 altogether, 
with exon 2 splicing directly onto exon 4. Alternatively, the mutation could cause 
intron 3 to remain in the rnRNA or the recruitment of a cryptic splice site. All these 
possibilities would result in a premature termination of the polypeptide and 
incomplete folding of the Greek-key motifs or degradation of the unstable mRNA 
(Kannabiran et al. 1998). 
The analysis of this region with the ESE finder revealed that the mutation introduces 
a binding site for the SR protein SF2/ASF. ESEs are by definition in the exons 
themselves and this splice site mutation is in the intron. SR proteins are thought to act 
by promoting the binding of proteins involved in splicing, early in spliceosome 
assembly (Liu et al. 1998). Hence, if SF2/ASF were to bind to the newly created 
recognition site, it may not be able to promote the binding of the splicing machinery 
to the splice site. ESTs representing the murine homologue of this gene were 
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expressed in the embryonic eye (Unigene database, 
http://www.ncbi.nlm.nih.govientrez/query.fcgi?db=unigene)  hence this protein may 
be involved in the normal splicing of CRYBA1/A3 mRNA. 
5.4.7 Silent polymorphisms 
The silent C-->T transition in exon 5 of the CRYBA1 /A3 gene was detected in 13% of 
the families studied. Population frequencies of this allele were not assessed as it did 
not appear to cause disease. A silent C—>G transversion at this same base was 
described by Bateman et al. (Bateman et al. 2000) in a large Brazilian family with 
congenital cataract. Recently it has been found that many so called 'silent mutations' 
may actually have an effect on mRNA splicing (Cartegni et al. 2002). This region of 
exon 5 of CRYBAl/A3 was investigated for ESEs but none were identified in the 
region. The other two CRYBAl/A3 polymorphisms detected in our study were 
intronic, and not predicted to have an effect on the amino acid sequence. All these 
polymorphisms are likely to occur in more of the pedigrees than the results here 
suggest, as only one individual from each family was investigated by SSCP. 
5.4.8 CRYBB2 splice site mutation likely to be in the pseudogene 
The G—>A substitution identified at the exon 3 donor splice site of the CRYBB2 gene 
in pedigree crch40 would be expected to have a significant effect on the protein in a 
similar way to the mutation at the same position of the CRYBA1/A3 gene. However, 
the mutation does not segregate with disease in this pedigree, indicating that it has no 
effect on the phenotype (Figure 5.7). Repeat sequencing of this pedigree from 
independent amplification reactions confirmed this result. Unfortunately independent 
re-collection of samples from family members was not possible. 
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It is probable that the mutation observed is actually in a likely pseudogene CRYBB2- 
2. Evidence that this is a pseudogene is based on the lack of signal detected in 
hybridisation experiments using oligonucleotides specific for both genes, and splice 
site variants that would severely disrupt the protein sequence (Brakenhoff et al. 
1992). Since sequence variants have not previously been reported in the CRYBB2-2 
pseudogene in the region of exon 3, it is not possible to determine the extent of 
amplification of the pseudogene relative to CRYBB2, or to design primers specific for 
the pseudogene. It is expected that the level of amplification of CRYBB2 and the 
pseudogene using current primers would be similar. The sequences of the two copies 
of this gene are almost identical with nucleotide changes observed only in exon 4, 
following a splice site variant that would inactivate the putative CRYBB2 product 
(Brakenhoff et al. 1992). 
Vanita et al. (2001) described mutations of the CRYBB2 gene in a congenital cataract 
pedigree that are believed to be due to gene conversion between the gene and the 
pseudogene, as the mutant CRYBB2 sequence is identical to that of the pseudogene 
for a segment of between 9 and 104 bp in the pedigree. In this case the two sequences 
were distinguished by the use of PCR primers specific for the gene and pseudogene. 
As mentioned, this approach was not possible in our study due to sequence identity 
between the gene and the pseudogene in the region of exon 3. 
5.4.9 Limitations of SSCP analysis 
SSCP analysis does not detect 100% of sequence variants (Hayashi and Yandell 
1993). The method relies on the sequence variant causing a change in the three-
dimensional conformation of the single stranded DNA fragment that affects the 
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mobility of the fragment through the gel. Many factors such as the size of the 
fragment and the `G-FC' content affect its mobility (Hayashi and Yandell 1993; 
Hayashi 1999). It is difficult to predict the mobility change of a nucleotide 
substitution. SSCP analysis is most appropriate for small fragments (200-400 bp in 
length) with a low `G+C' content. As the length and complexity increase, detection of 
variants becomes more difficult. Also, variants may only affect the mobility under 
certain conditions, such as a specific temperature or in the presence of glycerol. SSCP 
gels must be electrophoresed at cool temperatures to avoid denaturing the single-
stranded conformation. All gels were electrophoresed at room temperature with a low 
power over an extended time period (-16 hours) to prevent overheating above room 
temperature, but lower temperatures may be required to detect some variants. It is 
possible that some mutations were undetected by this methodology. In fact this was 
observed with the P24T variant of CRYGD which not detected by SSCP. Conditions 
were not varied in order to detect it, as it was readily detectable by denaturing High 
Performance Liquid Chromotography for high throughput screening of the pedigree 
and controls. The only way to detect 100% of sequence variants is through direct 
sequencing. However, SSCP was considered an appropriately rapid, relatively 
efficient, and less expensive method for initial screening of these pedigrees. It was 
decided to undertake linkage analysis in large pedigrees at these loci in addition to 
SSCP because of the known limitations of the method. It is possible that mutations in 
the smaller pedigrees not investigated by linkage analysis were missed, however, 
linkage is not a valid approach in these small heterogeneous pedigrees. Linkage 
analysis is valuable when sufficient power is present, but otherwise it is necessary to 
rely on direct methods of mutation detection such as SSCP or direct sequencing in 
order to conclusively identify disease loci. 
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5.4.10 Other congenital cataract loci 
The other eight known cataract genes (CX46, CX50, MIP, BFSP2, PITX3, CRYAB, 
CRYBB1 and the recently reported TISF4) remain to be screened in the smaller 
pedigrees from this population to evaluate their contribution to this phenotype. The 
large pedigrees used here for linkage analysis were investigated at these loci and the 
analyses are described in Chapter 6. The gene for the membrane protein LIM2 has 
recently been associated with recessive congenital cataract (Pras et al. 2002) and two 
of our families displayed recessive inheritance. In addition, eight loci (at lpter-p36.1 
(Eiberg et al. 1995; Ionides et al. 1997), 3p (Pras et al. 2001), 9q13-q22 (Heon et al. 
2001), 15q21-22 (Vanita et al. 2001b), 17p13 (Berry etal. 1996; Ionides etal. 1998), 
17q24 (Armitage etal. 1995) and 20p12-q12 (Yamada et al. 2000) have shown 
linkage to autosomal dominant and recessive congenital cataract, but the genes at 
these loci have not yet been elucidated. It is likely that there are additional as-yet 
unmapped cataract loci. 
5.4.11 Summary 
The high degree of genetic and phenotypic heterogeneity observed in congenital and 
paediatric cataract significantly complicates investigations of this disorder. In 
Australian pedigrees of European ancestry, we have detected two causative crystallin 
mutations, both described previously in Indian pedigrees. Considering the different 
ethnic origins of the two populations, these mutations are likely to have arisen 
independently (although this is not confirmed). This is only the third report describing 
cataract mutations common to more than one family, indicating the critical nature of 
these residues to lens stability. Other than a non-disease causing splice site mutation 
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believed to be present in a pseudogene, we did not detect a single protein-altering 
polymorphism in the five crystallin genes, highlighting the conserved nature of these 
highly stable proteins. The low prevalence of causative mutations in the five 
crystallin genes studied here — only two pedigrees of 38 (5.3%) — indicates that these 
genes are not a common cause of paediatric cataract in this population. 
101 
Chapter 6 
Investigation of Known Cataract Loci in Four Large 
Pedigrees 
6.1 Background 
The investigation of crystallin genes in this population revealed only two causative 
mutations in 38 pedigrees. While it is possible that mutations were missed in the 
smaller pedigrees due to the limitations of SSCP, this number seems particularly low 
given the prevalence of mutations within these genes in the cataract literature, and 
suggests that other loci play an important role in cataract susceptibility in this 
population. The other loci previously associated with congenital cataract were 
investigated. As discussed, SSCP is time consuming, so investigations began with 
linkage analysis in a group of four pedigrees large enough to provide a chance of 
detecting significant linkage: crch13, crch30, crch32 and ctas17. All reported ADCC 
loci were investigated using linkage analysis, apart from PAX6 as there were no 
anterior segment anomalies in any of the four large pedigrees. However, anterior 
segment anomalies were detected in the smaller pedigrees crch01 (aniridia) and 
crch06 and crch22 (anterior cataract). These pedigrees are undergoing analysis at the 
laboratory of Professor Veronica van Heyningen (Western General Hospital, 
Edinburgh) at the PAX6 locus although they were still screened for crystallin genes 
mutations using SSCP as discussed in the previous chapter. 
6.2 Known genes 
The genes studied include the two connexin genes, Connexin 46 (CX46) and 
Connexin 50 (CX50), Major Intrinsic Protein of the lens (MIP), Beaded Filament 
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Structural Protein 2 (BFSP2), Heat Shock Factor 4 (HSF4) and PITX3. Mutations in 
each of these genes have been found in congenital cataract pedigrees and are all listed 
in Table 1.1. 
6.2.1 Connexins 
Two connexins, CX46 and CX50, are expressed in lens fibre cells and mutations in 
both have been linked to zonular pulverulent congenital cataract. Connexin subunits 
associate into hexamers to form connexons which bind to a connexon in the 
neighbouring cell membrane to form a channel for energy independent transport of 
small molecules (Francis et al. 1999; Kannabiran and Balasubramanian 2000). All 
vertebrate connexins have an asparagine at codon 61, 62 or 63 which is within the 
first extracellular loop of the protein. A family with zonular pulverulent cataract was 
shown to have a mutation resulting in the substitution of N63 with serine in CX46. 
While this is considered a conservative substitution since both residues are neutral 
under physiological conditions, the lack of this important asparagine is thought to 
interrupt the docking of the connexon hexamer with its counterpart on the membrane 
of the neighbouring cell (Mackay et al. 1999). Similarly, the P1 87L mutation of 
CX46, identified in another pedigree (Rees et al. 2000), is situated in the highly 
conserved Pro-Cys-Pro motif of the second extracellular loop. Again this mutation 
appears to be reasonably conservative and is predicted to affect protein docking. A 
third pedigree has been identified with a mutation in the CX46 gene. The insertion of 
a cytosine after coding nucleotide 1137 (1137insC) was found to segregate with 
disease (Mackay et al. 1999). This insertion causes a frame shift after codon 379, 
possibly resulting in replacement of the final 56 amino acids and addition of 31 amino 
acids also incorporated into the chain, severely affecting the structure of the protein. 
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Similar mutations have been identified in CX50 in pedigrees with zonular pulverulent 
congenital cataract. The E48K mutation is in the conserved first extracellular loop 
and is also predicted to affect protein docking (Berry et al. 1999). The P88S mutation 
is in the second transmembrane domain (Shiels et al. 1998) and the 1247M mutation 
is in the intracellular C-terminal tail of the protein (Polyakov et al. 2001). 
6.2.2 MIP 
Another protein involved in cell homeostasis is the Major Intrinsic Protein of the lens 
(MEP). This protein is a member of the aquaporin family (AQO) of transmembrane 
water channels (Berry et al. 2000). Normal M1P proteins form homo-tetramers in the 
cell membrane and allow the selective transport of water between cells in an energy 
independent manner. A second role as a cell to cell adhesion molecule has also been 
proposed (Francis et al. 2000b). MW represents greater than 50% of total membrane 
protein, which suggests it has a structural role (King and Yasui 2002). Two mutations 
have been identified in this gene in families with congenital cataract (Berry et al. 
2000). Both the E 134G and T138R mutations have been shown to affect water 
transport through cell membranes by preventing trafficking of the protein to the 
plasma membrane (Francis et al. 2000b). Additionally, when expressed with wild 
type protein, the mutants interfere with the function of the normal protein, in a 
dominant negative effect (Francis et al. 2000b). The phenotypes in the two families 
are quite different, even though the effects on the protein are similar. The T138R 
mutation causes a polymorphic progressive phenotype with punctate opacities in the 
mid and peripheral lamellae as well as anterior and posterior polar opacities, while the 
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E134G mutation causes a stable lamellar cataract in fibres developing during the late 
foetal period (Francis et al. 2000a). 
6.2.3 BFSP2 
Some inherited cataracts are caused by mutations of the lens specific cytoskeletal 
protein Beaded Filament Structural Protein-2 (BFSP2) (Conley et al. 2000; Jakobs et 
al. 2000). This protein is also known as phakinin, CP47 or CP49 and assembles with 
a second cytoskeletal protein, filensin, to form the beaded filament of the lens. An 
R287W mutation segregates with disease in a large family with juvenile-onset 
progressive cataract (Conley etal. 2000). The phenotype in older members of this 
family was a lamellar cataract. The positive charge of the arginine at residue 287 is 
well conserved amongst proteins of this class, therefore the authors believe this 
mutation to be causative of the progressive cataract in this family. They also speculate 
about the possible effect of mild mutations in this gene on later onset age-related 
cataract. The age of onset in this family ranged from 9 years to the late twenties. A 
second mutation, AE233 was found in a family with a congenital cataract consisting 
of spoke-like anterior and posterior sub-capsular cortical opacities (Jakobs et al. 
2000). The deletion is predicted to disrupt a hydrophobic stripe along an a-helix that 
is involved in an interaction with filensin. This hydrophobic stripe is highly 
conserved amongst other members of this protein family. From these two identified 
mutations, it appears that BFSP2 plays an important structural role both during early 
development (AE233) and later growth of the lens (R287W). 
6.2.4 HSF4 
Marner's cataract has been known to map to 16q22 for some time (Eiberg et al. 
1988), however the gene was only described recently. Following the refinement of the 
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critical region through the analysis of a Chinese pedigree with lamellar cataract, a 
mutation was discovered in the gene encoding Heat Shock Factor 4 (HSF4) (Bu et al. 
2002). This gene controls the expression of heat shock proteins via both activating 
and inhibitory activities. Subsequently, a mutation was identified in a pedigree with 
Marner's cataract which is characterised by zonular stellate and anterior polar 
opacities (Bu et al. 2002). Several other mutations have been described in other cases 
- of lamellar cataract (Bu et al. 2002). The effects of these mutations on HSF4 function 
are currently unknown. 
6.2.5 PITX3 
PITX3 is a homeobox protein involved in eye development. Several mutations in 
PITX3 have been found to cause cataracts. The first — a missense mutation S13N — 
was found at a highly conserved serine in a patient with congenital cataract and her 
affected mother (Semina et al. 1998). The second — a 17bp insertion — has been 
identified in a four-generation pedigree with congenital posterior polar cataract (Finzi 
et al. 2002). This mutation was originally described in a pedigree with both anterior 
segment mesenchymal dysgenesis and congenital cataract (Semina et al. 1998). It is 
possible that this mutation is responsible for only the congenital cataract part of the 
phenotype in this family and that a second modifying gene also segregating in this 
family is the cause of the anterior segment mesenchymal dysgenesis. This is further 
supported by a mutation, 550delG, in another family with isolated congenital cataract 
(Yang et al. 2002). The 17bp insertion results in a frameshift causing the alteration of 
the 82 C-terminal amino acids, while the 550deIG single base deletion results in 86 
novel amino acids. 
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6.3 Other mapped loci 
Several other loci at which the genes have not been identified have also been 
reported. Two phenotypes have been reported to map to the short arm of chromosome 
1. The Volkmann cataract consists of a progressive central opacity of both the 
embryonic and foetal nuclei, as well as the anterior and posterior Y-sutures (Eiberg et 
al. 1995). The gene has been localised to between lpter and marker D1S243 
following a genome-wide scan in the Volkmann cataract pedigree. A posterior polar 
cataract maps to an overlapping region (Ionides et al. 1997). The clinical 
characteristics of these two phenotypes are quite distinct. The posterior polar cataract 
is not progressive and does not involve the nucleus or sutures. While mapping 
information suggests the two phenotypes may be allelic, there may also be two 
distinct genes in the region responsible for cataract. 
A unique phenotype of central pouch-like cataract with sutural opacities has been 
found to link to 15q21-q22 in an Indian pedigree (Vanita etal. 2001a). This 
phenotype was identified in a single seven-generation Indian pedigree, and localised 
by recombinations to a small region of 1.2 cM between markers D155117 and 
D1551033. 
Anterior polar cataract has been linked to 17p13 in a four-generation British pedigree 
(Berry et al. 1996). The disease gene was found to map to a 13cM region between 
D175849 and D175796. There are no other reports of cataract mapping to this region. 
The distinctive Cerulean cataract has been shown to be caused by a mutation in 
CRYBB2 on chromosome 22. However, this phenotype also maps to 17q24 (Armitage 
et al. 1995). A genome-wide scan in a five-generation pedigree in which candidate 
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loci had been excluded revealed linkage to a 6 cM region between markers D17S802 
and D17S836. This locus was actually identified prior to the CRYBB2 locus, however 
the gene remains elusive. 
Posterior polar cataract has been mapped to 20p12-q12 in a genome-wide scan of a 
Japanese pedigree (Yamada et al. 2000). The region was localised by recombination 
events to between D20S851 and D20S96. The BFSP1 gene encoding the lens 
cytoskeletal protein filensin is located in this region as was considered to be an 
appropriate candidate gene, however no coding mutations were identified in the 
pedigree (Yamada et al. 2000). 
6.4 Aims 
We aimed to identify linkage to these known loci through the analysis of the four 
large pedigrees described in Chapter 5, and determine the causative mutations at any 
linked loci where cataract genes have been identified. 
6.5 Methods 
6.5.1 Genotyping 
Markers were chosen on the basis of their proximity to the target gene or region using 
physical maps and their reported heterogeneity. The marker closest to the gene with a 
heterozygosity of >70% was chosen (Table 6.1A). Markers reported in the literature 
as the peak or flanking markers for reported loci were chosen (Table 6.1B). Primer 
sequences for all markers were obtained from the Genome Database 
(http://www.gdb.org). The four large pedigrees described in Chapter 5 were 
genotyped and analysed by two-point linkage analysis carried out in MUNK, part of 
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the FASTLINK package (Lathrop et a/. 1984, with modification by Cottingham et al. 
1993). Disease gene frequency was set to 0.0001. Penetrance was set at 0.0 in wild 
type homozygotes and 0.95 in heterozygotes and mutant homozygotes, indicating 
highly penetrant dominant inheritance, reflecting the pattern of segregation in the 
pedigrees. LOD scores were calculated at a range of recombination fractions between 
0 and 0.5 for each marker. Allele frequencies were estimated from all founders in the 
pedigrees and are given in Appendix 3. Where less than four pedigrees were typed, 24 
unrelated unaffected individuals collected from nursing homes in Launceston, 
Tasmania were typed to estimate allele frequencies. 
Table 6.1: Location of markers for linkage analysis. Genetic positions are from the 
Marshfield map. Physical distances are calculated from the centre of the gene. 
ndidate genes 
Gene 
_ 
Marker Chromosome 
Genetic Position of 
Marker (cM) 1 
Distance from 
gene (Mbp)2 
Distance from 
gene (cM) 3 
CX50 D1S2635 1 165.62 11.5 12.40 
BFSP2 D3S1349 3 Not mapped genetically 0.1 0.12 
PITX3 D10S1268 10 160.11 1.6 1.52 
MIP D12S83 12 75.17 4.0 3.32 
CX46 D13S1236 13 2.77 1.9 4.1 
HSF4 D16S496 16 85.94 1.7 1.45 
, 
Locus Marker Chromosome 
Genetic 
Position of 
Marker 
(cM) 1 
Distance 
between 
markers 
(Mbp) 2 
Distance 
between 
markers 
(cM) 1 
Reference 
1pter-p36 D1S243 1 0.00 1.4 4.22 
Eiberg et al. 1995 
Ionides et al. 1997 D1S468 1 4.22 
15q21-q22 D15S117 15 51.21 0.3 1.12 Vanita etal. 2001a 
D15S1033 15 52.33 
17p13 D17S849 17 0.63 6.0 14.06 Berry et al. 1996 
D17S796 17 14.69 
17q24 D17S802 17 106.80 1.1 6.12 Annitage et al. 1995 
D17S836 17 112.92 
20p12-q12 D20S894 20 30.56 Yamada etal. 2000 
Genetic positions obtained from the Marshfield map 
2  Physical distances obtained from the UCSC Human Genome Browser 
3  Distance between marker and candidate gene in cM calculated from region specific 
recombination rates (Payseur and Nachman 2000) 
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Allele frequencies reported by the Centre d'Etude Polymorphisme Humain (CEPH) 
database (http://www.cephb.fr/) were also used and are given in Appendix 3. These 
frequencies are calculated from around 50 chromosomes or less (as are the founder 
frequencies calculated here). However, they are generally accepted as representative 
of the Caucasian population. LOD scores were also calculated using these frequencies 
to help assess possible inaccuracies in the founder frequencies. Selected CEPH 
individuals reported to be heterozygous (http://www.ceph.fr ) were included during 
genotyping as controls in order to directly compare CEPH frequencies and allele sizes 
with observed sizes in this data set, as the size of fragments detected can vary 
between systems. LOD scores were calculated at a range of recombination fractions 
between 0 and 0.5 for each marker with both sets of frequencies. Haplotypes for 
pedigree crch30 at chromosome 15 were estimated using Genehunter Plus. 
6.5.2 Sequencing 
The CX46 gene was sequenced in individuals from pedigree crch13 as described in 
Chapter 2.7.2. Primers were designed to sequence the one large exon in three 
overlapping fragments and are presented in Appendix 2. Fragment lb was designed 
as a smaller product to screen 50 unaffected unrelated controls collected from nursing 
homes in Launceston, Tasmania for the identified mutation. Probands from all other 
pedigrees in the collection were also sequenced for this mutation using fragment lb. 
6.5.3 Denaturing High Performance Liquid Chromatography 
Fragment lb was amplified and analysed by dHPLC in pedigree crch13 as described 
in Chapter 2.8. Samples were injected at 64°C. 
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6.6 Results 
6.6.1 Linkage analysis 
Maximum LOD scores obtained with both sets of allele frequencies are presented in 
Tables 6.2 (founders) and 6.3 (CEPH). Using the CEPH frequencies, D13S1236, the 
marker representing CX46, produced a significant LOD score of 4.37 (0=0.03) in 
pedigree crch13. The founder allele frequencies gave a LOD score of 2.96 (0=0.04) at 
this locus. Several individuals failed to genotype at this marker, however, as a 
significant LOD score was obtained (followed up by positive mutation identification 
described below), they were not repeated. A LOD score of 1.36 (0=0.08) was also 
obtained at D165496 using founder allele frequencies. This pedigree was not typed at 
additional markers following the significant result at CX46. 
Marker D1551033 within the 15q21-q22 locus gave LOD scores of 1.5 and 1.7 (0=0) 
for pedigree crch30 using founder and CEPH frequencies respectively. All other 
results were equivocal, although generally not indicative of linkage. While the 
majority of LOD scores at 0=0 were negative, the distances over which markers are 
excuded from linkage to the disease are small as would be expected. 
Most markers were excluded from linkage in crch32. D1551033 gave a maximum 
LOD score of 1.0 (0=0.26) with both frequency sets and D1051268 gave a maximum 
LOD score of 0.49 (0=0) with founder frequencies. 
Pedigree ctas17 was typed at several markers prior to the identification of the CRYGD 
mutation discussed in Chapter 5. Once the CRYGD mutation was identified, no 
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Table 6.2. Two-point LOD scores calculated with founder frequencies. 
Pedigree Locus Marker 0.0 0.05 0.1 0.2 0.3 0.4 max LCD theta 
Crch13 1pter-p36.1 
CX50 
CX46 
15q21-q22 
HS F4 
D1S243 
D1S468 
D1S2635 
D13S 1236 
D15S117 
D15S1033 
D16S496 
-10.28 
-21.72 
-7.47 
2.74 
-18.03 
-14.74 
1.04 
-3.85 
-9.01 
-2.62 
2.94 
-6.73 
-6.26 
1.33 
-2.55 
-6.04 
-1.42 
2.74 
-5.26 
-4.00 
1.36 
-1.29 
-3.06 
-0.37 
2.11 
-2.82 
-1.83 
1.13 
-0.63 
-1.48 
0.00 
1.37 
-1.35 
-0.81 
0.72 
-0.24 
-0.54 
0.04 
0.57 
-0.52 
-2.28 
0.24 
0.00 
0.00 
0.09 
2.96 
0.00 
0.00 
1.36 
0.50 
0.50 
0.39 
0.04 
0.50 
0.50 
0.08 
17p13 D17S796 -12.94 -4.37 -2.80 -1.22 -0.44 -0.08 0.00 0.50 
D17S849 -18.57 -8.92 -6.08 -3.01 -1.37 -0.45 0.00 0.50 
17q24 D17S836 -5.54 -1.96 -1.28 -0.61 -0.29 -0.15 0.00 0.50 
D17S802 -4.33 -1.78 -1.04 -0.36 -0.09 0.00 0.00 0.45 
Crch30 1pter-p36.1 D1S243 -2.05 -0.63 -0.18 0.17 0.22 0.14 0.22 0.27 
D1S468 -1.65 -1.10 -0.79 -0.42 -0.20 -0.07 0.00 0.50 
CX50 D1S2635 -2.46 -1.12 -0.73 -0.31 -0.09 0.00 0.01 0.44 
BFSP2 D3S1349 -7.80 -3.89 -2.60 -1.33 -0.70 -0.28 0.00 0.50 
PITX3 D10S1268 -6.56 -1.54 -0.89 -0.29 -0.04 0.04 0.04 0.42 
MIP D12S83 -7.23 -1.65 -1.02 -0.49 -0.29 -0.17 0.00 0.50 
CX46 D13S1236 0.02 0.03 0.04 0.04 0.04 0.02 0.04 0.20 
15q21-q22 D15S 117 -1.72 -0.07 -0.42 -0.86 -0.02 0.02 0.02 0.42 
D15S1033 1.54 1.39 1.24 0.91 0.59 0.28 1.54 0.00 
HSF4 D16S496 -0.91 -0.36 0.18 0.33 0.31 0.20 0.33 0.23 
17p13 D17S796 -6.55 -2.36 -1.51 -0.69 -0.28 -0.22 0.00 0.50 
D17S849 -3.97 -2.33 -1.69 -0.96 -0.52 -0.22 0.00 0.50 
17q24 D17S836 -3.50 -1.59 -1.04 -0.48 -0.19 -0.05 0.00 0.50 
D17S802 -5.54 -1.87 -0.96 -0.18 0.11 0.15 0.15 0.36 
20p12-q12 D20S894 -6.17 -2.05 -0.17 -0.48 -0.11 0.03 0.04 0.43 
Crch32 lpter-p36.1 D1S243 -27.82 -10.76 -6.99 -3.38 -1.55 -0.52 0.00 0.50 
D1S468 -19.30 -5.13 -2.79 -0.83 -0.11 -0.08 0.08 0.41 
CX50 D1S2635 -13.24 -5.01 -3.08 -1.27 -0.46 -0.09 0.00 0.49 
BFSP2 D3S1349 -15.46 -5.91 -2.60 -0.19 0.35 0.37 0.41 0.35 
P ITX3 D10S1268 0.49 0.41 0.37 0.20 0.09 0.04 0.49 0.00 
MIP D12S83 -16.65 -6.00 -3.51 -1.32 -0.42 -0.08 0.00 0.50 
CX46 D13S 1236 -5.71 -1.27 -0.48 0.17 0.34 0.26 0.34 0.31 
15q21-q22 D15S117 -10.92 -3.10 -1.95 -0.86 -0.35 -0.92 0.00 0.50 
D15S 1033 -12.53 -2.07 -0.38 0.83 0.98 0.59 1.00 0.26 
HSF4 D16S496 -7.14 -3.83 -2.59 -1.28 -0.59 -0.19 0.00 0.50 
17p13 D17S796 -14.55 -5.77 -3.68 -1.69 -0.73 -0.22 0.00 0.50 
D17S849 -15.33 -6.81 -4.63 -2.43 -1.24 -0.49 0.00 0.50 
17q24 D17S836 -12.99 -5.59 -3.28 -1.15 -0.28 0.02 0.04 0.44 
D17S802 -19.83 -10.23 -7.06 -3.81 -2.02 -0.81 0.00 0.50 
20p12-q12 D20S894 -21.23 -8.54 -5.71 -2.89 -1.48 -0.64 0.00 0.50 
Ctas17 1pter-p36.1 01S243 -6.51 -1.42 -0.69 -0.15 -0.26 -0.01 0.00 0.50 
D1S468 -17.07 -7.50 -5.07 -2.48 -1.13 -0.37 0.00 0.50 
CX50 D1S2635 -12.81 -4.87 -3.10 -1.45 -0.64 -0.21 0.00 0.50 
CX46 D13S1236 -3.62 0.09 0.51 0.65 0.49 0.24 0.66 0.18 
15q21-q22 D15S 117 -17.56 -5.58 -3.53 -1.59 -0.66 -0.19 0.00 0.50 
D15S1033 -9.78 -2.67 -1.49 -0.48 -0.08 0.05 0.05 0.42 
HSF4 D16S496 -4.97 -1.94 -1.08 -0.27 0.06 0.13 0.14 0.38 
17p13 D17S796 -8.24 -2.82 -1.73 -0.71 -0.26 -0.05 0.00 0.50 
D17S849 -12.68 -5.44 -3.39 -1.48 -0.59 -0.16 0.00 0.50 
17q24 D17S836 -3.42 -1.98 -1.10 -0.30 0.24 0.11 0.11 0.39 
D17S802 -10.88 -4.41 -2.75 -0.23 -0.54 -0.19 0.00 0.50 
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Table 6.3. Two-point LOD scores calculated with CEPH frequencies. 
Pedigree Locus Marker 0.0 0.05 0.1 0.2 0.3 0.4 max LOD theta 
Crch13 lpter-p36.1 
CX50 
CX46 
15q21-q22 
D1S243 
D1S468 
01S2635 
D13S1236 
D15S117 
D15S1033 
-13.72 
-21.72 
-8.03 
4.21 
-17.90 
-22.43 
-4.29 
-8.97 
-2.38 
4.31 
-6.71 
-7.14 
-2.77 
-5.99 
-1.22 
3.99 
-5.12 
-4.65 
-1.37 
-3.03 
-0.23 
3.06 
-2.64 
-2.22 
-0.66 
-1.47 
0.09 
1.97 
-1.16 
-1.06 
-0.25 
-0.54 
0.12 
0.85 
-0.40 
-0.40 
0.00 
0.00 
0.13 
4.37 
0.00 
0.00 
0.50 
0.50 
0.36 
0.03 
0.50 
0.50 
HSF4 D16S496 0.73 1.09 1.12 0.89 0.53 0.17 1.12 0.08 
17p13 D17S796 -19.88 -4.75 -2.65 -0.82 -0.12 0.07 0.07 0.42 
D17S849 -18.57 -8.92 -6.08 -3.01 -1.37 -0.45 0.00 0.50 
17q24 D17S836 -12.24 -3.76 -2.43 -1.23 -0.68 -0.33 0.00 0.50 
D17S802 -5.35 -0.83 -0.16 0.36 0.43 0.28 0.43 0.27 
Crch30 1pter-p36.1 01S243 -7.67 -0.74 -0.27 0.11 0.19 0.13 0.19 0.30 
D1S468 -1.65 -1.10 -0.79 -0.42 -0.20 -0.07 0.00 0.50 
CX50 D1S2635 -3.96 -1.21 -0.80 -0.37 -0.13 -0.02 0.00 0.48 
BFSP2 D3S1349 -7.80 -3.88 -2.59 -1.33 -0.68 -0.28 0.00 0.50 
PITX3 D10S1268 -6.68 -1.76 -1.09 -0.44 -0.14 -0.01 0.01 0.46 
MIP D12S83 -7.29 -1.64 -0.98 -0.42 -0.20 -0.11 0.00 0.50 
CX46 D13S1236 0.02 0.03 0.04 0.04 0.04 0.02 0.04 0.20 
15q21-q22 D15S117 -2.43 -1.11 -0.69 -0.28 -0.09 -0.01 0.00 0.46 
D15S1033 1.71 1.54 0.38 1.03 0.67 0.32 1.71 0.00 
HSF4 D16S496 0.48 0.52 0.53 0.49 0.38 0.22 0.53 0.10 
17p13 D17S796 -11.42 -2.70 -1.66 -0.72 -0.27 -0.06 0.00 0.49 
D17S849 -3.86 -2.27 -1.65 -0.94 -0.51 -0.22 0.00 0.50 
17q24 D17S836 -3.80 -1.76 -1.14 -0.52 -0.21 -0.05 0.00 0.50 
017S802 -10.76 -1.94 -0.99 -0.18 0.11 0.15 0.16 0.37 
20p12-q12 D20S894 -5.93 -1.86 -1.12 -0.38 -0.06 0.05 0.05 0.41 
Crch32 1pter-p36.1 D1S243 -33.84 -11.19 -7.23 -3.49 -1.60 -0.55 0.00 0.50 
D1S468 -19.46 -5.15 -2.81 -0.85 -0.12 0.07 0.07 0.41 
CX50 D1S2635 -22.18 -5.16 -3.15 -1.31 -0.13 -0.10 0.00 0.49 
BFSP2 D3S1349 -15.53 -3.94 -1.88 -0.21 0.34 0.37 0.40 0.35 
PITX3 010S1268 0.40 0.33 0.27 0.16 0.07 0.02 0.40 0.00 
MIP D12S83 -16.51 -5.87 -3.39 -1.23 -0.35 -0.04 0.00 0.47 
CX46 D13S1236 -8.52 -3.95 -2.39 -0.74 -0.03 0.17 0.17 0.40 
15q21-q22 D15S117 -11.33 -3.17 -1.94 -0.84 -0.35 -0.10 0.00 0.50 
D15S1033 -24.02 -2.17 -0.42 0.83 0.98 0.59 1.00 0.27 
HSF4 D16S496 -4.67 -3.17 -2.23 -1.14 -0.54 -0.19 0.00 0.50 
17p13 D17S796 -22.82 -6.54 -4.31 -2.13 -1.00 -0.35 0.00 0.50 
D17S849 -15.40 -6.81 -4.62 -2.41 -1.23 -0.48 0.00 0.50 
17q24 D17S836 -19.56 -5.85 -3.41 -1.21 -0.32 0.00 0.02 0.47 
D17S802 -25.80 -10.45 -7.15 -3.85 -2.03 -0.82 0.00 0.50 
20p12-q12 D20S894 -21.30 -8.62 -5.79 -2.99 -1.57 -0.69 0.00 0.50 
Ctas17 1pter-p36.1 D1S243 -8.58 -1.49 -0.78 -0.22 -0.06 -0.02 0.00 0.50 
D1S468 -17.17 -7.69 -5.22 -2.58 -1.18 -0.39 0.00 0.50 
CX50 D1S2635 -18.99 -4.79 -3.07 -1.44 -0.64 -0.21 0.00 0.50 
CX46 D13S1236 -3.62 -0.78 0.51 0.65 0.49 0.24 0.66 0.18 
15q21-q22 D15S117 -16.99 -5.69 -3.61 -1.63 -0.68 -0.19 0.00 0.50 
D15S1033 -13.70 -2.91 -0.70 -0.68 -0.21 -0.03 0.01 0.47 
HSF4 D16S496 -3.41 -1.52 -0.83 -0.15 0.11 0.14 0.15 0.37 
17p13 D17S796 -10.45 -3.13 -1.92 -0.77 -0.25 -0.03 0.01 0.47 
D17S849 -13.56 -6.22 -4.02 -1.81 -0.74 -0.22 0.00 0.50 
17q24 D17S836 -3.78 -2.31 -1.37 -0.46 -0.06 0.07 0.08 0.41 
D17S802 -10.74 -3.91 -2.40 -1.03 -0.44 -0.15 0.00 0.50 
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further markers were genotyped in this pedigree. Results of interest for each pedigree 
are summarised in Table 6.4. 
Table 6.4 Maximum LOD scores of interest 
Pedigree Locus Marker 
Founders 
Max LOD 	Theta 
CEPH 
Max LOD 	Theta 
Crch13 CX46 D13S1236 2.96 0.04 4.37 0.03 
HSF4 D16S496 1.36 0.08 1.12 0.08 
Crch30 15q21-q22 D15S1033 1.54 0.00 1.71 0.00 
Crch32 15q21-q22 D15S1033 1.00 0.26 1.00 0.27 
PITX3 D10S1268 0.49 0.00 0.40 0.00 
6.6.2 Mutation analysis of the Connexin 46 gene in pedigree crch13 
6.6.2.1 Sequence Analysis  
After obtaining a significant LOD score of 3.14 at D13S1236 in pedigree crch13, the 
CX46 gene was investigated by sequencing three overlapping fragments covering the 
whole coding exon. A mutation was identified in several affected individuals in 
fragment 1 (Figure 6.1, 6.3). The G—>A substitution at nucleotide 218 of the mRNA 
results in an Arg—>His substitution at codon 76. As this fragment was quite large 
(496bp) and difficult to sequence due to a high `G+C' content, a smaller fragment 
was amplified for confirmation of this mutation (fragment lb, Appendix 3). 
6.6.2.2 Denaturing High Performance Liquid Chromatography 
Denaturing HPLC was used to screen all individuals in the pedigree. The optimal 
temperature for the detection of the mutation was determined to be 64°C, however, 
the profiles obtained were not always readily identified as wild type or mutant (Figure 
6.2). The 12 individuals displaying these ambiguous profiles were directly sequenced 
at fragment lb to determine their genotype. All affected individuals were found to be 
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Figure 6.1. Sequence variant 218G--÷A of the CX46 gene in pedigree crch13, 
resulting in R76H. 
1 00 - 
Figure 6.2. Representative dHPLC profiles of pedigree crch13 at fragment lb of 
CX46. Green is wild type sequence; blue represents the R76H mutation; orange is an 
example of an ambiguous profile that was followed up by sequencing. 
heterozygous for the mutation, and the majority of unaffected individuals were 
homozygous wild type. However, as indicated in Figure 6.3, unaffected individuals 
IV:4, V:7, V:8, V:9, V:27 and VI:15 also carry the mutation, resulting in a penetrance 
of 20/26 or 77%. The genotype for all these individuals was confirmed by direct 
sequencing. For individuals IV:4, V:7, V:8 and V:9, independent samples were 
obtained, which confirmed these results. 
6.6.3 Reduced penetrance model 
The LOD score was recalculated using an autosomal dominant model with 77% 
penetrance in heterozygotes as observed in the pedigree. The maximum LOD score 
was increased from 2.96 under the high penetrance model to 3.42 (0=0.04) under the 
reduced-penetrance model. 
6.6.4 The phenotype 
The phenotype in this pedigree is a faint lamellar nuclear opacity with fine gold dots 
or haze and in some cases with needle like peripheral riders (Figure 6.4). Half of 
those with cataract had not had surgery and had good or minimally reduced vision. 
The mean age for surgery was 27 years (age range 10-67 years). 
6.6.5 Analysis of controls and other pedigrees 
Fifty unrelated unaffected individuals (100 chromosomes) and a proband from all 
pedigrees in the study were screened for the R76H mutation by direct sequencing, as 
this appeared significantly more reliable than the dHPLC. The mutation was not 
detected in any of these individuals. 
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Figure 6.3. Pedigree diagram of Crch13. Genotypes for marker D13S1236 and the G218A (R76H) mutation of CX46 are 
indicated. Shaded symbols indicate presence of ophthalmologist-confirmed cataract. `+' indicates heterozygous mutation 
carrier, `-' indicates wild type. Individuals with no genotypes have not been typed. The proband is marked with an arrow. 
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Figure 6.4. Photograph of the lens of individual VI:3 of pedigree crch13 showing 
the pulverulent phenotype in the nucleus with cortical riders. 
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Figure 6.5. Predicted topology of Connexin 46 by HMMTOP. The location of the 
R76H mutation and other reported mutations are marked. The first and last residues 
of each transmembrane domain are numbered. 
6.7 Discussion 
6.7.1 Comparison of different allele frequency sets 
The majority of results were similar between both sets of allele frequencies used, and 
the trends agree in every case. However, the analysis of D13S1236 in pedigree crch13 
with the CEPH frequencies gave a significant LOD score of 4.37, whereas the result 
with the founder frequencies was a LOD of only 2.96. Inspection of the allele 
frequencies (Appendix 3) revealed the origin of the difference to be frequencies for 
alleles 114bp and 132bp. The pedigree contains many individuals with allele 114. 
This allele is not present in the CEPH set and was therefore given a low frequency of 
0.01 for the LOD score calculations. Thus, to have so many affected individuals 
carrying this allele becomes unlikely by chance, and the significance of the LOD 
score increases. In the frequencies calculated from the founders, many individuals 
have this allele, indicating that it is common in the population being studied here. 
Thus the sharing becomes more likely by chance, and the LOD score is no longer 
significant. Both frequency estimates are calculated from 28 chromosomes. There are 
only 25 founders in the 4 pedigrees. Therefore neither frequency set is likely to be 
very accurate. This raises the question of the usefulness of using CEPH allele 
frequency if the common alleles are different between the populations. The most 
accurate linkage results would be obtained by the typing of additional individuals 
from the south-eastern Australian population to give more accurate allele frequencies. 
However because the CX46 gene is small, it was investigated in this pedigree by 
direct sequencing to remove speculation. The usefulness of the CEPH frequencies 
needs to be evaluated on a case by case basis. In general they can be a useful resource 
for Caucasian populations, especially if there is insufficient data from the population 
under investigation. However, they should be used with caution and the limitations of 
the population recognised. 
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6.7.2 The Connexin 46 R76H mutation in pedigree crch13 
6.7.2.1 Predicted effects  
The CX46 R76H mutation identified in pedigree crch13 is the fourth amino acid of 
the second transmembrane domain. A schematic of the structure of the CX46 protein 
as predicted by the HMMTOP program (www.enzim.hu/hmmtop)  is given in Figure 
6.5. All species represented in Genbank have an arginine at this point. Histadine 
appears to be a relatively conservative substitution as it does not change the structural 
predictions by HMMTOP (which asseses transmembrane domains) or PS1PRED 
(which searches for all secondary structure). However, this residue is highly 
conserved across species suggesting that this mutation is likely to be causative of the 
phenotype in this pedigree. The lack of gross effects on protein structure is implied by 
the incomplete penetrance observed in the pedigree. The mRNA for CX46 is encoded 
in one large exon so there is no requirement for the splicing out of introns. Therefore, 
it is unlikely that putative exon splice enhancers would be functional and they were 
not investigated. Other reported mutations of this gene include N63S and P187L. 
These two mutations, as well as the E48K mutation of CX50 are in the extracellular 
loops and are believed to affect docking of the protein with the neighbouring cell 
(Berry etal. 1999; Mackay etal. 1999; Rees et al. 2000). The P88S mutation of CX50 
is in a transmembrane domain and causes a zonular pulverulent phenotype (Shiels et 
al. 1998). In vitro mutagenesis of the phylogenetically conserved P88 suggests that it 
plays a role in the voltage gating of gap junctions. It is yet to be determined if this is 
functionally significant in the non-innervated lens (Shiels et al. 1998). The functional 
effect of the novel R76H mutation detected in this study also remains to be 
determined. 
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6.7.2.2 Modification of the phenotype 
Several individuals of pedigree crch13 have been classified as unaffected but have 
been clearly shown by direct sequencing to carry the R76H mutation identified in all 
affected individuals in the pedigree. Individuals V:27 and VI:15 have been examined 
and are clearly unaffected, however, carrier individuals IV:4, V:7, V:8 and V:9 have 
not been seen by an ophthalmologist and it is possible that they are affected sub-
clinically, as DNA was collected from family members by mail-out of buccal swab 
kits. These individuals are currently being contacted for clinical assessment. 
It appears from the presence of unaffected mutation carriers V:27 and VI:15 that this 
mutation is not fully penetrant. Recalculation of the two-point LOD score with a 
penetrance in carriers of 77% (as described in section 6.6.3) resulted in an increased 
LOD score compared with the fully penetrant model as would be expected. This 
indicates that the model used for linkage analysis more accurately fits reality and that 
the presence of the mutation correlates well with the genotype of marker D13S1236, 
despite missing values due to failed PCR. The failure rate for this marker suggests 
that a different marker should have been typed to represent this locus, however, as 
discussed, it was chosen to directly sequence the candidate gene to overcome all the 
problems with this marker definitively. 
The only other report of a mutation with incomplete penetrance causing ADCC is a 
5bp insertion in the CRYGC gene causing a zonular pulverulent phenotype (Ren et al. 
2000). The phenotype of the reported pedigree is quite variable. All 26 affected 
patients carried the mutation, however two displayed only minimal cataract. One 
mutation carrier displayed no visible opacity and one obligate carrier was not 
examined. The variability was suggested to be due to modification by environmental 
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factors, although what these factors may be was not hypothesised. This may also be 
the case with pedigree crch13. 
Ren et al. (2000) also suggest the possibility of a modifying gene acting in the 
pedigree with incomplete penetrance. The phenotype in their pedigree showed 
variability both between individuals and between the two eyes of patients. However, 
the authors suggest that a modifying gene would act evenly on both eyes and propose 
that environmental factors are more likely to be the cause of the variation. It is 
difficult to separate the effect of environment from genes, however, the presence of a 
modifier gene in pedigree crch13 is supported by individuals IV:4 and V:27. These 
unaffected individuals passed on the R76H mutation to their offspring, who also 
remain unaffected. Environmental factors are unlikely to show this type of pattern, 
unless there are significant household effects. As the majority of mutation carriers in 
the pedigree are affected, it appears that the R76H mutation does cause the 
phenotype. However, these carriers may also carry a protective allele of a different 
gene, which has been passed onto their offspring. Alternatively the affected 
individuals may carry a second harmful allele, however this may be less likely 
considering that the phenotype is expressed in multiple distant branches of the 
pedigree. 
The Lop10 mutation in mice may provide some insight into gene interactions in the 
development of congenital cataract. This phenotype was recently shown to be caused 
by a substitution mutation of the murine cx50 gene (G22R) (Chang et al. 2002), 
however, the phenotype is variable and dependent on the genetic background of the 
mouse (Runge et al. 1992). Functional analyses of this mutation revealed that at least 
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part of the phenotype is caused by a reduction in the levels of phosphorylated cx46, 
although the mechanism of interaction between cx50 and the phosphorylation of cx46 
is still unknown (Chang et al. 2002). 
6.7.3 The remaining pedigrees 
6.7.3.1 Crch32 
The range of recombination values over which linkage is excluded is an important 
consideration. All markers (except Dl 0S1268) are excluded from linkage at 0=0 in 
pedigree crch32. In most cases, this exclusion extends to at least 0=0.1. This 
recombination fraction equates to 9.8 Kosambi centiMorgans (as calculated by 
mapfun from the linkage utilities package, available from 
http://linkage.rockefeller.edu/soft/), which is a considerable distance. Because the 
markers were chosen to be as close as possible to the candidate gene, the range over 
which linkage is excluded includes the candidate gene when known. Although 
positive LOD scores are reached in some instances, they are not significant and they 
are a considerable distance from the candidate gene of interest. For D13S1236, 
linkage is only excluded to 0=0.02 which is approximately 2 cM. The CX46 gene is 
located 1.88 Mb from marker D13S1236. In this region of chromosome 13, 
comparisons of physical and genetic maps have shown there to be 2.18 cM/Mb 
(Payseur and Nachman 2000). Therefore, 1.88 Mb equates to 4.1 cM and linkage to 
the CX46 gene cannot be excluded in this pedigree. 
For one marker linkage could not be excluded at any recombination fraction: 
D10S1268, representing PITX3. The linkage simulations carried out on this pedigree 
and presented in Chapter 5 indicate that a LOD score of 9.32 at 0=0.05 is 
theoretically possible in this pedigree, under the conditions used in the simulations. 
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The marker used in simulation had four equally frequent alleles which is rarely the 
case with real markers. Simulation with actual marker frequencies observed in the 
founders for D1OS1268 gave a maximum LOD score at 0=0.05 of 10.22, and an 
average LOD of 6.66. This indicates that the pedigree should have sufficient power to 
detect significant linkage at this locus. The equivocal LOD score at the PITX3 locus 
may be caused by a lack of information at this marker. The heterozygosity of this 
marker was observed to be 80% in the founders. The CEPH database reports an 
observed heterozygosity of 74% in its population, hence the marker should contain 
sufficient information. However, allele 139 is common in both populations (0.37 in 
founders and 0.46 in CEPH population) and many individuals in the pedigree are 
homozygous for this allele. This reduces the information content of this marker. The 
typing of additional markers in this region is therefore required to evaluate the 
importance of this result. 
For adjacent markers on 15q, D15S1033 and D15S117, the range of excluded values 
of 0 is only 0.05 and 0.09 respectively. As the markers at 15q21-22 are separated by 
only 280 kb, the exclusion results indicate that there is unlikely to be linkage to a 
gene between these markers. However, linkage cannot be excluded at distances 
beyond 0.09 on either side of the markers, and results are more inconclusive further 
away. The gene at this locus, while unknown, was found to be located between 
D15S117 and D15S1033 by recombinations in informative indivuals in the pedigree 
of Vanita etal. (2001), hence the distances over which exclusion of linkage was 
observed should encompass the disease gene. For other loci where the candidate gene 
has not been identified, the typing of additional markers may be required to exclude 
or identify linkage over greater distances. 
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Although further work is required, it is possible that the phenotype in pedigree crch32 
is caused by a gene at a novel locus. If typing of additional markers around PITX3 
and CX46 does not reveal linkage, pedigree crch32 should be the subject of a 
genome-wide scan to identify a possible novel cataract locus. 
6.7.3.2 Crch30 
There is less power to detect linkage with pedigree crch30 than with the other large 
pedigrees in the study, with a maximum simulated LOD score of 2.5 and average 
LOD of 0.91 (Table 5.2). Marker D15S1033 gave a LOD score of 1.5 (0=0) using 
founder frequencies and a LOD score of 1.7 using CEPH frequencies. The p-value for 
this LOD score can be calculated from the X2 distribution (Nyholt 2000): 
X2=observed LOD x 2 x loge 10 = 1.7x2xloge 10 = 7.82. 
The corresponding p-value is 0.003, which is significant for confirmation of linkage, 
as a LOD score of genome-wide significance has previously been identified at this 
locus (Vanita et al. 2001b). The empirical p-value, calculated by simulating 
genotypes in SLINK over 1000 replicates under the null hypothesis of no linkage, 
with the allele frequencies observed for D15S1033, was also 0.003 (0.3% of LOD 
scores were greater than a threshold of 1.7). Since congenital cataract is so 
heterogeneous and there was no prior hypothesis that pedigree crch30 would link to 
this locus, it may be more appropriate to employ a genome-wide significance level of 
0.000049 (Lander and Kruglyak 1995). However, simulations indicate this would not 
be possible in this small pedigree. In summary, this locus should be the first to be 
followed up in this pedigree, but the result is not statistically significant. The LOD 
score at the second marker at this locus - D15S117 - is -1.7 (0=0), which is 
approaching the criterion for exclusion. Using the CEPH frequencies, linkage to 
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D15S117 is excluded in this pedigree at 0=0 with a LOD score of -2.43. Haplotypes 
for the two markers were estimated with GeneHunter Plus. There did not appear to be 
a segregating haplotype, however, allele 1 of D15S1033 is carried by all affected 
individuals (Figure 6.6). This is contributing to the positive LOD scores obtained at 
this marker. In contrast, there does not appear to be any segregation of D15S117 
alleles, resulting in the negative LOD score observed. The typing of additional 
markers and haplotype analyses are required to further investigate this locus. As the 
gene at this locus has not yet been determined, we could not check for mutations by 
direct sequencing as was done with the CX46 gene in crch13. Markers representing 
other mapped loci with as yet unknown genes also give inconclusive results. The 
observed LOD scores do not approach significance and the possibility that the gene 
lies nearby could not be excluded. 
Three loci (CX50, PITX3 and MIP) are only excluded over small recombination 
values. CX50 is approximately 11 Mb from the marker D1S2635, hence this gene is 
not excluded from linkage in this pedigree as the LOD score is -0.73 at 0=0.1. The 
CX50 gene has not been placed on any genetic maps, so it is difficult to know its 
genetic distance from the marker, however, using the average recombination rate in 
that region of chromosome 1, it appears to be around 12.4cM from the marker (Table 
6.1). A similar situation exists for PITX3 and MIP. BFSP2 is excluded over a larger 
distance (0=0.13), with the marker being only 27kb from the gene. 
The results at all loci in pedigree crch30 are equivocal, neither including nor 
excluding linkage, due mainly to the lack of power. The pedigree would benefit from 
the typing of additional markers at all loci so that detailed haplotype analyses can be 
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Figure 6.6: Pedigree Crch30 with 2 marker haplotyes for chromosome 15 markers showing no segregating haplotype 
but segregation of allele 1 of D15S1033 with paediatric cataract. Shaded symbols indicate presence of 
ophthalmologist-confirmed cataract 
carried out to reduce the number of candidates to be investigated by immediately 
excluding those loci where there is no segregating haplotype. 
6.8 Summary of the investigation of congenital cataract genes 
In summary, the analysis of all known cataract genes and loci discussed in this 
Chapter and Chapter 5 revealed three causative mutations in large pedigrees. Two of 
these (P24T of CRYGD and R76H of CX46) were identified by linkage analysis and 
the third (splice site mutation of CRYBAl/A3) was detected by SSCP analysis. There 
is no strong evidence that the congenital cataract phenotype in pedigree crch32 links 
to any known congenital cataract locus, although further work is required to confirm 
exclusion or linkage at a few loci. Additional investigations are also required at all 
loci for the smallest of the pedigrees investigated by linkage analysis. The loci 
previously linked to recessive forms of congenital cataract have not been investigated 
in this population. These loci may also play a role in autosomal dominant congenital 
cataract as CRYAA does (Litt et al. 1998; Pras et al. 2000). The molecular cause of 
the congenital cataract observed in the remaining 41 pedigrees is currently unknown. 
While these pedigrees are too small to be useful individually in gene identification 
studies, they will be important for the determination of the relative contributions of 
cataract genes to the overall causes of familial cataract. 
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Chapter 7 
Discussion 
Research into the molecular causes of congenital cataract has given insights into lens 
biology through the study of the effect of the mutations on the protein functions. This 
study aimed to determine the causative mutations in a collection of congenital 
cataract pedigrees and, where possible, identify novel genes involved in 
cataractogenesis. A novel gene was identified on the X chromosome and shown to be 
associated with Nance-Horan Syndrome (NHS), an X-linked pleiotropic syndrome 
involving congenital cataract and dental anomalies. Mutations were also identified in 
three large pedigrees from south-eastern Australia with autosomal dominant 
congenital or familial cataract (ADCC). 
Congenital syndromes contribute significantly to health care costs because sufferers 
require long-term care and management. NHS is one such disorder, with most 
affected males suffering severe visual defects from an early age and also requiring 
extensive dental care. Learning disabilities and mental retardation associated with the 
syndrome place added difficulties onto patients and their families. The gene for 
Nance-Horan Syndrome (NHS) was identified in our study in the pedigree in which 
the syndrome was first described. This may lead to the development of pre-natal 
testing in families known to carry the gene, and earlier molecular diagnosis and 
appropriate treatment in sporadic cases. Current clinical diagnoses are often not 
confirmed until tooth eruption. If isolated X-linked cataract is in fact a genetically 
distinct disorder from NHS, management of the disorder, particularly in sporadic 
female cases, can be based on the molecular diagnosis or exclusion of NHS rather 
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than on variable clinical findings, even in the absence of knowledge of the causative 
gene for isolated X-linked cataract. The protein encoded by this novel gene does not 
belong to any known family of proteins and its function is yet to be determined. 
However, it appears to be involved in the development of a range of tissues. The 
determination of the function of this gene will provide insights into the developmental 
biology of many tissues, in particular the eye, tooth and brain. 
There are many approaches that can be taken in order to elucidate the function of the 
protein. Homology searches did not reveal any significant similarity to known protein 
families. However, putative nuclear localisation sequences were identified, 
suggesting the protein is targeted to the cell nucleus. This can be tested through 
tagging of expressed protein with green flourescent protein and investigating the 
cellular localisation of the protein (Gomes et al. 2003). Additionally, the truncating 
mutations identified in NHS pedigrees can be introduced to the expression contruct 
and the effect these have on cellular localisation can be investigated. 
X-inactivation can play an important role in the expression of a phenotype in females. 
The phenotype may only be expressed in cells where the disease chromosome is the 
active allele, leaving other cells healthy. This may result in a "mosaic" pattern of 
disease expression. There are many X-linked genes that escape inactivation in 
females and appear not to be subject to the dose correction that chromosomal 
inactivation allows. It would be interesting to understand the effect of X-inactivation 
on the mild and variable phenotype observed in females with NHS. A chromosome 
wide study of inactivation indicated that nearby genes RAI2 and SCML2 are 
inactivated (Carrel etal. 1999). However, the process appears to act in a gene specific 
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manner and the physical proximity of inactivated genes does not necessarily imply 
the inactivation of NHS. There are several ways this can be investigated. Methylation 
of CpG dinucleotides is thought to be a key mechanism in gene inactivation. A simple 
method for investigation methylation patterns involves treatment of the genomic 
DNA with sodium bisulphite which converts unmethylated cytosines to uracil, while 
leaving methylated bases intact. The target region is then amplified by PCR and 
sequenced (Uhlmann et al 2002). Methylated cytosines remain as cytosines while 
unmethylated nucleotides are detected as thymines (uracil is amplified as thymine in 
PCR). This technique would require genomic DNA from the tissue of interest at a 
time when the gene would normally be expressed, as methylation may be used to 
silence genes at various stages in development. More sophisticated techniques also 
exist. Rodent/human somatic cell hybrids provide such a method. Hybrids are 
generated containing an inactivated human X chromosome. Transcripts of the gene of 
interest are detected through RT-PCR. If a transcript is detected, the conclusion is that 
the gene has escaped inactivation (Carrel et al. 1999). This type of technique may be 
useful in this case to determine if the gene escapes inactivation and therefore the 
mutant alleles in females with NHS tend to be expressed. If this were the case, the 
mild phenotype could be attributed to a co-dominant mode of action. 
A putative paralogue of NHS was identified on chromosome 6. While this predicted 
gene requires confirmation in the laboratory and extensive functional analyses to 
determine its role, it may also be involved in the development of the eye and other 
tissues. 
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While the discovery of novel genes is important for understanding the biology, it is 
also important to society and the affected families to understand the cause of their 
disabilities. As the genetics community moves towards the study of complex 
multifactorial traits, it is important to continue the study of Mendelian traits in order 
to identify novel genes and determine their functions. The sequencing of the human 
genome assisted in the discovery of the NHS gene, and greatly reduced the time and 
resources required. In silico analysis is an important tool in the overall process. 
However, genes and their functions cannot be definitively predicted by computer 
programs, as evidenced by the process of gene identification undergone in this 
project. While the in silico analyses indicated a promising candidate for a novel gene, 
the predictions were not 100% correct, with unpredicted exons identified in the 
laboratory. As the human sequence improves and algorithms for gene prediction 
become more powerful, gene prediction in silico should become more accurate. An 
exon was identified approximately 350kb upstream from the rest of the gene but was 
not predicted and was only found following the investigation of ESTs in other 
species. Comparative genomics is an increasingly powerful tool as the genomes of 
more organisms are completely sequenced. 
Familial cataract is genetically heterogeneous, with mutations in 14 genes identified 
as causing ADCC and mutations of two genes responsible for autosomal recessive 
forms of the disease. Several other loci have also been mapped, although the genes 
are yet to be characterised. Two of the three mutations identified in known cataract 
genes in this study (CRYBAl/A3 and CRYGD) were previously reported in pedigrees 
from India, while the third (CX46) is novel. Until now, only the Q155Stop mutation 
of CRYBB2 had been identified in more than 1 pedigree although Kannabiran et al. 
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(1998) and Bateman et al. (2000) report different mutations of the same base in 
CRYBA1/A3. 
The three mutations identfied here are in genes well known to contribute to cataract 
formation from studies of both mice and humans. However, to definitively assign 
cause to these mutations, functional studies should be conducted. For example, in 
order to study the effect of the P24T mutation of CRYGD, site directed mutagenesis 
could be used to introduce the mutation to an expression vector containing the 
CRYGD coding sequence. The mutant protein can then be expressed in E. coli and 
isolated and its properties investigated and compared to those of wildtype CRYGD. 
These types of experiments have been conducted for other mutations of this gene 
including the R58H and R14C variants (Pande et al. 2000, Pande et al. 2001). These 
experiments show that the R58H mutant protein is less soluble than wildtype and that 
R14C protein forms disulfide linked oligomers where wildtype protein does not. 
Similar experiments have been carried out for a Connexin50 mutation (P88S). 
Xenopus oocytes injected with the mutant protein failed to form functional gap 
junctions compared to wildtype protein (Pal etal. 1999). A similar system could be 
used to test the R76H mutation of CX46 identified here. 
There remain 31 pedigrees in this collection with ADCC for which no mutation has 
been identified, although only five of the 14 known genes have been thoroughly 
investigated in all pedigrees. In addition, one large pedigree does not show strong 
evidence of involvement of any of the known cataract loci by linkage analysis, 
indicating that an as yet unknown locus may exist for this disease. Following further 
work to confirm exclusion of known loci, this pedigree would be an ideal candidate 
133 
for a genome-wide scan. Other monogenic disorders also display extreme 
heterogeneity. For example there are 19 known genes for the retinal degeneration 
disease retinitis pigmentosa and at least 17 additional loci (Phelan and Bok 2000). 
The remaining pedigrees in this collection are currently too small to contribute to 
linkage analyses. They cannot be used in a pooled analysis due to the heterogeneity of 
the disorder. There are likely to be too many loci involved in such a large collection 
of pedigrees, so any effect would be too dilute to detect. It is not feasible to stratify 
the pedigrees on phenotype to improve the power, as similar phenotypes have been 
shown to be caused by different genes, such as zonular pulverulent cataracts being 
caused by mutations of CX46, CX50 and CRYGC (Shiels et al. 1998; Heon et al. 
1999; Mackay et al. 1999). Additionally the same mutation, such as the Q155X 
mutation of CRYBB2 can cause distinct phenotypes (Litt etal. 1997; Gill etal. 2000; 
Vanita et al. 2001a) as the P24T mutation of CRYGD detected here also does. 
Mutations would therefore be missed by the exclusion of a pedigree from a particular 
locus on the basis of phenotype alone. The best method for the identifying mutations 
in known genes in these small pedigrees is direct sequencing of the genes, however 
this is an expensive and time-consuming process. 
Linkage analysis in a few suitably large pedigrees revealed two cataract mutations, 
including one that was missed by SSCP. While SSCP is cheaper than sequencing it is 
still labour-intensive. Therefore a faster method of screening known genes in these 
pedigrees is required. Denaturing HPLC was investigated as an alternative. While less 
labour-intensive than gel-based techniques such as SSCP, dHPLC was also found to 
be problematic. The temperature at which a variant will be identified may be very 
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specific. It is not always the same as that calculated as the melting temperature of the 
strand and must be determined empirically for the most accurate result. As with 
SSCP, some variants are easier to detect than others. Retention time is related mainly 
to melting temperature of the strand which is dependent on the `G-FC' content and 
length of the fragment. The overall success rates for dHPLC are similar to or better 
than SSCP (Befit et al. 2000; Buyse et al. 2000; Ellis et al. 2000; Jones et al. 2000), 
however, in our experience it is necessary to employ multiple temperatures to be 
confident of having captured the majority of variants as the melting temperature of 
the strand can vary in different regions of the fragment. Also, it is still necessary to 
screen each individual exon, or even multiple fragments per exon for large exons. The 
limitation of SSCP are discussed in Chapter 5. It is obvious that neither method will 
detect all variants. 
Although not presented here, the splice site mutation in CRYBA1/A3 detected in 
pedigree crch08 by SSCP was not detected by dHPLC during trials of the method in 
our laboratory. This lack of confidence in the screening methods is what promted the 
linkage analysis of crystallin genes in the larger pedigrees. It is not clear if one 
method is "better" than the other. In fact they are complementary. In order to be sure 
of identifying all the variation, it would be necessary to conduct both SSCP and 
dHPLC at a range of conditions for both methods. In reality, this is not feasible and 
researchers choose one or the other and conduct experiments at a limited number of 
conditions. It is accepted that some variation will likely be missed this way, but the 
significant reduction in costs offset the risk. However, with the current state of high-
throughput sequencing technology and the accompanying reduction in cost of this 
technique, direct sequencing of the patient samples is a superior method for searching 
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for genetic variation. Even within the time frame of this project this decision was 
taken with the candidate genes for NHS to be directly sequenced in affected 
individuals, whereas the early investigations of crystallin genes were carried out by 
SSCP analysis. 
Although traditional linkage analysis is problematic in this data set, a haplotype 
approach may be useful. The typing of several microsatellite markers across 
candidate gene regions to establish haplotypes would be relatively cheap and fast. 
The non-segregation of haplotypes through a pedigree would immediately exclude 
that pedigree from further analysis at that locus. Therefore, only genes where a 
haplotype consistent with linkage was observed would need to be investigated in 
detail. Recombination events may also be useful in excluding genes. As congenital 
cataract is a rare and highly penetrant single gene disorder, phenocopies are not 
expected in these pedigrees. Only one affected individual with a different haplotype 
would be required to exclude a locus. This methodology was employed in the analysis 
of putative X-linked pedigrees. Two pedigrees were shown to not have segregating 
haplotypes and were excluded from further analysis. Mutations were not identified in 
the remaining pedigrees however, and it is unknown if the correct candidate gene for 
isolated X-linked cataract was sequenced, or indeed if there are uncharacterised 
regions of the NHS gene such as distal regulatory elements or additional 5'UTR 
sequence. In the case of the ADCC genes, the candidate genes are already well 
known, and the absence of mutations in these genes would be conclusive. Haplotype 
analysis at congenital cataract loci is underway in the largest of the small pedigrees, 
ctas16. 
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A potential problem with a haplotype approach still relates to the size of the 
pedigrees. In small pedigrees with only a few offspring (eg ctas34 and crch37, 
amongst others) it will still be difficult to determine if a haplotype is segregating. 
With only a few meioses in these pedigrees it is likely that a haplotype will segregate 
by chance and thus a large number of genes would still need to be investigated. As 
well, if there are no unaffected offspring it cannot be established that an alternative 
haplotype segregates with unaffected status. Also, as illustrated by the shared 
haplotype observed in the large NHS pedigree crch2551, the shared region may be 
very small and could be missed if the markers selected are too few or uninformative. 
It is also feasible that there will be recombinations between the gene of interest and 
the typed markers, further reducing the power. 
An alternative to this traditional genotyping approach may be to use single nucleotide 
polymorphisms (SNPs) that are within the genes themselves and therefore more likely 
to be in linkage disequilibrium with the causative mutation. In theory, a SNP map 
could be typed across the region of the candidate gene which should determine if the 
same chromosome is inherited by all affected individuals. In practice this requires 
informative SNPs to be located in appropriate places and high-throughput SNP 
genotyping to be cost effective. In smaller pedigrees, SNPs may be uninformative and 
thus the size of the pedigree will still also be a limiting factor in determining SNP 
segregation with disease phenotype. 
These small pedigrees are of limited value for the identification of novel loci. 
However, they remain an important resource for the investigation of known genes. 
Genotype-phenotype correlations have been difficult to establish, due to the large 
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numbers of genes and mutations and relatively small numbers of pedigrees with a 
wide range of phenotypes. Some generalisations can be made such as all mutations 
identified to date in connexin genes give rise to pulverulent phenotypes (Shiels et al. 
1998; Berry et al. 1999; Mackay et al. 1999; Rees etal. 2000; Polyakov etal. 2001). 
The pedigree collection in this study represents a significant contribution to the 
overall numbers of congenital cataract pedigrees in the literature, as only around 40 
pedigrees with ADCC have previously been described in detail. Collection of ADCC 
pedigrees from south-eastern Australia is ongoing, and several more pedigrees have 
been identified since this study began. If all cataract genes can be evaluated in these 
pedigrees, genotype-phenotype correlations may emerge based on greater functional 
understanding, allowing for the preferential investigation of candidate genes in the 
diagnosis of congenital cataract pedigrees. 
A genome-wide scan in pedigree crch32 may reveal a novel cataract locus. The 
identification of a potentially novel cataract-causing gene in this pedigree is likely to 
reveal information about lens biology and cataract formation. It is currently unknown 
to what extent congenital cataract genes contribute to age-related cataract. An 
understanding of lens biology has been enhanced through the study of congenital 
cataract pedigrees. This knowledge may be useful in treating age-related cataract 
which is a significant cause of blindness in older individuals. A study of the 
prevalence of cataract in Australia revealed that 6% of individuals over 50 years of 
age had undergone surgery for age-related cataract, and that 50% of the study group 
had significant nuclear opacities and 25% had moderate cortical opacities (Mitchell et 
al. 1997). The basic mechanism of cataract formation is believed to be the 
degradation of lens proteins over time in response to stresses such as oxidative 
138 
damage by UV light (Ottonello et al. 2000). As with congenital cataract, a range of 
phenotypes have been described. The nuclear and cortical forms are thought to have a 
strong genetic component (Heiba et al. 1995). Heritability has been estimated at 48% 
for nuclear cataract (Hammond et al. 2000) and 53-58% for cortical cataract 
(Hammond et al. 2001). Surprisingly, the congenital cataract genes have not been 
investigated in a cohort of late-onset cataract patients. This type of investigation may 
reveal similarities between the two forms with particular variants possibly 
contributing to genetic susceptibility for late-onset cataract. Surgery to remove late-
onset cataracts is one of the most frequent operations in Australia, leading to a 
significant cost burden. Estimates range from $U52020 to $US4500 per quality-
adjusted life year in Western countries (Busbee et al. 2002; Kobelt et al. 2002). A 
clearer understanding of the genetics and molecular mechanisms of this multifactorial 
trait could lead to improved diagnostic and preventative techniques as well as 
alternative treatments. 
ADCC is referred to as a monogenic disorder. However, the results presented here 
and in the literature suggest that it is more complex than mutations in any given gene 
giving rise to the phenotypic spectrum, even within a single pedigree. This is 
illustrated by the difficulty in assigning genotype-phenotype correlations. For 
example, the CRYBAl/A3 splice site mutation identified in crch08 gives rise to a 
similar phenotype as described in an Indian pedigree with the same mutation 
(Kannabiran et al. 1998). This fits with the `monogenic' descriptions. However, the 
P24T mutation of CRYGD in pedigree ctas17 gives rise to a nuclear cataract, whereas 
the identical mutation in an Indian pedigree causes a lamellar opacity. This suggests 
that either environmental factors or differences in the genetic backgrounds between 
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the Australian and Indian families are affecting the phenotype, more in line with a 
'complex' disorder. Phenotypic variation can also be seen within families as 
illustrated by pedigree crch13 in which all affected individuals carry the R76H 
mutation of CX46. This mutation appears to cause an opacity, however it is not fully 
penetrant and it is likely that other factors such as modifier genes or environmental 
effects are acting within this pedigree. There is only one other report of incomplete 
penetrance in a pedigree with congenital cataract. This is possibly due to 
ascertainment bias as, to date, only large pedigrees with multiple affected individuals 
have been thoroughly examined. Pedigrees with apparently unaffected individuals 
may be due to incomplete penetrance of the mutation. This will only be resolved as 
mutations are identified in smaller pedigrees. 
Animal models are being investigated for the effect of modifying genes. As 
mentioned in Chapter 6, the Lop10 mutation in mice was found to be a cx50 mutation, 
however, the phenotype was dependent on the genetic background of the mouse and 
interactions with cx46 were believed to be involved. A similar animal model is the 
Upjohn Pharmaceuticals Limited (UPL) rat. This rat expresses a semi-dominant 
cataract. The phenotype is believed to be caused by a point mutation in CX50, 
however, a second locus acting as a quantitative trait locus (QTL) has been mapped in 
these rats. This second locus is thought to affect the age at which the cataract matures, 
but the gene has not yet been isolated (Yamashita et al. 2002). These are examples of 
animal models of a `monogenic' disorder that display evidence for multilocus 
involvement. As laboratory animals are more homogeneous than humans due to 
inbreeding and close control of their environment, it is possible to detect the effects of 
modifying genes. Linkage analysis and genome wide scans may be useful for 
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detecting modifier loci in some large human pedigrees, however, in most cases, the 
effects are probably too small to be found in this way. Therefore animal models 
become very important for investigation of gene-gene interactions. Mutations with 
the major effect can be introduced onto different genetic backgrounds and the 
differences in phenotype (caused by modifier genes) mapped through linkage 
analysis. Identified genes can then be tested in human pedigrees. Candidates for 
modifier genes may also be identified through an understanding of biochemical 
pathways and cell biology. 
Modifying genes are also being found to play a role in other human `monogenic' 
disorders such as the P-thalassemias which are caused by mutations of thei3-globin 
genes. However, the genotype-phenotype correlations are weak. There are now two 
well defined secondary modifing loci and several tertiary modifiers that are less well 
characterised (Weatherall 2001). It is becoming evident that many diseases previously 
classified as `monogenic' are in fact multifactorial and very few genes actually act in 
isolation. Experience from the research into 13-thalassemia has suggested that even 
though genome scans may be able to identify these modifier loci, it is still neccesary 
to understand how the gene interacts at a molecular level with the cellular machinery 
in order to fully disect the medical significance of mutations in such a gene. 
This investigation into the genetic causes of familial cataract in south-eastern 
Australia has revealed two mutations previously reported in Indian pedigrees with 
interesting implications for genotype-phenotype correlations (or lack of them), and a 
novel mutation of a connexin gene whose functional effect is yet to be determined. A 
novel developmental gene responsible for Nance-Horan Syndrome has also been 
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identified. This represents a significant advance in cataract genetics and the 
investigations of NHS gene function will provide novel insights into developmental 
biology. 
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Appendix 1 - Pedigrees with Familial Cataract 
The pedigree's number in the study is given along with the type of inheritance 
observed: 
ADCC — Autosomal Dominant Congenital Cataract (includes all dominant 
inheritance) 
ARCC — Autosomal Recessive Congenital Cataract 
NHS — Nance-Horan Syndrome 
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Appendix 2- Primer Sequences and PCR Conditions 
All primers were designed using Primer3 (http://www-genome.wi.mit.edu/cgi-
bin/primer/primer3_www.cgi).  
Primer sequences for microsatellite markers were obtained from the Genome 
DataBase (http://www.gdb.org/) and are not listed here. 
Section 3.3.4 Primer sequences for novel STR markers on the X chromosome. 
STRs are named after the repeated sequence followed by the clone name. Optimal 
Mg2+ concentration and annealing temperature (°C) is also given. 
Marker Forward Reverse Mg2+ 	Temp 
TG Z93022 TGAGGAAAATATCTCATTGCAGAA TGGCTCTTGGAGGGTATTTG 1.5 	60 
GA Z93242 TGCAGCAAGAGATGAAGACAA TATTTATTGCAGCCCCCTTG 1.5 	52 
CA Z93929 GCAGTGGAAGAGTCCCTCAG CCCGATTTCCTCTAAAACAGTG 1.5 	60 
GT Z92542 TCACTGACTTGGCTTGAAGG TGAGACAGCAGGTAGCCAAA 1.5 	60 
CA1 Z92542 TCCTAATTTCATTGATTTCCAGGT TGAGGCCTATTTGGATTTTGTT 1.5 	60 
CA2 Z92542 CCTGCTCTTGGGGAAGATAA TGCTTCTGCTCACAATGACC 1.5 	60 
TG/AG Z92542 AATGAATGGTTTCGGCTGTG ATGCGCTAATTCCTGGTGAG 1.5 	60 
GT Z94056 AGCCTGGCCCTGTTCTAGTT TTCTCTCTGGGGAAATGCAG 1.5 	60 
Section 3.3.5 Primers for the amplification of coding exons of candidate genes for 
NHS. Optimal Mg2+ concentration and annealing temperature (°C) is also given. 
Gene Exon Forward Primer Reverse Primer Mg2+ Temp 
PPEF1 4 CCCTCCCTCCTGTGTATTCC TCATTCATAACCACAGGCACA 1.5 60 
5 AATCCAGGTGGACTGCTTTTT GAAGAGAAAAGCTTGCAAAACA 1.5 60 
6 GTGGAACACCAACAGCATTT ACC G CTCTTGATGAAGACAA 1.5 60 
7 AGTGCCTTACATGGGCTAGG TTCAACAGTTATTGGGCATCTG 1.5 61 
8 CGTGCTTGCTCCACCTTTAC AG GCAAAC GATGTAGGACCA 1.5 60 
9 AATGCCCTGAGAACACTTGG CCTCCCCCAAGAAAAATGTTA 1.5 60 
10 TTTTCCCTTCTCCTCCTTC ATGGCAGCATTTTCCAGAGT 1.5 57 
11 GCTICCCTTTITGCATGACT CAATCTGGTCTTTCTTGGCTCT 1.5 60 
12 CTGAACCTGTCAGAAAAACAAAAC TCCCTGAGAGAAGATTCATGC 1.5 60 
13 GCAGAGGGTTGGACTAAAGC AGTGTCATTGTTGCCACTGC 1.5 61 
14 CAGCGAAATCTGGTTTGTTGT TGGGAATGTCACCAACAATTT 1.5 60 
15 CGTGAACCTGACCCTCTTTT TCCGTGATACCAGTGCTCAG 1.5 60 
16 AAAATGAAACACAACAGGATGA GGAAGCAAGGAAAATGAAAAG 1.5 60 
17 CCAAGGAGGTTGCATTCTTT CCCTGGCTAGGTTTTAGCTG 1.5 60 
18 TGCTAAAAGCGATCAGTGTCA CCAATGAAGGTGTCAAACCA 1.5 60 
19 CCTTGCCTTAGGTGGGGTCTT ATTTGG GC CTAGCTGTTTCA 1.5 60 
STK9 2 CTTCCTTCAGACGGT-ITTGG GGAGAGTGAGACCCAAATTGTT 1.5 60 
3 CCACTGAGAAGCAATGTCAGTATAG TACATG CC CACAC G CAAAG 1.5 60 
4 GAATCCCCAGTCGGAAAAAC TGACCAGCTAGATCCCACTTC 1.5 60 
5 TGGAATTCTTTGAATAGTAGCTTGAA AAATAAAAGAATCGGGCAAATG 1.5 60 
6 GGCCTACCTAATTTGGGAAA GCAATGCCAATGCTTATGAA 1.5 60 
7 TTTTTGCTGCCACAGTTTTC TGTGACTCAAAAGAATGTTCCTC 1.5 60 
8 GCTGAAATATTTTGCCCACA TCAGCAGATGTGGAAATGTCA 1.5 60 
9 TTTTTCAGTTGCCAAAATAATCT TGTGCAATGAACAATGACTCAA 1.5 60 
10 CATGTCCTTCCCCAAATGTT AAAAGCAGGCTATGGTCACA 1.5 60 
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11 TTTGACTTTGTAATGTTCTTAACGAT AGC CACCTCCTCCACCTACT 1.5 60 
12A TGTCAGCTATTGAGGGAAACTG AAG GTTGCTCACAGACTTG GA 1.5 60 
12 B GAGTCCCTCCTACAGGACCA GCCACCAGATTCAGTCAAGG 1.5 60 
13 CATCCCTAGGAACAGGATGC GGCAGTAATGATGTTGAACAAA 1.5 60 
14 GCAATATTGTCATCAATGTGTGG AG GAGAGG GGAACCTGTTGA 1.5 60 
15 CGTGAAAACTGCTTTGACCA AAGGCCTAGCAGGAGAAAGG 1.5 60 
16 TTTGTCACACAATGGCAAGAA TTTGATTGC CAAGTGCAAAG 1.5 55 
17 CTCTTGGGTGTGGTTGCATA CC GCTCCTCAGGACAGTTAC 1.5 60 
18 CCAGCCTTATGGTC GCTCTA CACAGAGGACACATGCCAAC 1.5 55 
19 GTGGGCAGAAGTGGCCAATA GTCTAGGGTCGTTATGGCAGC 1.5 58 
20 CC CCAAGCTTCATTCCACT CAGGTGTCATTGGCTGGAC 1.5 55 
21 TCCTGGCAGCTCTGAGTGA AGAGGTGATTCAGGGCATTG 1.5 60 
SCML2 2 TCATTTTTGTTTAAGGGAAACAG AAAGGCTTTATTTCAAAAGTTCAGT 1.5 60 
3 TGGTAAGTCCTACATAGAAAATGAAGA CACTAGTGAGGAAGAAAACTATGCTG 1.5 60 
4 GGCATGGAACTAAAACCCATT TCACACAGACGTCCTCCAAC 1.5 58 
5 TTCTGGTGACATAGCTGTCCA AAGGCCACTTAAAGCCATTTC 1.5 58 
6 TTGCCCATGTICAAAGTFCT TTTGCTTTTCCATGTCACAGA 1.5 58 
7 GCAACTTTTCACTTC GAGCA AATCACAATGCCAC CAATGA 1.5 58 
8 TGAGGAGACAATGCCTTAATTG CATTTCTAAAGACCCTCATCATACT 1.5 58 
9 TCATGACACACAC GGGAGTT AGGACTTCGAAGACACTGAAAA 1.5 62 
10 G GTTTTCTGTGAGTGAAGTG GA AGGGGGAAGGGACTGAATTA 1.5 60 
11 TCTCTCTGAGGTTACTGACATCCTT TTTGAGGAGAACACAAGGAAAA 1.5 58 
12 CAGAAGTGTTTCATGCTGATGAT CCAGTCCTGGGAGGTGTAAA 1.5 58 
13 TGCTAGGGATGAGATTTTTAACCT AAAGACAAACACATTGAGAGTCAC 1.5 58 
14 AGGTTCCAGGAATGAGACCA CCTGCACAGAGGTCATTCAA 1.5 58 
15 CAGCTGCTGTATTTTACATGTTCT GGTTGGTGACTCCAGGAAAA 1.5 58 
RS1 1 AG GC CAGGGCTCAACTTAAT TGCAATGAATGTCAATGGTT 1.5 62 
2 AG G G GTGTTG GTAG CTTTCAT TC CTCTATGTTATTTTTGGCTAGGA 1.5 62 
3 TTGGC CATTGTAGCAAAGC CAGCTGAGTGGGAAAAAG GA 1.5 62 
4 GCAAAGCAGATGGGTTTGTT GCCACGCTGGTAGAGAGG 1.5 62 
5 GGCTTTTTGCAGACATGCAC GTGCGAGCTGAAGTTGGTTT 1.5 62 
6 GGAACCCTTCTTCCTTTTCC GCGAAATATAGC CCTGTCCA 1.5 62 
SCML1 4 AAAGCATTCTTACCGGCTTG TGTACCAAATTGGGCTCTCC 1.5 58 
5 TTCCAACAAAGAGAGCATTC C TCAAAGG CATTACAGCAG GA 1.5 58 
6 TCTGCAATGAGCTGCTCTCTA TCCACACTAAGAAGGCATTGG 1.5 58 
RAI2 1 TGC CATTTTCCATAGTCATAGC CTCAGCTCTGATGC CACTTG 1.5 60 
2 TGGGTTATGCTCCCTGGTTA TCATGACGTAGGTGGCATTG 1.5 60 
3 AGAGCC CAGTGGTGATGC GGGGATGGGAATAGGGACT 2.0 60 
4 CTTTTAGCTC CCC CTTGTCC CATGCCACTGGGAAGTTICT 1.5 60 
5 AGCCTC CCCCTGAGACAC TTTTTGATTGGGAGCATGTG 2.0 58 
6 AGAAGACTCC GTGCTTCAGG CAAAGCACTTTGTGGCAATG 2.0 62 
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Section 4.2.2 Primers for amplification of predicted exons from adult human brain 
cDNA. 
Exon numbers are those given to the exon predictions by Genescan. The Unigene 
clusters are those that were linked to form the 3'UTR. 
Predicted 
exon 
Forward Reverse 
5'end GCTGCTCATGCTGGACCTA 
exon 1 CTGTGGCTTTGGAAAATGCT 
exon 2 GGAGTAGCAGGGGAGAAAGC 
exon 3 CCAACCTGGACATAGAGAGTAAGC CGCGGTAGTACACACTCAGCTTAC 
exon 4 TAAACTGACGCCTCCTCTGG 
exon 4a GACGAACATATTTTTCCCAAG CCAACACACCCAACAGGATA 
exon 5 TTCCACACTGGACAAGCAGA TATTGGGTTTTTCGGCCTCT 
exon 6 GAGACCCAAGGAAATGTGGA TGACAGTGTTGGAGGGGTCT 
exon 8 ATGTCCCCGGAATCTTTTCT 
Hs.77385 TACGCAATCTCCTTCCTTGTG 
Hs.282164 GAAGGAGGAAGCCTGGTCTAAG CAATAGCTCTGTGGCATGCTTAG 
Hs.21470 CTGGAAATGACGGTTTCTTATCG 
Section 4.2.3 Primers for amplification and sequencing of all detected regions of NHS 
gene.  
Exon 1 was sequenced in 3 overlapping fragments (A-C), exon 6 in 8 overlapping 
fragments (A-H) and exon 8 as 2 overlapping coding fragments (A & B) and 7 
untranslated fragments (UTR A- UTR G). Optimal Mg 2+ concentration and annealing 
temperature (°C) is also given. 
Exon Forward Primer Reverse Primer Mg2+ Temp 
1 — A* GCGCACCCCTAAATTTCT CTGCCTGCACAGCCATTG 
0. 0. 
	 0
  tr?
 in  
CNI  C
V
  	
 
60 
1 — B* GCTTGGAGGAGACCAGAAAGT CCTGGAAGAGGCTGCAAG 62 
1 — C* GCTGCTCATGCTGGACCTA GGTGGGAAGGCGAGAGTAGT 60 
2 TGCAGTAGTCTGGACTTCCACT CCCATGGATTTCATTTCAGG 62 
3 ACTCCCAAGGGGAAAAGAGA CTGATGTTTCCTCAGCAGCA 62 
lb TCTCTCTCTCTGATGCACCAAA TCATGCCCTGTTGACTCAGA 60 
4 GGGCCTATTTCTGACCTCATT AGCAGCACAGATTTTGAACA 62 
5 TCTTTCCTTACTTCCCGTCAAA CATCTGTACTAGGCGGAGGAA 62 
6- A CTGCCAGCCCACAGATCTAC GCTTGGAGCCTCACTGAAAT 62 
6- B TCCCCGGGAAGGTAATAGAG TGAGGGGCTGTGTTTAGTGA 62 
6- C TGACCACCAGTGATCCAGTG ACCACAGTCAAAGTGCATGG 62 
6- D CATCAGACAAAGCGGACACT TGGTGGAATATCCGAAGCAT 62 
6- E AATGGAAAACGCCAATCTTC AGAGGGTTGCTGTAGTGAGGA 62 
6- F CTTGGCATCTCCATCAAGTG TGCGGCCTAATCTTACTTGG 62 
6- G CCTTGCAATTACACCAACGA GAGGGTGCCTTCTGTACCTG 62 
6- H AAAACACGCCAACCAAAAAC ATTCCAGGAAGTGCCATGAG 62 
7 CAGTAGCGTGCTGGGTAACTT GGGCAAAACCTTTGTTGTA 62 
8- A TTTCATAAAAACGTGAACTGAGTGA GCAAAGCTCTTCGAGGAAAA 62 
8- B CCAGAGGTCTCCTGGTCTCA GTAAGGGTTTTGGCCTTTGC 62 
8 UTR A ACCGTTCCTCCCAGAGTTCA TGGCATTTGATATGAAAATGGTAT 60 
8 UTR B GATGAGTGGACATGTGGTCAA GCTCTGTGGCATGCTTAGGT 60 
8 UTR C ACAGTTTAGAAATTAGCTCCAGGTTC AAGTCAGATCCCTTCTTAATTCTCT 60 
8 UTR D AGGTTTTGAATGGGAGAGGT ATGTTCCCATGTGGTGTCAA 60 
8 UTR E GGACCACCATTTCTCATTGG AGGGAACTTCCTGC I I I i I CU 57 
8 UTR F GGATTTAAAATTCACTGTGGAAAA ACTGCAGCAAATGCACTCAC 57 
8 UTR G CAGAACATGCTGTTTGCTCTT GCCCCAAGAAATCAATTACG 55  
*' Required the addition of Q solution (Qiagen) for optimal results. 
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Section 5.2.5 Primer sequences for PCR amplification of coding exons of five 
crystallin genes. 
Optimal Mg2+ concentration and annealing temperature (°C) is also given. 
Gene Exon Forward Primer Reverse Primer Mg2+ 	Temp 
CRYAA CTCCAGGTCCCCGTGGTA AG GAGAG GCCAG CACCAC 1.0 	63 
CNI  CTGTCTCTGCCAACCCCAG CTGTCCCACCTCTCAGTGCC 1.0 	63 
GGCAGCTTCTCTGGCATG GAG CCAG CCGAG GCAATG 1.5 	65 
CRYBAl/A3 GGTCTTAGGAAGATCCCAAG AAGGAGAGGAAGGGCAAGGG 2.5 	60 
CGTGTGTGCTCTGTCTTCC GGTCAGTCACTGCCTTATGG 1.5 	63 
CCTCTGTTTTTCCTGATGT AACATCCTTCTTCCCCTAT 3.0 	60 
cr CAAACACTACATGTCTTTGG CTTGCTACCCTCATATGC 1.5 	58 
TGCTTCCTTGTATAATCC ACTATTGATGCAACCTCAGG 1.5 	55 
GGTTTGCTACCATTATCTTGG TCATCCACTTAGGTGTGATTT 1.5 	60 
CRYBB2 TGCTCTCTTTCTTTGAGTAGACCTC CCCATTTTACAGAAGGGCAAC 2.5 	63 
ACCCTTCAGCATCCTTTGG GCAGACAG GAG CAAGG GTAG 1.5 	63 
•zr GCTTGGAGTGGAACTGACCTG GGCAGAGAGAGAAAGTAGGATGATG 2.0 	65 
G CC CCCTCACCCATACTC CCCCAGAGTCTCAGTTTCCTG 2.5 	65 
CCTAGTGGCTTATGGATGCTC TCTTCACTTG GAG GTCTG GAG 1.5 	63 
CRYGD 
Z.—
 CN1
 Ce) 
CTGCTATATAGCCCGCCGC AGTAGGGCTGCAGGTTGGG 1.0 	63 
GATCACCCTCTACGAGGAC GTGAGTGTCCTGAGGACCT 3.0 	60 
CTTTTTATTTCTGGGTCCG CCAGGAACACACAGAAAAT 3.0 	60 
CRYGC 1+2 TCACACTGAACTCGCATCA AACTCACTTGGGGGATGAG 2.5 	63 
3 CGAGTAGACAGTCTCCCAC TATTAGGTTCCAAAATGGG 1.5 	56 
* Required the addition of Q solution (Qiagen) for optimal results. 
Section 6.5.2Primers for amplification and sequencing of Connexin 46 gene. 
Optimal Mg2+ concentration and annealing temperature (°C) is also given. 
Fragment Forward Reverse Size 
bp) 
Mg2+ 	Temp 
1 CGGTGTTCATGAGCATTTTC GACGTAGGTCCGCAGCAG 496 1.5 	60 
2* GCAGGACAATCCCTCGTC GGTCAGGGCTAGCAGTTTGA 532 1.5 	56 
3 TCGGGTTCCCACCCTACTAT TGCACTTTGGTTTTGGTTTC 579 2.0 	56 
lb CAGACTTCACCTGCAACAAC CTCTTCAGCTGCTCCTCCTC 202 1.5 	60 
* Required the addition of Q solution (Qiagen) for optimal results 
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Appendix 3 - Allele Frequencies for Microsatellite Markers 
• Sections 3.3.3, 3.3.4 Allele frequencies observed for markers on chromosome X 
Calculated from 22 unrelated unaffected individuals from the south-eastern 
Australian population. 
Marker Allele Frequency 
observed 
Marker Allele Frequency 
observed 
DXS1224 153 0.08 DXS999 257 0.04 
155 0.52 263 0.07 
157 0.04 265 0.29 
159 0.04 269 0.04 
161 0.14 271 0.04 
163 0.18 273 0.52 
DXS1053 192 0.04 DXS365 199 0.02 
194 0.38 200 0.02 
196 0.25 201 0.02 
200 0.25 202 0.02 
202 0.04 203 0.04 
204 0.04 205 0.20 
DXS1195 230 0.02 207 0.24 
232 0.07 209 0.13 
234 0.50 211 0.07 
236 0.41 213 0.04 
DXS418 131 0.04 215 0.02 
133 0.07 0XS989 169 0.10 
135 0.04 175 0.04 
137 0.16 177 0.13 
139 0.13 179 0.35 
141 0.30 181 0.07 
143 0.07 183 0.04 
145 0.07 185 0.07 
147 0.04 187 0.04 
149 0.04 189 0.04 
153 0.04 191 0.04 
TG Z93022 217 0.08 193 0.04 
231 0.15 195 0.04 
233 0.08 CA2 Z92542 442 0.04 
235 0.42 444 0.70 
237 0.19 446 0.26 
239 0.08 CA Z93929 144 0.01 
TG/AG Z92542 211 0.01 153 0.03 
213 0.06 155 0.06 
215 0.56 157 0.34 
217 0.09 159 0.34 
219 0.24 161 0.13 
221 0.04 163 0.06 
165 0.03 
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Section 5.2.3 Allele frequencies observed at markers representing crystallin genes 
Calculated from 22 unrelated unaffected individuals from the south-eastern 
Australian population 
Marker Allele Frequency 
observed 
Marker Allele Frequency 
observed 
D2S2358 199 0.09 D21S1890 147 0.03 
200 0.13 151 0.08 
202 0.07 153 0.20 
204 0.27 155 0.08 
206 0.33 157 0.03 
208 0.02 159 0.08 
210 0.09 161 0.03 
D11S1347 175 0.03 163 0.08 
177 0.11 165 0.20 
185 0.03 167 0.08 
189 0.12 169 0.05 
191 0.13 171 0.03 
193 0.24 173 0.03 
195 0.07 D22S926 294 0.05 
197 0.06 296 0.05 
199 0.07 298 0.10 
201 0.11 300 0.22 
D17S841 258 0.02 302 0.40 
260 0.02 304 0.13 
262 0.13 306 0.05 
264 0.70 
166 0.09 
270 0.04 
Section 6.5.1 Allele frequencies at markers representing known cataract loci. 
Calculated from founders within the pedigrees and reported by the CEPH database 
Marker Allele 
Frequencies 
Founders 	CEPH Marker Allele 
Frequencies 
Founders 	CEPH 
D1S2635 140 0.18 0.00 D1S468 172 0.07 0.02 
142 0.09 0.00 177 0.05 0.02 
144 0.02 0.07 179 0.00 0.02 
145 0.14 0.07 181 0.21 0.29 
146 0.00 0.09 183 0.14 0.09 
148 0.24 0.20 185 0.05 0.05 
150 0.20 0.00 187 0.38 0.37 
151 0.02 0.14 189 0.10 0.14 
152 0.07 0.16 D15S1033 154 0.18 0.05 
155 0.02 0.11 159 0.05 0.02 
157 0.00 0.11 161 0.29 0.45 
161 0.02 0.02 163 0.23 0.23 
D3S1349 114 0.13 0.09 165 0.23 0.21 
118 0.06 0.11 167 0.02 0.02 
124 0.10 0.12 D15S117 128 0.16 0.20 
128 0.23 0.22 132 0.31 0.33 
132 0.40 0.32 134 0.30 0.14 
136 0.04 0.09 140 0.09 0.16 
140 0.04 0.04 142 0.14 0.12 
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D10S1268 131 0.03 0.04 144 0.00 0.01 
137 0.03 0.04 D17S796 142 0.00 0.14 
139 0.37 0.46 158 0.03 0.01 
141 0.06 0.11 160 0.17 0.16 
14.3 0.14 0.04 162 0.33 0.29 
147 0.00 0.02 164 0.08 0.01 
149 0.03 0.09 166 0.08 0.16 
151 0.16 0.05 168 0.28 0.14 
153 0.09 0.12 170 0.03 0.03 
155 0.03 0.04 D17S849 249 0.07 0.02 
157 0.06 0.02 251 0.40 0.50 
D12S83 80 0.18 0.20 253 0.14 0.20 
82 0.05 0.10 255 0.14 0.16 
84 0.08 0.17 256 0.03 0.10 
86 0.11 0.10 257 0.12 0.02 
88 0.48 0.30 270 0.10 0.00 
90 0.01 0.09 D17S802 162 0.00 0.01 
92 0.01 0.02 168 0.03 0.08 
94 0.01 0.02 170 0.03 0.01 
D13S1236 112 0.04 0.00 172 0.06 0.05 
114 0.56 0.00 174 0.12 0.28 
124 0.00 0.06 177 0.38 0.10 
126 0.04 0.11 178 0.26 0.25 
128 0.29 0.43 180 0.03 0.08 
130 0.00 0.35 182 0.03 0.01 
132 0.07 0.07 184 0.06 0.07 
D16S496 208 0.17 0.16 D17S836 197 0.26 0.32 
212 0.03 0.02 199 0.08 0.02 
214 0.00 0.04 201 0.50 0.50 
216 0.17 0.18 203 0.13 0.11 
218 0.63 0.42 205 0.03 0.05 
220 0.00 0.11 D20S894 259 0.06 0.04 
224 0.00 0.05 261 0.09 0.20 
D1S243 143 0.00 0.20 263 0.03 0.01 
145 0.03 0.00 265 0.34 0.30 
147 0.28 0.01 266 0.03 0.01 
149 0.28 0.14 268 0.09 0.09 
151 0.10 0.20 270 0.03 0.07 
154 0.00 0.05 272 0.15 0.17 
156 0.03 0.01 274 0.18 0.09 
158 0.06 0.09 276 0.00 0.02 
160 0.22 0.05 
162 0.00 0.12 
164 0.00 0.05 
166 0.00 0.03 
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